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Extracorporeal life support (ECLS) is a technique for providing life support in severe but 
potentially reversible cardiorespiratory failure. The technique oxygenates blood outside 
the body, obviating the need for gas exchange in the lungs and, if necessary, provides 
cardiovascular support.  
Initially ECLS was used as a device to take over the functions of the heart and lungs to 
permit surgical operations on the heart and great vessels. As experience with 
extracorporeal circulation was gained during the 1950s it appeared that the life 
supporting technique itself became lethal when used for more than a few hours. The 
development of the artificial lung machine – the early membrane oxygenators – then 
demonstrated that it would be possible to conduct prolonged extracorporeal circulation 
also outside the operating room. A logical next step was to attempt the use of this 
technique in the care of patients whose respiratory failure was unmanageable with 
conventional mechanical ventilation. 
When used with extra-thoracic cannulation for respiratory support the technique is called 
extracorporeal membrane oxygenation (ECMO). This enables the lungs to rest with use 
of minimal ventilator settings, thereby preventing injury from high oxygen concentration 
and barotrauma. Especially in term newborns with pulmonary disease sustained 
pulmonary hypertension exacerbated the disease and frequently resulted in death. It 
appeared that in many of these patients the process was reversible if the patient could 
be supported through a critical period of adaptation.  
In 1976, Bartlett et al. reported the first successful use of ECMO in the management of 
neonatal respiratory failure. By 1981 they had treated 45 newborns, of whom 25 
survived.1 In 1996 the UK-Collaborative ECMO trial group performed the first and only 
randomised controlled clinical trial showing a survival benefit of ECMO, without a 
concomitant rise in severe disability at 1 year of age.2,3 
To date, ECMO has been used in over 18,000 newborns in 153 centers in 14 different 
countries.4 
 
The ECMO circuit for newborn makes use of two catheters, one placed into the right 
internal jugular vein, positioned in the right atrium, and the other in the right common 
carotid artery (veno-arterial or VA ECMO). Blood is drained passively via the venous 
catheter, and then passed on to a pump, which maintains flow in the circuit. A 'bladder 
box' and servo system prevent the pump from working if venous drainage becomes 
inadequate for any reason. Blood then passes the membrane oxygenator where it is 
oxygenated and the carbon dioxide pressure is regulated. Warmed in a heat exchange 
column before re-entering the body, blood is returned via the common carotid artery at 
systemic pressure. This type of ECMO is able to support both pulmonary and cardiac 
function. (Fig. 1) A different type, veno-venous (VV) ECMO in which the drainage and 
reinfusion vessels are both veins and therefor provide mainly pulmonary support, is 
becoming increasingly popular. Its particular, theoretical advantage is uninterrupted 
cerebral arterial blood supply. Moreover, oxygenated blood will enter the pulmonary 
arterial system and as such could be advantageous in neonates with pulmonary 
hypertension. 
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Figure 1 
 
 
 
ECMO is most commonly used to support mature newborn infants. Limiting factors are 
required size of the cannulae and systemic heparinization of the patient during ECMO. In 
neonates of less than 35 weeks gestational age the risk of intracranial haemorrhage is 
too high.5 The smallest cannula capable of providing adequate ECMO flow is an 8 Fr. 
Therefore it is more difficult to perform cannulation in a child weighing less than 2000 
grams. Also, as ECMO is not intended to delay inevitable death, it is important to 
establish the patient’s diagnosis before the initiation of ECMO. Patients with a known 
lethal congenital anomaly or major uncorrectable cardiac lesion are excluded from 
ECMO treatment. Apart from these general criteria, Beck et al. developed specific criteria 
to predict 80% mortality. Especially the AaDO2/time interval was established as a major 
criterion for institution of ECMO, in a population of infants with severe acute lung disease 
treated conventionally.6 Criteria for institution of ECMO in neonates are now derived from 
the ELSO guidelines.7 
 
The most important indications for ECMO treatment in newborns are respiratory failure 
and pulmonary hypertension caused by meconium aspiration syndrome (MAS), 
congenital diaphragmatic hernia (CDH), sepsis and idiopathic persistent pulmonary 
hypertension of the newborn (i-PPHN).4 Table 1 shows the number of ECMO runs for 
neonatal respiratory failure by diagnosis according to the ELSO registry report, July 
2004.4 
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Table 1 
Diagnosis Total Runs Average Run Time (hrs) % Survival 
CDH 4491 231 53 
MAS 6560 129 94 
PPHN 2914 144 78 
Sepsis 2384 138 75 
Survival to discharge or transfer. 
 
 
Acute care 
 
Newborns treated with ECMO are critically ill. Nutrition is an important factor in the acute 
care of these patients in view of the fact that children admitted to an ICU may suffer from 
malnutrition.8 It is common practice to withhold enteral nutrition from these patients and 
to feed them with total parenteral nutrition. This practice largely springs from fear of 
developing necrotising enterocolitis (NEC). In theory NEC may be due to an affected 
splanchnic circulation, subsequently leading to intestinal ischemia, in patients with 
hypoxic periods prior to ECMO and hemodynamic alterations during ECMO.9,10 However, 
enteral nutrition was shown to be adequate in pediatric ECMO patients without the 
occurrence of major complications.11 Data on intestinal permeability, safety and feasibility 
and the occurrence of complications in newborns receiving enteral nutrition during 
ECMO are still scarce.  
 
A second factor in the acute care of ECMO patients is drug use. ECMO is known to alter 
drug disposition through expanded circulation volume, the presence of a non-pulsatile 
blood flow and reduced plasma protein levels, with effects on pharmacokinetics and 
pharmacodynamics.12 
Morphine and midazolam are widely used drugs to provide adequate sedation and 
analgesia during ECMO. Plasma concentrations of morphine were found to drop during 
ECMO, especially over the first 10 days.13 For midazolam, Mulla et al. reported that the 
distribution volume in ECMO-treated neonates was three to four times greater than that 
in critically ill neonates not treated with ECMO.14 
Taking into account that factors such as increased tolerance after prolonged morphine 
intake also reduce the predictability of the effect of these drugs, morphine and 
midazolam therapy should be guided by clinical monitoring, preferably by validated pain 
or comfort scales.15-17 
Severe (primary of secundary) pulmonary hypertension in neonates is common in the 
neonatal intensive care setting.18 Over the years no single therapy has been established 
to be effective in all cases and this condition is still a major reason for ECMO support. 
Recent observations suggest that the phosphodiesterase (PDE) inhibitor sildenafil 
(Viagra) is promising in the treatment of pulmonary hypertension in adults and 
children.19,20 However, very little is known of its (side-)effects in neonatal persistent 
pulmonary hypertension and its use during ECMO.  
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Long-term outcome 
 
Since the UK-ECMO trial showed a survival advantage of ECMO over conventionally 
treated neonates with severe respiratory failure, morbidity has become increasingly 
important.2 Bennett et al. showed that 13% of the children were moderately to severe 
disabled at four years of age. They also concluded that the range of morbidity widens 
with increasing ages when assessment of cognitive skills, co-ordination, behavioural 
difficulties and sensory loss can be more precise.21 However, these findings may have 
been influenced by patient selection.  
Pulmonary function testing is also included in the assessment of morbidity after ECMO 
support. Because ECMO could potentially result in survival of infants with severe 
respiratory dysfunction – or alternatively could result in survival of infants who might be 
spared aggressive ventilation and consequent volutrauma – it is essential to investigate 
their respiratory function independent of the fact whether ECMO results in a survival 
advantage. Cross-sectional data from different studies suggest that forced expiratory 
flow in ECMO survivors decreases in the first year of life.22,23 Longitudinal data during the 
first year of life are not yet available. 
 
 
Study Objectives 
 
The main objectives of our studies were: 
 
1. To evaluate the feasibility of enteral nutrition in newborns treated with ECMO. 
2. To describe the pharmacokinetics and pharmacodynamics of analgesia and 
sedation during ECMO. 
3. To evaluate the long-term follow-up of neonates treated with ECMO; i.e. overall 
outcome at the age of 5 years. 
4. To evaluate pulmonary sequelae during the first year of life and at 5 and 8 years 
of age. 
 
ECMO is a complexe technique used mainly in severely ill newborns with respiratory 
failure. In the knowledge that most ECMO treating centers tend to withhold enteral 
nutrition from these patients in fear of complications and inadequate intestinal perfusion 
we evaluated in Chapter 2 over a five-year period the feasibility and tolerance of a 
protocol of routine enteral nutrition in neonates requiring ECMO.  
In Chapter 3 the effect of enteral nutrition on gut function during ECMO was evaluated. 
Since splanchnic circulation is at risk of inadequate perfusion during cardiopulmonary 
bypass we hypothesized that plasma gut hormone levels in patients on ECMO would be 
lower with a decreased response to enteral nutrition. 
In Chapter 4 we evaluated whether ECMO increases the risk of developing a 
chylothorax after congenital diaphragmatic hernia repair.  
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As a preliminary report of a study on the pharmacokinetic and pharmacodynamic 
poperties of midazolam and morphine administered during VA-ECMO, chapter 5 
describes the plasma concentrations of midazolam and morphine during ECMO. In the 
line of drug therapy during ECMO we evaluated in Chapter 6 the use of sildenafil 
(Viagra®) in the treatment of neonatal persistent pulmonary hypertension.  
We assessed morbidity in ECMO survivors at the age of 5 years, when they start primary 
school and major decisions for their school careers must be made. 
The results of this nationwide extended follow-up program are described in Chapter 7. 
Next, Chapters 8 and 9 describe pulmonary sequelae of ECMO survivors during the first 
year of life and at ages 5 and 8 years. 
This thesis is completed by a general discussion (Chapter 10) and summary.  
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Abstract 
 
Objectives 
To evaluate over a 5-yr period the feasibility and tolerance of a protocol of routine enteral 
nutrition in neonates requiring extracorporeal membrane oxygenation (ECMO).  
 
Design 
Retrospective medical chart review.  
 
Setting 
Level III children’s hospital, pediatric surgical intensive care unit.  
 
Patients 
Neonates treated with venoarterial ECMO (VA-ECMO) between January 1997 and 
January 2002. Patients with congenital diaphragmatic hernia were excluded.  
 
Interventions 
None.  
 
Measurements and Main Results 
Charts of all neonates treated with VA-ECMO were reviewed. Feasibility was evaluated 
by recording the time period needed for enteral nutrition to reach 40% of total fluid intake; 
tolerance was evaluated by reviewing data on enteral nutrition related morbidity. Sixty-
seven of the 77 eligible patients received enteral feeding during ECMO. Thirty-six of 
these patients (54%) received 40% of total fluid intake as enteral nutrition within a 
median of 3 (range, 2 - 4) days. Over the years there was a trend toward an increasing 
usage of enteral nutrition from 71% to 94% (p = .07). Enteral nutrition was temporarily 
discontinued in 16 patients, with 14 showing gastric retentions, one showing discomfort, 
and one showing aspiration. Symptoms of bilious vomiting, blood-stained stool, or 
abdominal distention were not present.  
 
Conclusion 
Neonates on ECMO in this series tolerated enteral feeding well and did not show serious 
adverse effects. Overall, it is our experience that routine use of enteral feeding in 
critically ill neonates on VA-ECMO is feasible.  
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Introduction 
 
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a type of heart-lung 
bypass that provides short-term support for selected critically ill patients with acute 
therapy-resistant respiratory or cardiac failure. ECMO can be used for reversible 
disorders only. Worldwide, > 20,000 newborns have been treated so far, 18,703 of whom 
for respiratory failure.1 Conditions most commonly treated with ECMO in the neonatal 
period are meconium aspiration syndrome, primary or secondary persistent pulmonary 
hypertension of the newborn, congenital diaphragmatic hernia, sepsis, and pneumonia. 
 
As critically ill neonates have limited endogenous nutrient stores and relatively high 
nutritional requirements, early institution of nutritional support is important.2,3 Enteral 
nutrition in neonates stimulates intestinal hormone secretion.4 These hormones may be 
instrumental in stimulating structural and functional changes occurring in the gut and 
other organs when adapting to enteral nutrition.5,6 Moreover, early administration of 
enteral nutrition, at least in critically ill adults, is known to reduce sepsis-associated 
morbidity and cost.7,8  
 
Parenteral nutrition has been traditionally preferred over enteral nutrition in the neonatal 
ECMO patient for different reasons. First, splanchnic circulation may be adversely 
affected by hypoxic periods and the need for vasopressor therapy before ECMO. This 
may lead to intestinal ischemia, which in its turn increases the chance of developing 
necrotizing enterocolitis (NEC) and facilitates bacterial translocation and eventually 
sepsis.9-11 Second, the hemodynamic alterations present in patients on cardiopulmonary 
bypass also have a negative effect on gut barrier function.12,13 And finally, other 
complications such as aspiration or intestinal distention due to obstruction are thought to 
occur.  
 
In earlier publications we evaluated intestinal permeability in ECMO patients, as well as 
gut responses to starvation and reintroduction of enteral feeding, in both premature 
neonates with NEC and in term-born infants. Intestinal integrity in ECMO patients was 
compromised but did not deteriorate after introduction of enteral nutrition.14,15 After these 
prospective evaluations, we developed a protocol providing for enteral nutrition in 
neonatal ECMO patients. Except our previous data and those from Pettignano et al.16 in 
pediatric ECMO patients, there are no data on the effects of enteral nutrition in newborns 
during ECMO.2  
 
Therefore, we evaluated the use of enteral nutrition in neonates receiving VAECMO at 
our institution. We hypothesized that enteral nutrition in neonates on ECMO is feasible 
and tolerated without major complications. 
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Patients and methods 
 
From January 1997 till January 2002, 112 neonates in our pediatric surgical intensive 
care unit were treated with VA-ECMO, of whom 82 (73.2%) survived. According to the 
Dutch law, there is no need for Institutional Review Board approval in cases of a 
retrospective chart review. Indications for ECMO were derived from the “classic” criteria 
of the Children National Medical Center ECMO Team, which remained unchanged during 
the study period.17 We excluded from analysis 35 patients with a congenital 
diaphragmatic hernia who received ECMO before surgery because hospital practice 
dictates continuous suctioning of the nasogastric tube during ECMO and surgical repair 
following decannulation. In ten of the 77 remaining patients, enteral nutrition was 
withheld for various reasons. In three of them, once a stable situation was obtained and 
enteral nutrition could be introduced, weaning from ECMO had already started and the 
decision was made to start enteral nutrition following decannulation. One remained 
hemodynamically instable and developed severe intracerebral bleeding, after which the 
ECMO run had to be stopped and the patient died. Two other patients had ongoing 
stomach retentions before introduction of enteral nutrition, and in four patients the 
clinician in charge preferred to withhold enteral nutrition. Hence, 67 patients were 
included for analysis (Fig. 1).  
 
 
Figure 1 Flow-sheet of included and excluded patients. ECMO, extracorporeal membrane 
 oxygenation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Eligible patients 
112 
Congenital 
Diaphragmatic 
Hernia  
35
Study group 
67 
No enteral feeding 10 
-short ECMO-run (n = 3) 
-hemodynamic instability (n = 1) 
-stomach retentions (n = 2) 
-clinician’s preference (n = 4) 
Patients considered 
for enteral nutrition 
77 
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Feeding Regimens 
By protocol, all patients received continuous morphine (10 - 20 µg/kg/hr) and midazolam 
(0.1 - 0.2 mg/kg/hr) infusions. They routinely received infusions with glucose 10%, and 
total parenteral nutrition was introduced 24 hrs after initiation of ECMO. Total parenteral 
nutrition consisted of a combination of glucose 10% with 10% amino acids (Aminovenös 
N-paed 10%, Fresenius, the Netherlands) and lipids 20% (Intralipid 20%, Pharmacia 
Upjohn, the Netherlands). Hospital protocol dictated half the amounts of amino acids and 
lipids on the first day, 12 ml/kg/24 hrs and 6 ml/kg/24 hrs, respectively. On the second 
day, glucose with amino acids was given at 24 ml/kg/24 hrs and lipids 20% at 12 
ml/kg/24 hrs. Enteral feeding regimens were not strictly protocolized, but enteral nutrition 
was usually introduced when a hemodynamically stable situation on ECMO was reached 
without stomach retention. Stomach retention was then measured every 2 hrs. All 
patients had nasogastric or occasionally transpyloric feeding tubes in place before 
initiation of ECMO. The physician in charge decided the volume of enteral nutrition to be 
given. In principle, the concept of minimal enteral feeding was applied to the first 24 hrs, 
after which amounts were increased daily taking fluid restrictions into account. In 
general, the policy regarding fluid intake in neonates on ECMO dictates a maximum of 
100 ml/kg/ day (blood- and platelet transfusions not included).  
 
Breast milk was advocated as the primary source of food in all children. If not available, a 
regular infant formula was given, Nutrilon Premium (Nutricia, Zoetermeer, the 
Netherlands).  
 
Outcome 
We retrieved each patient’s birth weight, gestational age, diagnosis, age at initiation of 
ECMO, duration of ECMO treatment, and time elapsed from the start of ECMO to 
introduction of enteral nutrition. We also recorded daily intakes of enteral nutrition and 
maximum administered amounts of vasopressor drugs during enteral nutrition. 
Approximately 20% of the fluid intake is provided with continuous medication, leaving 
80% available for nutrition. Feasibility was evaluated by recording the time period 
needed for enteral nutrition to reach 40% (half of the amount available for nutrition) of 
total fluid intake.  
 
Tolerance was evaluated by recording symptoms of stomach retention, bilious vomiting, 
aspiration, and NEC-related symptoms such as blood-stained stool, abdominal 
distention, and number of positive blood cultures during ECMO.  
 
Statistical Analysis 
Data are presented as median with the interquartile range (IQR). Changes in feasibility 
over the years were analyzed with a Cox regression analysis using 1997 as year of 
reference. A univariate analysis of variance was performed to compare time of onset of 
enteral nutrition over the years.  
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The influence of various variables on feeding intolerance was evaluated by logistic 
regression analysis. Factors included in the analysis were Apgar scores at 1 and 5 mins, 
gestational age, time to beginning enteral feeding, use of vasoactive drugs, morphine 
dosage, and type of feeding tube. A Spearman correlation was performed to study the 
relationship between dopamine and volume of stomach retention.  
 
 
Results 
 
The underlying diagnoses of the 67 enrolled neonates who received enteral nutrition in 
the period 1997 - 2002 are presented in Table 1. Their median gestational age was 40 
(IQR, 38 - 42+6) wks with a median birth weight of 3300 (IQR, 2885 - 3700) g. Six of the 
67 patients died: five before the age of 30 days and one at the age of 38 days. The 
median duration of ECMO treatment was 7 (IQR, 5 - 9) days. The median intensive care 
unit stay was 15 (IQR, 11 - 20) days. 
 
 
Table 1  Underlying Diagnosis 
 No. 
Meconium aspiration syndrome 39 
Persistent pulmonary hypertension of the Neonate 14 
Sepsis 7 
Pneumonia 4 
Congenital cystic malformation of the lung 2 
Pertussis 1 
Total 67 
 
 
Start and Amount of Enteral Nutrition 
At the start of enteral nutrition, the median ECMO flow was 280 (IQR, 180 - 360) ml/min. 
Over the 5-yr period, enteral nutrition was started at a median of 45 (IQR, 23 - 41) hrs 
after start of ECMO. In 58 of the 67 patients (87%), gastric feeding tubes were in place. 
Nine patients received enteral nutrition through a transpyloric feeding tube.  
 
On the first day of enteral nutrition, feeds were given as an hourly bolus of 1 - 4 ml, in 
50% of the cases. However, amount and frequency ranged from 8 times 1 ml to 24 times 
10 ml on the first day. The amount was daily increased by clinician preference toward a 
maximum ranging from 8 times 35 ml to 24 times 15 ml on the fourth day.  
Over the course of ECMO therapy, every child received bolus feeds. 
 
Feasibility 
Figure 2 shows the mean amounts of enteral nutrition, parenteral nutrition, and 
continuous medication as a percentage of the total fluid intake per day.  
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Figure 2 Interval between start of extracorporeal membrane oxygenation (ECMO) and start of  
 enteral nutrition in hours together with the percentage of patients receiving nutrition. 
 
 
Thirty-six of the 67 (54%) neonates reached 40% of total fluid intake as enteral nutrition, 
at a median of 3 (range, 2 - 4) days. A Cox regression analysis showed that only in the 
year 2000, the relative risk for enteral nutrition to reach 40% of the total fluid intake was 
5.5 (95% confidence interval, 1.9 - 15.8) times higher than in 1997 (p = .002).  
The median interval between start of ECMO and start of enteral nutrition decreased 
significantly from 67 (IQR, 48 - 88) hrs in 1997 to 37 (IQR, 30 - 43) hrs in 2000 and to 40 
(IQR, 34 - 54) hrs in 2001 (analysis of variance, p = .0001). Over the years there was a 
trend toward an increasing usage of enteral nutrition from 71% to 94% (Fig. 3; Chi-
quadrate test, p = .07). 
 
Tolerance 
In 14 patients, enteral feeding was discontinued because of gastric retentions. They 
showed a median of 9 (IQR, 5 - 14) ml of retention the moment enteral feeding was 
discontinued for a median period of 24 (IQR, 12 - 47) hrs (Table 2).  
 
In four patients, feeding was not successfully resumed during ECMO. In one other 
patient, enteral feeding was discontinued for 8 hrs because of discomfort, without 
stomach retentions. In one other patient, enteral feeding was stopped because milk was 
aspirated from the endotracheal tube. This did not result in a clinically documented 
aspiration pneumonia with a prolonged ECMO run.  
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Figure 3 Parenteral and Enteral nutrition as mean percentages of the total fluid intake. ECMO, 
 extracorporeal membrane oxygenation. 
 
  
Symptoms of bilious vomiting, bloodstained stools, or abdominal distension had not been 
noted in any of the 67 patients. In all cases, enteral nutrition was discontinued 
approximately 2 hrs before decannulation and successfully restarted thereafter.  
 
The influence of Apgar scores at 1 and 5 mins, gestational age, time to beginning of 
enteral feeding, use of vasoactive drugs, morphine dosage, and type of feeding tube on 
feeding intolerance was evaluated by logistic regression analysis. None of the predictors 
had a significant influence on feeding intolerance (chisquare 6.165; df 8; p = .63).  
 
Use of Vasoactive Drugs 
Dopamine was given to 80% of patients on enteral nutrition during ECMO. The median 
amount was 7 (IQR, 3 - 10) µg/kg/min, with a maximum of 20 µg/kg/min.  
 
 
Table 2 Enteral feeding related morbidity 
  
No. 67 
Median time-period to stop enteral 
 nutrition in hrs (range) 
Gastric Retentions (median 9 ml, range 4 - 31ml) 14 24 (range 8 - 60) 
Discomfort 1 8 
Aspiration 1 Not resumed during ECMO 
Positive blood cultures with enteric bacterium 1  
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Dopamine together with dobutamine (5 µg/kg/min) was given in three of the patients and 
together with noradrenaline (0.5 µg/kg/min) in four other patients. They were added near 
the end of an ECMO run.  
 
There was no significant correlation between volume of stomach retention and the 
dosage of dopamine at the moment enteral nutrition was discontinued because of 
stomach retentions (Spearman correlation -.06, p = .8).  
 
Sepsis-Related Morbidity 
From the daily routinely taken blood cultures of the ECMO system, 13 were positive in 13 
different patients. One blood culture revealed Enterococcus faecalis. The other 12 blood 
cultures revealed Staphylococcus epidermidis. Three were considered contaminants in 
the absence of clinical and biochemical signs of sepsis. All other patients were treated 
with antibiotics successfully. Enteral nutrition was never discontinued because of a 
positive blood culture. 
 
 
Discussion 
 
In this study we evaluated feasibility and tolerance of routine enteral nutrition in neonates 
on VA-ECMO during a 5-yr period. We found that enteral nutrition was well tolerated and 
that no major complications occurred. Over the years, enteral nutrition was introduced 
approximately 1.5 day sooner after the start of ECMO and there was a tendency toward 
a greater proportion of patients receiving enteral nutrition. In 54% of the patients, enteral 
nutrition reached 40% of the total fluid intake within a median time of 3 (range, 2 - 4) 
days.  
 
For several reasons (i.e., concern about inadequate gut perfusion, caused by absence of 
pulsatility, vasoconstrictive effects of many vasopressor drugs used pre-ECMO, and 
hypoxia), ECMO centers commonly withhold enteral nutrition. However, 80% of our 
ECMO patients who were fed enterally received dopamine. Clinically, negative effects on 
gut function in these patients were not noted. Also, the use of inotropic drugs did not 
correlate with the amount of retention. 
 
To our knowledge there are no reports on feasibility and safety of routine enteral nutrition 
in newborn ECMO patients. Pettignano et al.16 reported their experience with enteral 
nutrition in 13 pediatric ECMO patients with a median age of 72 months. Enteral nutrition 
was well tolerated, and patients obtained adequate nutrition within 4 days without 
developing major complications.16  
 
Although the majority of the patients described by Pettignano et al. (69%) were treated 
with venovenous ECMO, preserving pulsatile blood flow to the gastrointestinal tract, all 
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our patients were treated with VA-ECMO. Still, we noted no major complications such as 
bloodstained stool or other NEC-related symptoms.  
 
However, enteral feeding was temporarily stopped because of gastric retentions in 14 
(21%) neonates. A study conducted in preterm neonates receiving enteral nutrition while 
low umbilical artery catheters were in place showed a 14% incidence of gastric 
residuals.18 A proportion of 15% with feeding intolerance was reported by Pettignano et 
al.16 Our patients did not receive any prokinetic medication, unlike the patients in the 
study of Pettignano et al. In 71% of our patients, enteral feeding could be successfully 
reintroduced after a median of 24 hrs, still during ECMO. It is questionable whether our 
policy to withhold enteral feeding for as long as 24 hrs is justified. To answer this 
question, we need to better document retention volumes in relation to amount of enteral 
nutrition and also the standard use of prokinetic drugs in this special group of patients.  
 
Fluid intake restriction is a known barrier to adequate nutrition in critically ill children.19 
Neonates on ECMO have a restricted fluid intake of 100 ml/kg/day. Given the fact that 
approximately 20% of the fluid intake was provided with continuous medication such as 
furosemide, midazolam, and morphine, 80% was available for nutrition (Fig. 3). Providing 
half of the amount available for nutrition by enteral nutrition seemed a feasible goal. 
However, this was reached in 54% of the neonates. One might expect that over the 
years increasing experience should have led to higher proportions reaching this goal; 
however, this was only true in 2000. The one trend observed over the years was a 
decrease in the median interval between start of ECMO and start of enteral nutrition.  
 
The incidence of positive blood cultures in our patients was 19%. This was higher than 
the 6.5% overall incidence of culture-proven infections mentioned in the ELSO registry 
report.1 A previous report from us on septic complications in neonates on ECMO did not 
show any influence of the feeding route, that is, parenteral vs. enteral nutrition.20 
Coagulase- negative staphylococci were the microorganisms cultured most frequently. 
There was only one positive blood culture with E. faecalis in which gut mucosal integrity 
and bacterial translocation may have played a role.  
 
 
Conclusions 
 
We found that over a 5-yr period, enteral feeding was well tolerated and not associated 
with serious adverse effects. Overall, it is our experience that routine use of enteral 
feeding in critically ill neonates on VA-ECMO is feasible. In fact, they could benefit from 
the early introduction of enteral nutrition because it plays an important role in the 
maintenance of gut mucosal integrity and has been associated with improved 
gastrointestinal immunologic function and reduced septic morbidity, in both adults and 
children.7,8,21 An additional advantage is cost reduction.  
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However, we are aware that the retrospective nonrandomized nature, the lack of a 
comparison group of parenterally fed neonates, and the absence of available information 
on caloric intake and uptake in this study could limit the interpretation of the results.  
 
Nevertheless, our findings in these 67 patients lead us to suggest that the introduction of 
enteral nutrition in neonates on ECMO between 24 and 48 hrs after the start of ECMO is 
a safe procedure, provided patients do not show gastric retentions. With restriction of a 
maximum fluid intake of 100 ml/kg in neonates on ECMO, it seems reasonable to 
achieve approximately 50% of the nutritional fluid intake for enteral nutrition within 3 
days. Future studies should focus on the caloric intake and protein uptake in ECMO 
patients receiving enteral nutrition.  
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Abstract 
 
Objectives 
The objective of this study was to gain insight into the hormonal responses to enteral 
nutrition in critically ill newborns requiring venoarterial extracorporeal membrane 
oxygenation (ECMO) by analyzing plasma gut hormone levels of gastrin, cholecystokinin 
and peptide-YY in relation to enteral nutrition.  
 
Methods 
In 24 consecutive neonates treated with venoarterial ECMO intestinal hormone 
secretions were determined by radioimmunoassay at 2-day intervals. Twelve received 
parenteral nutrition only. In 12 enteral nutrition was introduced later. The findings in these 
patients were compared with those of 16 measurements in eight non-ECMO treated age-
matched controls. Mixed model analysis of variance was used for statistical analysis.  
 
Results 
Concentrations of gastrin, cholecystokinin and peptide- YY were significantly higher in 
ECMO patients receiving enteral nutrition compared with ECMO patients who received 
parenteral nutrition (62, 3.8 and 59.4 pmol/l versus 46, 3.1 and 34.7 pmol/l, respectively). 
Overall, plasma hormone levels did not differ from those in age-matched controls.  
 
Conclusions 
Intestinal hormone levels showed normal responses after introduction of enteral feeding, 
comparable with those in age-matched controls without ECMO. These results do not 
provide an argument for withholding enteral nutrition even in the most severely ill 
neonates on venoarterial ECMO.  
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Introduction 
 
Gut hormones are regulatory peptides produced in endocrine cells in the gastrointestinal 
mucosa that control gastrointestinal function, including motility, intestinal fluid secretion, 
blood flow, absorption and immunity.1 They may be instrumental in stimulating structural 
and functional changes occurring in the gut and other organs when adapting to enteral 
nutrition.2-4 Term and preterm infants experience major plasma hormone surges in the 
neonatal period.2 However, Lucas et al. found that these did not occur in infants deprived 
of enteral feeding, suggesting that plasma hormone elevation after birth is related to 
feeding rather than to postnatal age.3 In fact, even very small quantities of enteral 
nutrition induced significant elevations of gut hormones in neonates.3 They suggested 
that infants dependent on total parenteral nutrition from birth might benefit from the 
biologic effects of this ‘‘minimal enteral feeding’’ concept, but further investigations in 
critically ill term and preterm neonates is warranted.3  
 
Centers providing extracorporeal membrane oxygenation (ECMO) in critically ill 
newborns usually withhold enteral substrate from these neonates and feed them 
parenterally. ECMO is a method of providing life support in severe but potentially 
reversible respiratory or cardiac failure, used particularly in mature newborn infants. 
Conditions most commonly treated with ECMO in the neonatal period are meconium 
aspiration syndrome, primary or secondary persistent pulmonary hypertension of the 
newborn, congenital diaphragmatic hernia, sepsis and pneumonia.  
 
Enteral nutrition may be withheld from these patients for various reasons, such as the 
notion that splanchnic circulation may be adversely affected both by hypoxic periods and 
by the need for vasopressor therapy before ECMO. The splanchnic circulation is also at 
risk of inadequate perfusion during cardiopulmonary bypass.5 Disturbed splanchnic 
circulation may lead to intestinal ischemia, which in its turn increases the chance of 
developing necrotizing enterocolitis and facilitates bacterial translocation and eventually 
sepsis.6-8 It is not known whether intestinal hormone secretion is also affected in these 
patients. As ECMO can be considered a very prolonged bypass procedure, it carries a 
risk of abnormal gut hormone profiles. In fact, plasma hormone levels are expected to be 
decreased and remain so after enteral nutrition is introduced.  
 
In our ongoing research on gut function in critically newborns and children we evaluated 
intestinal permeability in ECMO patients. We also evaluated gut responses to starvation 
and reintroduction of enteral feeding both in premature neonates with NEC and in term 
born infants. Intestinal integrity, as evaluated by sugar absorption tests, was 
compromised in ECMO patients but did not deteriorate after introduction of enteral 
nutrition.9,10 After these prospective evaluations we developed a protocol using enteral 
nutrition as a standard in neonatal ECMO patients. Other than our previous data and 
those from Pettignano et al. in pediatric ECMO patients, there are no data available on 
gut function or the effect of enteral nutrition during ECMO.11,12  
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The aim of the present study was to gain more insight into the hormonal responses of the 
gut in neonates requiring venoarterial ECMO. We hypothesized that plasma gut hormone 
levels in patients on ECMO would be lower with a decreased response to enteral 
nutrition. Plasma concentrations of gastrin (mainly produced in the gastric antrum), 
cholecystokinin (CCK, produced in the duodenum and jejunum) and peptide-YY (PYY, 
produced in the ileum and colon) were analyzed in neonates during enteral nutrition and 
during parenteral nutrition. Findings from these neonates were compared with findings in 
age-matched controls.  
 
 
Materials and methods 
 
Patients 
In 24 consecutive ECMO patients, plasma concentrations of gastrin and CCK and PYY 
levels were determined in all patients during a period of parenteral nutrition and in 12 of 
the 24 patients during a period of enteral nutrition after informed consent (Fig. 1).  
 
Allocation to enteral or parenteral feeding in this group of 24 patients was not 
randomized but based on the underlying disease. For instance, patients with congenital 
diaphragmatic hernia, all subjected to continuous suctioning of the nasogastric tube as 
part of a delayed surgical approach, were given total parenteral nutrition.  
 
All patients had nasogastric feeding tubes in place before initiation of ECMO. Enteral 
nutrition was initiated at 24 x 1 ml and was increased each day by 0.5 - 1 ml.kg-1.h-1 as 
tolerated. Breast milk was advocated as the primary source of food in all children. If not 
available, a regular infant formula was given (Nutrilon Premium; Nutricia, Zoetermeer, 
the Netherlands).  
 
 
Figure 1    Flow chart showing number of patients and number of blood samples drawn. 
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In addition, plasma concentrations of gastrin, CCK and PYY were measured during 
starvation and during enteral nutrition in eight control patients matched for birthweight 
and gestational age who underwent thoracic surgery for major congenital anomalies, 
such as esophageal atresia.  
 
Hormone Analysis  
Every other day at 8:00 AM 3-ml arterial blood samples were drawn and collected in 
glass tubes containing ethylene diamine tetra-acetate. Samples were centrifuged within 
30 minutes of sampling and plasma was stored at -80°C until assayed.  
 
Gastrin, CCK and PYY were all measured by radioimmunoassay as described 
previously.13-19 The antibody used for measurement of gastrin was raised in rabbits.15,17 
Directed towards the COOH-terminal bioactive site of sulfated and nonsulfated gastrins, 
it binds gastrin-17 and gastrin-34 with almost equal affinity. Cross-reaction with 
structurally related cholecystokinin and unrelated peptides was absent or negligible.15,17 
The intra-assay variation was below 10% in the working range of the standard curve. The 
detection limit of the assay was 0.1 pmol/l of incubation mixture. The antibody used for 
measurement of CCK was also raised in rabbits.13,14 It binds with almost equal affinity to 
biologically active CCK peptides containing the sulfated tyrosine region. It shows less 
than 2% cross-reactivity with sulfated gastrins and does not bind to unsulfated forms of 
gastrin or structurally unrelated peptides, like insulin, secretin, pancreatic polypeptide, 
bombesin and neurotensin. The detection limit of the assay was between 0.5 and 1.0 
pmol/l CCK in plasma. The intra-assay precision ranged from 4.6% to 11.5% in the steep 
part of the standard curve.  
 
PYY was measured in plasma by a recently described, sensitive and specific 
radioimmunoassay.18,19 The antibody used in the PYY-assay was raised in hens and 
binds to PYY1-36 and PYY3-36 with almost equal affinity.18 Although there is no detectable 
cross-reactivity with the structurally related peptide pancreatic polypeptide, cross-
reactivity with neuropeptide Y is negligible. The antibody does not cross-react with 
unrelated peptides.18 The detection limit of the assay is obtained at a final concentration 
in the incubation mixture of 0.3 pmol/l. Intra-assay variation ranges from 6% to 11% in 
the working range of the assay.  
 
Statistical Analysis  
All data are presented as median with range unless stated otherwise. The effect of 
enteral feeding on gut hormone levels, both in ECMO patients and controls, was 
evaluated by calculating the ratios of the geometric means (enteral feeding versus 
parenteral feeding). Groups were compared using mixed model analysis of variance. 
Differences were considered statistically significant when p < 0.05.  
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Results 
 
From a group of 24 ECMO-patients 75 blood samples were taken to determine plasma 
gastrin, CCK and PYY concentrations. Patient characteristics and underlying diagnoses 
are presented in Table 1. Fifty-one samples were drawn during total parenteral nutrition: 
14 of these from 12 patients in whom enteral nutrition was started later (Fig. 1). The 
median postnatal age of these 24 patients at time of sampling was 5 days (range, 1 - 19 
days). Twenty-four samples were drawn after start of enteral nutrition in 12 patients 
(median postnatal age at time of sampling 8 days; range, 3 - 13 days). The median 
(interquartile range) amount of enteral nutrition as a percentage of the total fluid intake 
was 10% (6% to 25%) at time of sampling.  
 
Plasma concentrations of gastrin, CCK and PYY were significantly higher in patients fed 
enterally; p = 0.04, p = 0.047 and p = 0.022, respectively (Table 2). Figures 2 through 4 
show the median gut hormone levels per day of age during enteral nutrition and 
parenteral nutrition. The median age of onset of enteral nutrition was 4 days (range, 3 to 
9 days).  
 
 
Table 1 Patient Characteristics of 24 ECMO-patients  
Birthweight, median (grams) (range)  3245 (2150 - 4500) 
Gestational age, median weeks (range)  40 + 5 (37 ± 1 - 42 ± 2) 
Underlying diagnosis  
 Congenital Diaphragmatic Hernia 6 
 Meconium Aspiration Syndrome 11 
 Persistent Pulmonary Hypertension of the Neonate 4 
 Sepsis 2 
 Pulmonary bleeding 1 
 
Values are number of patients unless otherwise indicated. 
ECMO  extracorporeal membrane oxygenation. 
 
 
Table 2 Gut hormone plasma concentrations in 24 ECMO-patients 
 Gastrin 
(pmol/l) 
Cholecystokinin 
(pmol/l) 
Peptide-YY 
(pmol/l) 
Enteral nutrition (n = 24) 62.0 (45.3 - 95.8) 3.8 (2.9 - 4.8) 59.4 (43.0 - 75.6) 
Total parenteral nutrition (n = 51) 46.0 (33.0 - 60.0) 3.1 (2.5 - 3.8) 34.7 (26.7 - 54.7) 
Ratio of geometric mean 1.4 1.2 1.3 
 p = 0.04 p = 0.047 p = 0.022 
 
Plasma levels are expressed as median (range). 
ECMO  extracorporal membrane oxygenation. 
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Figure 2 Mean Cholecystokinin plasma levels per day of age 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Mean Gastrin plasma levels per day of age 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 Mean Peptide-YY plasma levels per day of age 
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Eight of the 12 enterally fed patients (17 measurements) were fed with breast milk, three 
patients (six measurements) received standard formula and in one measurement the 
patient was given a combination of breast milk and standard formula. The plasma 
concentrations of CCK, gastrin and PYY in breast milk-fed patients did not differ 
significantly from those in patients given standard formula. Median CCK plasma 
concentration was higher in breast milk-fed patients (3.8 versus 3.4 pmol/l (p = 0.4). 
Median PYY and gastrin concentrations were lower in breast milk-fed patients (58 versus 
61.5 pmol/l (p = 0.9) and 58.2 versus 60.8 pmol/l (p = 1.0) respectively).  
 
Plasma gastrin, CCK and PYY concentrations were also measured after surgery in 16 
blood samples from eight age-matched control patients who underwent thoracic surgery. 
Birthweight and age did not differ from those in the 24 ECMO patients. Nine samples 
were drawn during starvation and seven during enteral nutrition at a median postnatal 
age of 6 days (range 1 - 20 days). Median plasma concentrations are presented in 
Table 3. Plasma gastrin, CCK and PYY concentrations were higher in patients fed 
enterally, but differences were not significant (Table 3). During enteral feeding gastrin 
and PYY concentrations were lower in surgical patients, but CCK concentration was 
lower in ECMO patients. Plasma gut hormone concentrations in surgical patients showed 
the same trend as in patients on ECMO; they all increased after start of enteral nutrition. 
In surgical patients CCK and PYY levels seem to increase more than in ECMO patients; 
however, without reaching significant difference (CCK, 1.7 versus 1.2; p = 0.6; PYY, 1.9 
versus 1.3; p = 0.3).  
 
 
Table 3 Gut hormone plasma concentrations in 8 thoracic surgery patients 
 Gastrin 
(pmol/l) 
Cholecystokinin 
(pmol/l) 
Peptide-YY 
(pmol/l) 
Enteral nutrition  
 (n = 7) 
41 (31 - 106) 3.7 (2.2 - 30.3) 61.1 (21.6 - 147) 
Total parenteral nutrition  
 (n = 9) 
25 (13 - 620) 2.1 (1.5 - 7.2) 32.6 (17 - 44.4) 
Ratio of geometric mean 1.4 1.7 1.9 
 p = 0.33 p = 0.44 p = 0.057 
Plasma levels are expressed as median (range) 
 
 
Discussion 
 
In this study we measured gut hormone profiles in neonates on ECMO fed enterally and 
we found a normal pattern in comparison with age-matched controls. Differences 
between patients fed with breast milk or standard formula were not statistically 
significant.  
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However, as allocation to enteral or parenteral feeding in determining plasma hormone 
concentrations was not randomized but based on the underlying diseases, the results 
may be biased. Patients with congenital diaphragmatic hernia, for instance, are given 
total parenteral nutrition during the entire ECMO period because our protocol dictates 
closure of the diaphragm after successful decannulation.  
 
Few data are available on gut hormone levels in patients with impaired intestinal 
function. In 1997 Gounaris et al. found these to be low in premature patients with 
necrotizing enterocolitis.20 We previously reported increased CCK and PYY levels in 
premature infants with an ileostomy after necrotizing enterocolitis and reintroduction of 
enteral nutrition.10 Median plasma gastrin, CCK and PYY levels of the ECMO patients in 
our study were in the same range as those in healthy neonates in previous studies.20-24 
However, taking into account the substantial inter-laboratory variation of 
radioimmunoassay for gastrin, CCK and PYY, comparison with absolute values reported 
in the literature is not directly feasible.22,23 For this reason we measured gut hormone 
levels of age-matched patients after thoracic surgery using the same radioimmunoassay 
in the same laboratory. These levels were not consistently higher than the gut hormone 
levels measured in patients on ECMO. Mean hormone levels during total parenteral 
nutrition and mean gastrin and PYY levels after start of enteral nutrition were even higher 
in patients on ECMO. A recent study performed at our institution with the use of the 
same radioimmunoassay revealed similar gut hormone profiles in neonates after bowel 
surgery for congenital intestinal anomalies and in age-matched controls who underwent 
surgery for other reasons.25  
 
The plasma gut hormone levels in patients receiving enteral nutrition showed great 
variability. Secretion of gut hormones is influenced by various factors. In adults, the 
concentration of gastrin increases in response to protein-enriched feeds with a peak 
concentration within the first hour after a meal. CKK concentrations also rise after a 
protein or fat enriched meal. Once feeding is interrupted, concentrations decrease to 
preprandial levels within approximately 30 minutes. PYY-levels increase after a fat 
enriched meal, although slower, and concentrations of PYY remain higher for a few 
hours after a meal.26,27 Studies in newborns by Lucas et al. showed similar findings: 
plasma concentrations increase with increasing intake, and hormone release in 
continuously fed infants differs from that in intermittently fed infants, who have a cyclic 
hormone release.28 Neonates in this study received different amounts of enteral nutrition 
varying from 24 x 1 ml to 24 x 15 ml at time of sampling. Although blood samples were 
taken at a fixed time point in the morning, time between feeding and sampling could still 
vary. This best explains the variability in plasma concentrations.  
 
In 1993 Marchini et al. found significantly higher CCK levels in breast-fed infants 
compared with formula-fed infants during the first 5 days of life.22 We did not find any 
statistical differences between these groups. Failure to reach statistical significance 
might be attributable to the fact that ECMO patients did not receive their total intake as 
enteral nutrition (i.e., 10% of their total fluid intake) and the amount of milk ingested 
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cannot be excluded as an important factor for the level of hormone secretion. In contrast, 
in Marchini et al.’s study all patients received total enteral nutrition.  
 
In conclusion, we found no evidence that previous respiratory and circulatory failure and 
nonpulsatile blood flow during ECMO negatively affected gut hormone secretion in term 
critically ill neonates. Gut hormone secretion normally increases after the introduction of 
minimal enteral feeding. Thus, our study does not provide an argument to withhold 
enteral feeding in critically ill neonates on venoarterial ECMO, as has been common 
practice in many ECMO centers because of the fear of intestinal ischemia and eventually 
the development of necrotizing enterocolitis. However, there is no conclusive evidence 
for this policy. In fact, critically ill neonates may benefit from the early introduction of 
enteral nutrition, as it is instrumental in the maintenance of gut mucosal integrity and has 
been associated with improved gastrointestinal immunologic function and reduced septic 
morbidity both in adults and children.29-31 A vigorous enteral feeding protocol has been 
instituted in our hospital in an attempt to replace the use of total parenteral nutrition with 
its intrinsic morbidity. 
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Abstract 
 
Background 
The authors noticed a relatively large number of patients with congenital diaphragmatic 
hernia (CDH) repair after extracorporeal membrane oxygenation (ECMO) who had a 
chylothorax (CT). The data are reviewed. 
 
Methods 
The charts of patients from 1990 until 2000 with CDH, treated with or without ECMO, 
together with the charts of patients treated with ECMO for other reasons and patients 
with esophageal atresia (EA) repair were reviewed. The diagnosis of CT was made if 
aspirated fluid appeared chylous and contained more than 90% lymphocytes or if the 
triglyceride level was more than 1.50 mmol/l. 
 
Results 
Eighty-nine patients with CDH were analyzed. Postoperatively, 10% had a CT—21% in 
CDH patients with ECMO treatment and 6% in CDH patients without ECMO treatment. 
This difference appeared to be significant (p < .05). The presence of a patch as 
independent variable for the development of CT also showed significance (p < .05). 
 
Conclusions 
Chylothorax presented in almost all cases as a left-sided fluid accumulation, and a patch 
was present in the majority of patients with CDH. Therefore, CT should be considered 
the result of the severity of the defect rather than the consequence of ECMO as a 
therapeutic modality. 
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Introduction 
 
Over the years the treatment of congenital diaphragmatic hernia (CDH) has changed its 
focus from immediate surgery towards a delay in surgery until the child is stable, with 
increasingly lower mortality rates in recently published series.1-3  
 
Extracorporeal membrane oxygenation (ECMO) is used in these children as one of the 
treatment modalities. This technique of cardiopulmonary bypass allows support of the 
infant and concomitant lung "rest". It is mainly aimed at overcoming the reversible 
components of pulmonary hypertension and improving lung compliance. The 
postoperative course of CDH repair can be complicated by an ipsilateral pleural 
effusion.4 This may be because of fluid filling the space resulting from removal of the 
herniated viscera in combination with a not fully expanded lung. An alternative 
explanation holds that the effusion is caused by a chylothorax (CT), resulting from 
trauma to the diaphragmatic lympathics during surgery.5 We noticed a relatively large 
number of chylothorax in patients with CDH repair after ECMO. For that reason, we 
reviewed our data and compared them with the occurrence of a CT after CDH repair 
without ECMO or after repair of esophageal atresia to evaluate whether ECMO results in 
a higher risk for the development of CT.  
 
 
Materials and methods 
 
We conducted a chart review of all patients with CDH admitted to the pediatric surgical 
intensive care unit at the Erasmus MC-Sophia from January 1, 1990 until January 1, 
2001. This unit functions as one of the 2 regional ECMO centers in the Netherlands. We 
also studied the charts of patients treated with veno-arterial ECMO for reasons other 
than CDH from the same period. To evaluate the effect of a thoracotomy with potential 
damage to the lymphatic drainage as a cause of CT in children, newborns with EA also 
were evaluated. Age, gender, birth weight, side of the hernia, indication for ECMO 
treatment, duration of ECMO treatment, and the use of prosthetic material for hernia 
repair, indicating a larger defect, were noted. We created 4 groups of patients: CDH and 
ECMO treatment, CDH without ECMO treatment, ECMO for reasons other than CDH, 
and patients after esophageal atresia repair.  
 
The treatment protocol for patients with CDH in our institution has been published before 
and consists of delayed surgery, inhaled nitric oxide (NO) and high-frequency oscillation 
(HFO) since 1999.6 Operative repair is performed routinely after successful decanulation 
from ECMO.  
 
The diagnosis of a chylothorax (CT) was made if a pleural effusion appeared chylous in 
enterally fed infants and if the fluid contained more than 90% lymphocytes or if the 
triglyceride level was more than 1.50 mmol/l.5,7  
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We traced 141 patients admitted for CDH in the study period, including patients with 
major congenital anomalies, prenatal diagnosis, and those who died within one hour after 
birth because of extreme pulmonary hypoplasia. Forty-nine (35%) patients died before 
surgical repair of the CDH. Three charts were not available for review, leaving 89 
patients for analysis. Of these patients 65 (73%) were treated without ECMO, and 24 
(27%) were treated with ECMO.  
 
In the same time span there were 114 patients treated with ECMO for reasons other than 
CDH (Table 1). In the same period, 118 patients with an EA underwent surgical 
correction. The charts of 15 patients were not available for review. Three patients died 
before surgical repair of the EA, leaving 100 patients for analysis. The patient 
characteristics show that non-CDH ECMO patients were significantly older and had a 
higher birth weight because of inclusion criteria for ECMO. CDH patients with or without 
ECMO were comparable for age, birth weight, and gender. EA patients were significantly 
younger and had lower birth weight than CDH patients (Table 2).  
 
Groups were compared, and differences were examined for statistical significance using 
the X2 or Fischer's Exact test as appropriate. p less than .05 was considered statistically 
significant. 
 
 
Table 1 Underlying diagnosis in patients treated with ECMO, excluding CDH 
Meconium aspiration syndrome 64 (56%) 
Persistent pulmonary hypertension of the newborn 25 (22%) 
Sepsis 14 (12%) 
Pneumonia 7 (6%) 
Other 4 (4%) 
Total 114 (100%) 
 
 
 
Table 2 Patient characteristics per group 
 CDH repair 
and ECMO 
CDH repair 
without ECMO 
EA repair ECMO  
for other reasons
Male 15 38 67 60 
Female 9 27 33 54 
Gestational age (wk) 39 + 1 38 + 5 37 + 2* 39 + 3† 
Birth weight (g) 3,087 3,095 2,495* 3,364† 
* Significantly lower than the other three groups 
† Significantly higher than the other three groups 
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Results 
 
Eighty-nine patients with a CDH underwent surgical repair. Sixty-nine of the defects 
(78%) were left sided, which is similar to that reported by Clark et al.8 In 41 of the 89 
patients (46%) the defect in the diaphragm was closed with a patch. This was in 21 of 24 
patients (88%) treated with ECMO and in 20 of the 65 CDH patients (31%) not treated 
with ECMO (Fig. 1). Postoperatively, 9 infants (10%) had a chylothorax—all but one on 
the side of the hernia. Five of the 24 CDH and ECMO group had a CT (21%). Four of the 
65 CDH patients not treated with ECMO had a CT (6.2%; Fig. 2). In the five CDH and 
ECMO patients, the mean age at operative repair was 11 days (range, 3 to 29 days), 
mean duration of ECMO therapy was 160 hours (range, 95.5 to 308.5 hours). Drainage 
was first required at a median of 10 days (range, 3 to 22 days) postoperatively. In all 
cases, treatment consisted of continuous drainage of the CT, with a mean of 9 days 
(range, 2 to 12 days). Three of the 5 children received a formula containing only medium-
chain triglycerides (Caprilon; Nutricia, Zoetermeer, The Netherlands) for approximately 6 
weeks, one of them after a 12-day period of cessation of enteral feeding. One child did 
not receive Caprilon because there was uncertainty about the diagnosis of CT. Once 
enteral feeding was introduced, and the aspect became more chylous, the drain 
production had already decreased and stopped spontaneously. Another child did not 
receive enteral nutrition because in the same period she underwent surgery for a bowel 
obstruction. Once normal milk formula was introduced, the chylothorax had already 
disappeared. In the 4 CDH patients without ECMO treatment, the median age at 
operative repair was 3 days (range, 2 to 138). In 2 cases, the postoperative wound drain 
was still in situ when chylous production started 2 days postoperatively. In the other 2 
cases, drainage was first required at, respectively, 3 and 13 days postoperatively. In all 
cases, continuous drainage was instituted for a mean of 11 days (range, 4 to 19 days). In 
one case, enteral feeding was withheld for 10 days after which Caprilon was introduced. 
In the other 3 cases, enteral feeding was changed to Caprilon. In the group of patients 
treated with ECMO for other reasons, CT developed in 4 of 114 patients (3.5%), one of 
them after a cardiothoracic procedure for a tricuspid insufficiency and ASD type II. Four 
of 100 patients (4%) had a CT after an esophageal atresia repair (Fig. 2). 
 
Statistical analysis showed that CDH patients treated with ECMO had a significantly 
higher chance of having a CT compared with CDH patients not treated with ECMO 
(p = .042) or EA patients (p = .04). Statistical analysis with the presence of a patch in 
CDH patients as an independent variable for the development of a CT also showed a 
significant difference (p = .044). 
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Figure 1 Incidence of chylothorax in CDH patients with or without a patch 
 
 
 
 
 
 
 
 
 
 
Figure 2 Incidence of chylothorax by group 
 
 
 
 
 
 
 
 
 
 
Discussion 
 
Chylothorax is defined as an accumulation of chyle in the thoracic cavity. The large 
losses of chylous fluid may lead to deficits in lymphocytes, proteins and immunoglobulins 
and, thus, to increased morbidity.7 Chylothorax has been reported after almost every 
type of thoracic procedure in children. In our series we found an incidence of 10%, which 
is low compared with previously described (smaller) series.5,9,10 In the literature, various 
pathogeneses for the development of a CT after CDH repair are mentioned. Mercer9 
described 5 cases of CT in patients after CDH repair with the presence of a hernial sac. 
In these cases, it was likely that lymph vessels present in the diaphragm and in the 
hernial sac were injured during surgery.9 Our series shows that the development of a CT 
is as common after EA repair as after CDH repair without ECMO, indicating trauma to 
the lymphatic ducts as a result of the surgical procedure. However, in our series, only 
one patient with a very thin hernial sac was identified. Klin et al11 proposed an alternative 
pathogenesis for the development of a CT in cases in which a hernial sac is absent, and 
direct trauma to the lymphatic ducts is less likely to occur. Large visceral herniation to the 
left thorax may produce significant pressure on the thoracic ducts which, at the level of 
the fifth thoracic vertebra, branches of toward the left side of the thorax. This back-
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pressure phenomenon of the visceral lymphatics may lead to small breaks in the thoracic 
duct.11 
 
According to Trevisanuto et al12 during ECMO therapy a similar mechanism could be 
responsible; the catheter positioned in the superior vena cava impedes the venous return 
and consequently (partially) obstructs the outflow of the thoracic duct into the superior 
caval vein. This would also increase pressure in the ducts, leading to (micro) 
perforations. Our data show an increased likelihood of CT in patients with a CDH after 
ECMO. If this pathogenesis would be the leading cause, one would expect the CT to 
occur on the right side where the venous cannula is situated. However, in our patients, 
all but one of the CT occurred on the side of the hernia (Table 3). Moreover, infants with 
CDH who require ECMO often have a larger defect. This is reflected in this study in the 
number of cases in which the defect was closed with a patch; 88% in CDH patients 
treated with ECMO and 31% in patients not treated with ECMO. The presence of a patch 
as an independent variable also showed a significant higher chance of a CT developing 
in patients after CDH repair. It seems, therefore, more likely that ECMO serves as a 
selection bias and not as a primary cause for the CT.  
 
Management strategies of a CT include repeated thoracocentesis or continuous 
drainage, complete cessation of enteral feeding, or the use of medium chain triglycerides 
formula for a prolonged period. Beghetti et al13 showed that a standard treatment 
protocol with conservative management for all children who presented with a CT was 
effective in 80% of their patients. All our CDH patients with a CT were treated 
successfully with conservative management. If conservative management fails, surgical 
ligation of the thoracic duct is a possibility, but indication criteria are controversial.5,13 
Recently, the use of Octreotide as a nonsurgical intervention to decrease chyle 
production has been suggested.14-17 Administering Octreotide either as a continuous 
intravenous infusion or as subcutaneous dosages was reported to be successful in 
pediatric patients after cardiothoracic surgery. Prospective studies still need to be 
undertaken on this aspect.  
 
 
Table 3 Clinical data for the nine patients with CDH and CT 
 Case  
No 
Side of Hernia Side of Chylothorax Hernial  
Sac present 
Patch 
 
CDH + ECMO 1  Left  Left - + 
 2  Left  Left - - 
 3  Left  Right - + 
 4  Left  Left - + 
 5  Left  Left - + 
CDH without ECMO 6  Right  Right - - 
 7  Left  Left - + 
 8  Left  Left + - 
 9  Left  Left - + 
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Chylothorax is a recognized complication after surgery for congenital diaphragmatic 
hernia. Treatment modalities such as ECMO improve survival of patients with a poor 
prognosis. Our data show an increase in the likelihood of chylothorax in patients with a 
CDH when ECMO is used. Our data also show that the presence of a patch increases 
the likelihood of chylothorax. Because in a large number of infants who require ECMO a 
patch is present, ECMO is more likely to be a selection bias for the development of a CT 
than the cause of the CT.  
 
It can not be excluded completely that direct trauma to the lymphatic ducts and a 
backpressure phenomenon caused by visceral herniation play a role in the pathogenesis 
of a chylothorax. The role of increased pressure caused by the ECMO cannula is not 
clear and is not supported by our study. Still, in cases of CDH repair in combination with 
ECMO treatment, the surgeon and pediatrician should be alert for the development of a 
chylothorax in the postoperative phase. 
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Abstract 
 
Adequate analgesia and sedation are cornerstones of Extracorporeal Membrane 
Oxygenation (ECMO) treatment protocols. Drug disposition is altered during ECMO. 
Most frequently used drugs in newborns on ECMO are benzodiazepines such as 
midazolam for sedation and morphine for analgesia. Studies on pharmacokinetics and 
pharmacodynamics of both medications are scarce. We conducted a prospective cohort 
study in neonates on ECMO to assess the pharmacokinetics of midazolam and 
morphine. This paper concentrates on the descriptive parameters of the patients and the 
plasma concentrations of morphine and midazolam in a group of 20 term newborns 
receiving veno-arterial-ECMO. Plasma concentrations of midazolam, 1-OH-midazolam, 
1-OH-midazolamglucuronide, morphine, morpine-M3G and morphine-M6G were 
analysed at separate time points after discontinuation of morphine and midazolam just 
after cannulation and after reintroduction of the medication. Time to restart of medication 
was noted as well as the dosages of midazolam and morphine used during ECMO. 
Plasma concentrations showed great variability. All but two infants needed both 
midazolam and morphine for adequate sedation and analgesia. Although the 
pharmacokinetic data are of importance for our understanding of drug metabolism during 
veno-arterial -ECMO clinical practice and dose adjustment is guided by observational 
assessment using validated instruments such as the COMFORT-behavior scale and the 
visual analogue scale for pain. 
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Introduction 
 
Extracorporeal membrane oxygenation (ECMO) was developed in the early seventies to 
provide partial heart-lung bypass for the neonate with life-threatening, reversible 
cardiopulmonary failure unresponsive to more conventional therapies. Adequate 
analgesia and sedation are cornerstones of ECMO treatment protocols. In general, 
sedation serves several purposes: to decrease anxiety, induce amnesia, decrease 
oxygen consumption and carbon dioxide production, prevent the patient from removing 
lines and promote synchronous breathing with the ventilator. In patients on ECMO 
sedation and analgesia seem even more critical since inadequate sedation with 
excessive patient movement may result in a position shift, or even dislodgement of the 
cannula causing a decrease in venous drainage and arterialized return. The most 
frequently used drugs for sedation in newborns on ECMO are benzodiazepines such as 
midazolam. Morphine and fentanyl are the most commonly used analgetics in this group 
of patients.1 During ECMO, disposition of drugs is altered due to expanded blood volume 
and increased volume of distribution, an intrinsic increase in intra- and extracellular 
volumes, the presence of a non-pulsatile blood flow and reduced plasma protein 
concentrations with resulting effects on pharmacokinetics and dynamics.2 Earlier studies 
on morphine pharmacokinetics reported an increased morphine clearance during ECMO 
and after discontinuation of ECMO.3,4 However, Geiduschek et al. did not find a decrease 
of serum morphine concentrations after initiation of ECMO, but concluded that morphine 
clearance for infants receiving ECMO is variable.5 The volume of distribution for 
midazolam in neonates on ECMO was 3 to 4 times greater compared to that in critically 
ill neonates not treated with ECMO together with an increased plasma half life.6  
 
Although knowledge of the pharmacokinetics of sedation and analgesia during ECMO is 
increasing, assessment of the effect of sedation and analgesia in ECMO patients 
remains limited and standards are lacking. We conducted a prospective cohort study in 
neonates on veno arterial (VA)-ECMO to assess the pharmacokinetics and 
pharmacodynamics of midazolam and morphine. In this chapter we concentrate on the 
descriptive parameters of the patients and the plasma concentrations of morphine and 
midazolam (pharmacokinetics).  
 
 
Patients and Methods 
 
From September 2002 until September 2003 neonates younger than 7 days of age 
treated with veno arterial extracorporeal membrane oxygenation were included. Approval 
for this study was obtained from the hospital ethics review board. Parents were asked to 
give informed consent for blood sampling, effect observations and use of clinical data for 
research. Those who were expected to die within 24 hours were excluded. 
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Sedative and analgesic regimen 
According to standard procedures infants received routinely 50 mcg/kg/hr morphine and 
0.2 mg/kg/hr midazolam at the time of cannulation. Several minutes after cannulation 
morphine and midazolam were stopped. We created three groups for the reintroduction 
of medication; reintroduction of midazolam alone, reintroduction of morphine alone and 
reintroduction of morphine and midazolam at the same time. There was no formal 
randomisation, reintroduction of midazolam and/or morphine was decided on by the 
consultant in charge and morphine or midazolam could be freely added if thought 
necessary in the course of the ECMO run. 
 
 
Assessment of pain and sedation 
Time to reintroduction was noted. Depth of sedation was assessed every 3 hours using 
the COMFORT-behavior scale, which rates 6 behavioural items, each scored on a 5-pont 
scale, resulting in a total score from 6 (no distress) to 30 (severe distress).7,8 In addition a 
Bispectral Index monitor (BIS) recorded a BIS-value at 60-minutes intervals (Bispectral A 
2000 version 3.12, Aspect Medical Systems, Natick, MA, USA, with pediatric BIS 
sensors). The BIS values may range from 100 (awake) to 0 (iso-electric EEG). To 
determine whether restlessness was induced by pain, trained nurses obtained VAS pain 
scores 9 together with the COMFORT-score.8 
 
Blood sampling 
Blood samples were taken on predetermined time points after stopping midazolam and 
morphine and during 24 hours after reintroduction of the medication (Fig. 1). Steady state 
samples were taken thereafter approximately once a day during the ECMO run. Blood 
samples (500 microliter) were taken from the venous site of the ECMO system and were 
collected in heparin tubes. After collection the samples were centrifuged and stored at -
80 ºC until analysis. 
 
Analytical methods 
Midazolam 
Midazolam, 1-OH-midazolam and 1-OH-midazolamglucuronide concentrations were e 
measured in serum using high performance liquid chromatography (HPLC) with 
ultraviolet detection at 230 nm. Temazepam was used as internal standard. 500 µl 0.05 
borate buffer (pH 9.2) was added to 200 µl serum. Following liquid-liquid extraction with 
6ml dichloromethane, the organic layer was evaporated to dryness at 37 ºC. The mobile 
phase was prepared as follows: 400 µl phosphoric acid 85% and 146 µl tri-etylamine 
were added to 530 ml water. The pH was adjusted to 3.2 with 10% potassium hydroxide 
and 470 ml acetonitrile was added. The residue was reconstituted in 200 µl of mobile 
phase and 75 µl was injected onto the analytical column (Lichrosphere 100RP-18 
encapped 5 µm, Merck). Total drug concentration of 1-OH-midazolam was measured 
after enzymatic hydrolysis of 200 µl serum with 100 Ul β-glucuronidase for 24 hours at 
37 ºC. The difference between total and unconjugated 1-OH-midazolam was taken as 
the 1-OH-midazolamglucuronide. The limits of quantification were 11 µg/l for midazolam 
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and 6 µg/l for 1-OH midazolam using 200 µl of serum. Inter- and intra-assay coefficients 
of variation were less than 8% and 13% respectively. Total recovery exceeded 90% for 
both compounds. 
 
Morphine 
Serum concentrations were assessed by HPLC. Plasma 0.2 ml was mixed with 0.2 ml of 
0.01 M ammonium hydrogen carbonate (pH 9.3) and spiked with 75 µl of appropriate 
dilutions of stock solutions of internal standards (Morphine-d3 at 37.5 ng/ml; M3G-d3 and 
M6G-d3 at 18.75 ng/ml). The supernatant was extracted with solid phase columns 
(BOND ELUT C18,1ml and 100mg). The eluate was evaporated to dryness under 
nitrogen. The residue was dissolved in 75 µl of mobile phase, a mixture of acetonitrile 
and 10 mM of ammonium formate (pH 3.0) with formic acid (8/92, v/v) and was splitted 
with a ratio of 1/5 at the entrance of the mass spectrometer. A quadripole mass 
spectrometer (PE SCIEX API 150EX, Toronto, Ontario, Canada) equipped with a turbo 
ionspray interface was used for signal detection. 
The intra-assay variability for all concentrations tested was below 10%. The inter-assay 
coefficient of variation for calibration standards and quality controls was also below 10%. 
 
Data analysis 
For this descriptive paper demographic data of the studied population are presented as 
median (IQR). Plasma concentrations of midazolam and morphine are plotted over two 
periods; period one after stopping the medication; period two after reintroduction of the 
medication.  
 
 
Figure 1 Timing of blood sampling and COMFORT scoring 
Time  
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30 
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1 
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12 
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18 
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21 
hrs
24 
hrs
After stopping midazolam and/or morphine   x x x x x   x 
After reintroduction of midazolam and/or morphine x x x x x x x   x 
COMFORT scoring x   x x x x x x x 
 
 
Results 
 
Patients characteristics 
From September 2002 until September 2003 27 infants received VA-ECMO support. 
Twenty of them were included in the study, because one died within 24 hours, 4 infants 
received ECMO when older then one month and the parents of two refused consent. 
The characteristics of these 20 patients are presented in Table 1. 
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Table 1 Patient characteristics 
 
 
Total group 
n = 20 
Gestational age (wk) 40.1 (38.3 to 41.6) 
Birth weight (g) 3195 (2800 to 3650) 
Males 9 
MAS 10 
CDH 6 
Sepsis 2 
PPHN 2 
Apgar score at 1 minute 4 (2 to 7) 
Apgar score at 5 minutes 7 (5 to 7) 
Oxygenation index prior to ECMO # 38 (21 to 54) 
AaDO2 prior to ECMO 599 (522 to 624) 
Age at start of ECMO support (hours) 22 (9.5 to 107) 
Duration of ECMO support (hours) 110 (74 to 162) 
Data given are number of infants or median (IQR) 
MAS Meconium aspiration syndrome 
CDH Congenital diaphragmatic hernia 
PPHN Persistent Pulmonary Hypertension of the Newborn 
#   Oxygenation index was calculated as: [(Mean airway pressure * FiO2)/PaO2] •100. 
 
 
Sedative and analgesic use 
After cannulation both morphine and midazolam were discontinued in all patients, except 
for two cases in which morphine was continued accidentally. The median (IQR) interval 
between discontinunation of medication and reintroduction was 10 (7.8 to 27) hours. 
For reintroduction of midazolam and morphine we created three groups. The first group 
was to consist of 7 patients in whom midazolam alone was reintroduced. However, in 2 
cases morphine was never discontinued. Then, in 4 other neonates of the first group 
morphine was eventually co-started after a median (IQR) period of 22 (18.5 to 24.8) 
hours because of insufficient sedation with midazolam alone. Thus in fact only one 
patient received midazolam alone as sedative during ECMO. The second group was to 
consist of 5 patients in whom morphine alone was reintroduced. However, only one 
infant in this group was adequately sedated with morphine alone. In the other 4 
midazolam was also started after a median (IQR) of 7.5 (7.1 to 27,4) hours. The third 
group consisted of 8 patients in whom midazolam and morphine were reintroduced at the 
same time.  
Median dosage of morphine used during ECMO support was 11.5 (10.1 to 15.5) 
µg/kg/hr. Median dosage of midazolam used during ECMO support was 0.15 (0.1 to 0.2) 
mg/kg/hr. 
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Plasma concentrations 
Plasma concentrations were measured after stopping midazolam and morphine and after 
reintroduction. Plasma concentrations over time of morphine, M3G, M6G, midazolam, 
1-OH-midazolam and 1-OH-midazolamglucuronide are presented in Figures 2 and 3.  
 
 
Figure 2 Midazolam, morphine and their metabolite concentrations after discontinuing medication by
 time of sampling 
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Figure 3 Midazolam, morphine and their metabolite concentrations after reintroduction of medication 
 by time of sampling 
 
The whiteline represents the Mean. Ss = steady state samples taken once a day 
 
 
Discussion 
 
Morphine and midazolam are often used in providing analgesia and sedation in neonates 
on ECMO. This paper describes the basic characteristics of a prospective cohort study in 
20 neonates on VA-ECMO with the intention in the future to assess the pharmacokinetics 
together with the pharmacodynamics (COMFORT, VAS) of midazolam and morphine in 
the majority of cases. Midazolam and morphine alone did not provide adequate sedation 
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midazolam, 1-OH-midazolam and 1-OH-midazolamgluconoride showed great variability 
between patients and over time.  
 
Morphine clearance for infants receiving ECMO has been described previously as 
variable. Geiduschek et al. found a mean morphine clearance, calculated on days 1, 3, 
and 5 of ECMO, of 11.7 +/- 9.3 (SD) ml/min/kg (range 2.6 to 34.5).5 Peters et al. 
compared morphine clearance during ECMO to postoperative infants not receiving 
ECMO aged 0-3 years3. They found a decreased morphine clearance at the start of 
ECMO, increasing rapidly within 14 days to equal that of postoperative infants. They also 
reported a 38.7% between-subject variability of which weight and age information 
explained 83% of the overall clearance variability.3 This finding suggests that increased 
clearance will result in decreased plasma concentrations and that dosing should be 
adjusted. However Dagan et al. found a lower morphine clearance during ECMO 
compared to the situation after decannulation.4 In our patients we noted a progressive 
increase of both M3G and M6G in combination with a stable morphine plasma 
concentration. The interpretation of the balance between the anti-analgesic effects of 
M3G and the even higher analgesic effect of M6G compared to the native compound is 
dependent on the way caregivers assess levels of pain and/or sedation of the individual 
newborn. 
 
Mulla et al. described the pharmacokinetics of midazolam in neonates receiving ECMO. 
Plasma concentration profiles of midazolam over time also showed great variability. Their 
main finding was that volume of distribution during ECMO increased from 0.8 (± 0.5) to 
4.1 (± 5) l/kg. Consequently plasma half life increased.6 A previous study by Mulla et al. 
described plasma concentrations of midazolam during ECMO. Mean plasma 
concentrations at 24, 48 and 72 hours increased, with levels at 48 and 72 hours 
exceeding those predicted, suggesting accumulation. The authors suggested that in the 
first 24 hours of ECMO, because of expanded circulating volume and sequestration by 
the circuit, significantly more midazolam is required to achieve adequate sedation.10 
However, with increasing distribution volume and increasing plasma half-life during 
ECMO, maintenance doses should be adjusted. 
 
There are no published studies on the use of midazolam and morphine together. There 
are also no known effects of midazolam on morphine formation clearance to M3G and 
M6G. A possible reason is that morphine is metabolised in the liver by the enzyme UDP-
glucuronosyl transferase (UGT2B7) into M3G and M6G, while midazolam is metabolised 
by the cytochrome P450 system (i.e. CYP3A4, CYP3A5 and to a much lesser extent by 
CYP3A7).11,12 In principle our group of term newborns can be used as a model to 
evaluate the combined use of sedative and analgesic drugs in this specific age group. 
 
With the variability in clearance and reported plasma concentrations of morphine and 
midazolam it remains difficult to predict pharmacodynamics. Initial dosing may be guided 
by age and weight, but changes in clearance and distribution volume (and their 
variability) during prolonged ECMO suggest that morphine and midazolam therapy 
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should be adjusted to prevent over- or under-sedation and should by guided by clinical 
monitoring. Estimating the efficacy in nonverbal patients is difficult. To quantify distress 
and levels of sedation, behaviour patterns can be measured using the COMFORT-
bevavior scale.8 A Bispectral index monitor (BIS) has also been described in assessing 
efficacy of sedation with propofol in infants under 2 years of age.13 However, standards 
as well as studies on assessing efficacy of sedation and analgesia in neonates on ECMO 
are lacking. 
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Abstract 
 
Recent observations of intracellular transport in smooth muscle cells suggest that the 
phosphodiesterase (PDE) inhibitor sildenafil (Viagra) is promising in the treatment of 
pulmonary hypertension in adults and children. Very little is known of its efficiency in 
neonatal persistent pulmonary hypertension (PPHN). We analysed retrospectively the 
effects of oral sildenafil in 15 consecutive neonates over more than two years with 
therapy resistant PPHN necessitating ECMO support. Eight survived (53%); seven, all 
with congenital diaphragmatic hernia, died. Survivors and non-survivors did not show 
significant differences in reduction of ECMO flow (p = 0.53) 24 hours after initiation of 
sildenafil or in duration of ECMO support (p = 0.23). The survivors had first received 
sildenafil significantly earlier after cannulation than the non-survivors; median (IQR) 
41 (17 - 90) hours versus 200 (161 - 334) respectively (p < 0.01). Patients with 
concomitant iNO administration at the start of sildenafil showed greater reduction in 
ECMO flow over the next 24 hours than patients who received sildenafil only. Two 
patients were successfully decannulated after previous failure due to rebound pulmonary 
hypertension. In 12 patients a significant decline in systemic blood pressure over the first 
2 hours after initial sildenafil administration of 9 mmHg (median) was established (p = 
0.02), not dosage related. 
 
We conclude that sildenafil therapy might be of benefit in individual cases of PPHN and 
that administration relatively early in the disease proces with concomitant administration 
of iNO might be favourable. In contrast with earlier studies in animals and adults, 
significant systemic hypotension was observed. 
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Introduction 
 
While primary pulmonary hypertension (PPH) in adults and children is rare, pulmonary 
hypertension (PH) among neonates requiring neonatal intensive care is not a rare 
disease, with incidences ranging from 0.43 to 6.8 cases per 1000 live births).1 PH in this 
group is subclassified according to the likely aetiology. The primary type is referred to as 
persistent pulmonary hypertension of the newborn (PPHN), or persistent foetal 
circulation, with pulmonary vascular resistance failing to decrease after birth despite 
radiographically normal lungs and no evidence of pulmonary parenchymal disease. The 
secondary type is associated with pulmonary parenchymal disease – as in meconium 
aspiration and hyaline membrane disease – or with hypoplasia of the lungs – as in 
congenital diaphragmatic hernia (CDH). Severe PH is also known to occur in infants 
following cardiothoracic surgery.2 Severity of illness and likely outcome of neonatal PH 
are related to the underlying disease and to potential changes in pulmonary vascular 
architecture, comprising thickening of the adventitial and medial layers and 
muscularisation of precapillary vessels.3 In the light of this heterogeneity, it is not 
surprising that so far no single therapy was found to be effective in all cases. Severe 
(therapy resistant) primary or secondary PPHN often leads to last resort support with 
Extracorporeal Membrane Oxygenation (ECMO), which is still unsuccessful in 6 - 46% of 
all neonates requiring ECMO, depending on the underlying pathology.4 
 
Apart from specific measures to treat the underlying condition in secondary PHN, 
treatment of PHN is based on preventing hypoxia and boosting pulmonary vasodilatation 
by selectively decreasing pulmonary vascular resistance (PVR) without affecting 
systemic vascular resistance (SVR). New therapies such as endothelin receptor 
antagonists, chronic anticoagulation, calcium channel blockers, L-arginine or citrulline 
therapy, have been mostly designed for and tested in adults. They have led to sustained 
clinical and hemodynamic improvement as well as better survival in selective patients 
with PPH. Inhaled nitric oxide (iNO) is currently regarded as the gold standard therapy in 
PPHN.5 It improves outcome in hypoxemic infants by reducing the incidences of the 
combined endpoints death or need for ECMO.6 However, about 40% of patients fail to 
respond, to iNO therapy. Those who do respond may develop severe, life threatening, 
rebound hypoxemia and pulmonary hypertension on withdrawal of NO after long-term 
therapy.7 
 
Continuous IV infusion of the prostacyclin (PGI2) epoprostenol (Flolan) has meanwhile 
become the mainstay of therapy for patients with PH other than PPHN.8 Its efficiency has 
been demonstrated in patients of all ages, but significant drawbacks are the high costs 
and adverse effects such as major systemic hypotension and tachyphylaxia. 
Furthermore, administration is difficult because of its very short half-life of 3 - 5 minutes 
necessitating continuous IV infusion and the risk of acute withdrawal leading to fatal PH. 
All this makes the use of Flolan in the neonatal population particularly challenging.  
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Recent interest has turned to phosphodiesterase (PDE) inhibitor therapy. Integral 
components of cyclic nucleotide signalling, PDEs are crucial for signalling homeostasis, 
cell adaptation and in crosstalks between different pathways. PDE inhibitors block the 
hydrolysis of cyclic nucleotides, causing accumulation of cAMP or cGMP. In the lung, 
cGMP is a final messenger for vascular smooth muscle relaxation. It is metabolised by 
PDE5, the predominant PDE in normal lungs, which may be upregulated in PPH,9 
causing increased turnover of cGMP. Inhibition of PDE5 is therefore a logical step to 
increase bioavailability of cGMP and thus support endogeneous vasodilatition. Recent 
studies have explored the therapeutic potential of PDE5 inhibitor sildenafil (Viagra) in 
PH. In adults with PPH, sildenafil was found to significantly improve effort tolerance, 
cardiac output and quality of life.10-17 Its long-term safety and efficacy have not been 
established yet.18 In animal models of acute and neonatal pulmonary hypertension it was 
shown to be a selective pulmonary vasodilatator with no effect on systemic arterial 
pressure.19-21 Both animal and clinical studies in adults demonstrated that sildenafil, 
administrated orally, intravenously or in aerolized form, potentiated the effect of iNO and 
facilitated its withdrawal.22-25 Current clinical experience with sildenafil in children is 
restricted to four single case reports,13,25-27 three case series11,14,22 and three randomised 
trials mainly in post-cardiac surgery patients beyond the newborn period.28,29 Sildenafil 
was reported to be just as effective as iNO in improving pulmonary vasodilatation, with a 
combination of the two being more effective than either therapy alone. It was found to 
attenuate the rebound PHT associated with withdrawal of iNO and no side effects were 
noted on systemic arterial pressure. Sildenafil was reported to augment the pulmonary 
vasodilator effects of iNO early after surgery for congenital heart disease, although 
systemic hypotension was observed.30 In view of the beneficial effects reported, sildenafil 
seems a promising agent in the treatment of PPHN.  
 
Nevertheless, populations described in these reports vary, with only few neonates. Thus, 
in order to learn more about the administration of sildenafil in PPHN and its efficiency 
and side effects, we retrospectively analysed the administration of sildenafil and its 
efficiency in 15 neonates with therapy resistant PHN in the course of ECMO treatment. 
To our knowledge we are the first to do so. 
 
 
Patients and methods 
 
This analysis includes all neonates treated with sildenafil for PPHN and in need for VA-
ECMO support hospitalised at the pediatric surgical intensive care unit (PSICU) of the 
Sophia Children’s Hospital between March 2002 and June 2004.  
 
The treatment algorithm used was based on publications as reviewed by Hansell in 
2003.4 Treatment included maesures for the apparent underlying disorder, adequate 
ventilation and lung recruitment using conventional artificial ventilation or high frequency 
oscillation (HFO), and administration of subsequently dopamine, dobutamine and 
noradrenaline to optimise systemic blood pressure and cardiac performance. Additional 
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iNO up to 20 ppm was administered as recommended by Clark et al.6 If treatment failed, 
veno-arterial ECMO was instituted according to the “classical” criteria of the National 
Medical Center ECMO Team, which remained unchanged during the study period.31 
Cardiac ultrasound was performed before iNO or after ECMO was started. Sildenafil 
(Viagra) administration was started when persistent pulmonary hypertension was 
assumed in spite of maximal conventional therapy. In the Netherlands sildenafil is 
available for enteral administration only. After an initial dose of 4 - 8 mg/kg, sildenafil was 
continued as a daily dose of 1 - 2mg/kg 12 hours after the first dose. Dosage was 
extrapolated from adult regimes using enteral doses.32,33 
 
We considered consistency of sildenafil administration regarding indication, time, route 
and dosage. Effects and side effects of sildenafil were assessed from the following 
parameters: survival, time on ECMO, evolution of ECMO flow (ml/kg/min) and the 
relation with concomitant iNO administration, echocardiography and systemic blood 
pressure before and after administration of sildenafil, oxygenation index before and after 
ECMO, and prevalence of rebound PHT during sildenafil administration. In non-survivors, 
histopathology of the lung was performed and verified for the presence of PHT.  
 
Data analysis 
Precise data from continuous electronic data monitoring and registration (PDMS) over 
the study period were available for retrospective analysis. 
Data are presented as median with interquartile range (IQR) due to skewed distribution. 
Mann-Whitney test or a chi-square test was used to compare data between subsets of 
the entire study population. The significance level was set at p < 0.05.  
 
 
Results 
 
Patient characteristics 
During the study period, 52 neonates received VA–ECMO support. The overall mortalilty 
rate was 23%. Seventeen neonates had been treated with sildenafil during the same 
period. However, two of these were excluded from analysis because their maximal 
medical treatment did not include ECMO. In one, with left-sided CDH, ECMO was 
contraindicated due to chromosomal abnormality (unbalanced translocation in 12q). This 
patient eventually died of ventilatory complications. The other patient, with an 
omphalocele associated with lung hypoplasia, finally developed PH. He was considered 
as contraindicated for ECMO in view of the extent of chronic lung pathology. He died 
because of therapy resistant PH, confirmed by lung biopsy. 
 
Characteristics of the remaining 15 patients are shown in Table 1. Nine of the 10 patients 
with CDH had left-sided CDH. Treatment with sildenafil was initiated at a median (range) 
age of 209 (8 to 3504) hours and at a median (range) time of 126 (-12 to 357) hours after 
start of ECMO. Oral dosage varied from 4 to 9 mg/kg/d (median 8) in 3 or 4 times daily 
(Table 2). 
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Table 1 Patient characteristics 
  Total group 
 n = 15 
 Survivors 
 n = 7 
 Deceased 
 N = 8 
Gestational age (wk) 38 +4 (38 to 40 +2 ) 40 (38=4 to 40+4)* 38+1 (37+2 to 39+4) 
Weight at cannulation (kg) 3.3 (3 to 4) 4 (4 to5)# 3 (2.7 to 3.2) 
Males/Females 6/9 2/5 4/4 
CDH 10 2 8 
PPHN 2 2 0 
CCAML 1 1 0 
Cardiomyopathy 2 2 0 
Age at start of ECMO support (hrs) 24 (12 to 24) 12 (11 to 23)† 24 (24 to 288)† 
Duration of ECMO support (hrs) 200 (149 to 302) 195 (122 to 235)‡ 262 (152 to 349)‡ 
Oxygenation index prior to ECMO 49 (24 to 66) 26 (22 to 54) 50 (32 to 79) 
Oxygenation index post ECMO 6.3 (3.4 to 15) 3.9 (1.5 to 7.7)§ 7.7 (5.4 to 23)§ 
Data are presented as median (IQR) or number of patients. 
CDH   Congenital diaphragmatic hernia 
PPHN  Persistent Pulmonary Hypertension of the Newborn 
CCAML Congenital cystic adenomatoid malformation of the lung 
*   Survivors had significantly higher gestational age (p = 0.042) 
#   Survivors had a significantly higher weight at time of cannulation (p = 0.007) 
†   p < 0.01 
‡    p = 0.2 
§   p = 0.052 
 
 
 
Table 2 Parameters of sildenafil administration 
 Dose 
(mg/kg/d) 
Frequency 
(times daily) 
P (t = 0) 
(mmHg) 
P (t = 2) 
(mmHg) 
Start after 
cannulation (hrs)
Entire population 
 (n = 15) 
 
8.0 
(6.0 - 8.0) 
3.0 
(3.0 - 3.0) 
55 † 
(50 - 60) 
46 † 
(45 - 53) 
126 
(41 - 204) 
Deceased  
 (n = 8) 
8.0 
(4.5 - 8.0) 
3 
(3.0-3.0) 
53 
(48-59) 
(n = 8) 
45 
(39 - 48) 
(n = 6) 
200‡ 
(161 - 334) 
Survivors  
 (n = 7) 
6.0 
(6.0 - 8.0) 
3 
(3.0-4.0) 
60 
(55 - 62) 
(n = 7) 
51 
(45 - 53) 
(n = 6) 
41‡ 
(17 - 90) 
Data are presented as median (IQR). 
P  (t = 0): mean arterial systemic pressure at sildenafil administration 
P  (t = 2): mean arterial pressure 2 hours after sildenafil administration 
†  p = 0.02  
‡  p < 0.01 
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Effects of sildenafil  
1.  ECMO flow reduction 
ECMO flow at (t = 0) and 24 hours after (t = 24) sildenafil administration was used to 
calculate flow reduction (Table 3). Survivors and non-survivors showed no significant 
difference in ECMO flow reduction. (p = 0.53).  
 
2.  Concomitant iNO administration 
Typically, iNO was stopped at the start of ECMO, but restarted however when ECMO 
flow did not diminish. Seven patients received iNO and sildenafil concomitantly; 4 
survivors versus 3 non-survivors. Median (IQR) time on ECMO in the group without 
iNO was 279 (164 - 352) hours, in the group with iNO 179 (142 - 232) hours (p = 
0.19).  
ECMO flows at initiation (t = 0) and 24 hours after (t = 24) sildenafil administration 
were compared between patients who received sildenafil as well as NO (10 to 20 
ppm) and patients who only received sildenafil (Table 3). ECMO flow reduction was 
significantly greater in the former group (p = 0.048).  
 
3.  Time on ECMO support 
Median (IQR) ECMO support in the survivors was 195 (122 - 235) versus 262 (152-
359) hours in the non-survivors (Table 1). This difference was not statistically 
significant (p = 0.23).  
 
4.  Echocardiographic findings 
Six patients (2 survivors, 4 non-survivors) underwent echocardiography both before 
ECMO and more than 48 hours after sildenafil administration. Amelioration of PH was 
expressed as reduction of pulmonary artery pressure based on tricuspidal 
incompetence (TI), ductal shunt velocities and artery Doppler acceleration time. 
Amelioration was observed in one patient, stable PH was observed in four, and one 
patient showed an increase in PH. 
 
5.  Mode of prescription  
Survivors and non-survivors did not show differences in median dosage (IQR); 6.0 
(4.5-8) versus 8.0 (6 - 8) respectively (p = 0.96) or frequency of administration (both 
3.0 times daily) (p = 0.40) (Table 2). Sildenafil was first administered significantly 
earlier after cannulation in survivors compared with non-survivors; i.e. median (IQR) 
41 (17 - 90) hours versus 200(161 - 334) (p < 0.01)(Table 3). Proportions of patients 
who received both sildenafil and iNO did not differ between non-survivors and 
survivors (43% versus 50%) (Pearson Chi Square p = 0.78).  
 
6.  Prevention of rebound pulmonary hypertension 
In four patients complete weaning of ECMO (flow < 50 ml/min) had been 
unsuccessful first because of rebound pulmonary hypertension, but was successfully 
accomplished later on, after administration of sildenafil. Two of them died after all of 
rebound pulmonary hypertension after decannulation, proven by lung biopsy.  
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7.  Side effects 
Change in mean systemic arterial pressure was calculated over the first 2 hours after 
initial sildenafil administration. Cardiovascular support for three patients had been 
changed in between first and final measurements and they were therefore excluded 
from analysis. The remaining 12 patients showed significantly diminished systemic 
arterial pressure (p = 0.02) (Table 2). Changes in mean systemic arterial pressure did 
not differ between survivors and non-survivors (p = 0.8). We did not establish a 
correlation with dosage (p = 0.4). 
 
Histopathology 
The eight non-survivors died at a median (IQR) age of 396 (300 - 463) hours, 69 (14 -
212) hours after decannulation. Cause of death was mostly PPHN. Histopathology 
revealed thickening of the adventitial and medial layers and muscularisation of 
precapillary pulmonary vessels. Two non-survivors died from causes other than 
circulatory failure; one because of ventilatory failure due to pulmonary parenchymal 
disease (prominent presence of hyaline membranes in lung autopsy and significant 
amount of pulmonary hypoplasia), one from sepsis. All non-survivors had CDH.  
 
 
Table 3 Evolution of ECMO flow after administration of sildenafil (t = 0) 
ECMO flow (ml/kg/min) t = 0 (hours) t = 24 (hours) t0-t24 
Entire population (n = 15) 24 (12 - 58) 22 (7 - 53) 3 (0 – 18) 
Deceased (n = 8)  23 (5 - 50) 12 (0 - 48) 0 (0 – 30) 
Survivors (n = 7) 58 (12 - 71) 30 (11 - 59) 4 (1 – 23) 
iNO ⊕ (n = 7) 52 (0 - 66) 12 (0 - 48) 17 (0 - 30)† 
iNO ∅ (n = 6) 19 (14 - 49) 28 (11 - 56) 0 (-9 - 3)† 
Data are presented as median (IQR). 
INO ⊕   Coadministration of iNO and Sildenafil at t = 0 
INO ∅   no iNO coadministered at t = 0 
†    p = 0.048 
 
 
Table 4 Oxygenation index pre- and postECMO 
 OI preECMO (%) OI postECMO (%) OI pre-postECMO (%) 
Entire population (n = 15) 49 (24 - 66) 6.3 (3.4 - 15) 29 (20 - 55) 
Deceased (n = 8) 50 (32 - 79) 7.7 (5.3 - 23) 37 (21 - 75)# 
Survivors (n = 7) 26 (22 - 54) 3.9 (1.5 - 7.7) 24 (18 - 47)# 
NO ⊕ (n = 7) 65 (48 - 84) * 7 (3.8 - 14) 53 (32 - 80)$ 
NO ∅ (n = 7) 24 (21 - 49) * 5.6 (2.2 - 25) 20 (16 - 24)$ 
OI    oxygenation index  
INO ⊕   Coadministration of iNO and Sildenafil at t = 0 
INO ∅   no iNO coadministered at t = 0 
#    p = 0.06 
$    p < 0.01 
*    p < 0.01 
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Discussion 
 
In this study we described retrospectively our 2 years experience with enteral 
administration of sildenafil in 15 neonates for therapy resistant primary or secondary 
PHN during their time on veno-arterial ECMO.  
 
We used ECMO flow reduction (ml/kg/min) as an indirect parameter to assess decline of 
pulmonary hypertension due to sildenafil administration. ECMO flow reduction at 24 
hours after initial sildenafil administration tended to be higher in the survivors as 
compared with the non-survivors, but the difference was not significant. All non-survivors 
had CDH. Previously it was shown that only few CDH patients respond to iNO.34 
Aetiology and pathophysiology of PH in CDH is still not entirely understood and it might 
be different from other forms of neonatal PH.35,36 Successful therapy therefore probably 
needs to be tailored to the individual situation.  
 
Concomitant iNO administration seemed to have an additional effect on reducing PH. 
This was reflected by the observation that those with concomittant iNO showed greater 
ECMO flow reduction than did those treated with sildenafil only. Although three of the 
seven patients who received iNO concomitantly finally died, not PPH but sepsis and 
ventilatory failure were the cause of death in two of the three. In addition, the group who 
received iNO showed a significantly higher decrease in oxygenation index from 
cannulation to decanullation. Previous studies have already suggested that concomitant 
sildenafil and iNO administration would be more beneficial to PH than either one 
alone.21-24 
 
The survival rate in our study population (47%) is less than that observed in the general 
neonatal ECMO population. This is not surprising in view of the fact that our study 
population cannot be considered representative for the general population. Moreover, the 
non-survivors’ significantly lower gestational age and weight at cannulation as compared 
to the survivors might be considered extra risk factors for the bad evolution, but their 
immaturity could also be interpreted as the cause for being less susceptible to treatment; 
in fact they might be ‘less-responders’.  
 
Failure of weaning of iNO has been repoerted to become successful after sildenafil 
administration.22,23 We noticed successful weaning of ECMO in four patients following 
sildenafil administration after earlier failure. Still, two of them later died because of 
rebound PH. 
 
Amelioration of pulmonary hypertension could not be objectified by echocardiography 
(only in 1 out of 6 patients studied). Yet, little is known about correct estimation of PH by 
echocardiography during ECMO support as cardiac output is partially taken over by 
ECMO and TI is difficult to evaluate.37 Furthermore, measurement of neonatal PH by 
echocardiography in general is not always straightforward.38 Although echocardiography 
was performed in all patients before cannulation for ECMO, it was not standardly 
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performed after administration of sildenafil. Often clinical evolution, particularly when 
favourable, did not necessitate echocardiography.  
 
In our population dose variation (4 to 9 mg/kg/d), frequency of administration (3 to 4 
times daily) and survival were not correlated. Interestingly is the observation, in the 
survival group sildenafil was administered significantly earlier after cannulation than in 
the group of deceased patients, which might indicate that earlier administration in the 
disease proces is more efficient in reducing pulmonary hypertension. This could correlate 
with previous animal study observations that sildenafil does not only lower pulmonary 
vascular resistance by specific pulmonary vasodilatation, but also inhibits remodelling of 
the pulmonary vasculature.39,40  
 
Although not observed in studies concerning sildenafil administration in animals and 
adults, we found a significant reduction in systemic blood pressure in our population, in 
line with the findings of a recent study concerning sildenafil administration in neonatal 
surgery for congenital heart disease.30 Systemic hypotension can increase the 
pulmonary to systemic blood pressure ratio and consequently negate the beneficial 
effects of sildenafil, or even lead to circulatory failure when cardiovascular support 
already was maximised. Hence, sildenafil might not be a selective pulmonary 
vasodilatator in neonates. As we only examined differences in systemic tension after the 
first dose, which was a loading dose, and 3 - 4 times higher than the subsequent doses, 
fall in systemic tension could be related to the loading dose. However, we did not notice 
dose dependency. We also did not study the persistency of hypotension, which is an 
important factor. If persistency of hypotension would be confirmed in following 
observations and studies, the use of sildenafil in the neonatal population could be 
considered limited.  
 
Our results should be interpreted cautiously, in view of the retrospective analytic nature 
of this study. Also, sample size is still small and a control group is absent. Procedures 
such as echocardiography were not standardised and medical treatment policy for iNO 
and sildenafil on ECMO were not protocolised. Moreover, we analysed indirect 
parameters such as ECMO flow, duration of ECMO support and survival as indicatiors of 
efficiency, but are well aware that these depend on several factors and are not only 
linked to the presence of PH, which makes interpretation delicate. Then, our study 
population can not be considered as representative for the general group of neonatal 
PPH. Firstl, PPH in our study population was highly severe, as reflected by the fact that 
all neonates required ECMO support that even threatened to fail. Second, the distribution 
and occurrence of the underlying pathologies do not match the general population and all 
patients contraindicated for ECMO are not represented. 
 
Finally, we feel that route of administration could be a key factor determining the 
usefulness of sildenafil in the critically ill neonate. Oral administration, like in our study 
population, is associated with unpredictable bioavailability, which depends on absorption 
from the gastro-intestinal tract. The intravenous formulation would therefore seem 
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potentially more appealing in these patients. However, international multicenter studies 
are still hampered by the absence of a proper dose finding and safety study. In addition, 
other potential long-term risks like retinal damage linked to PDE6 inhibition41,42 and 
specific issues like tolerance – requiring dose increase with long-term exposure – and 
rebound effects after withdrawal should be evaluated. Outcome measures should include 
evaluation of PH by regular echocardiography. Pharmacokinetic studies are necessary to 
determine optimal dosing of sildenafil in neonates of different gestational ages and 
weights.  
 
In conclusion, in this small group of neonates with pulmonary hypertension receiving 
ECMO treatment the concomittant use of iNO and oral sildenafil significantly reduced 
ECMO flow. Despite the drawbacks of the study, we might conclude therefore that there 
might be a place for sildenafil in neonatal persistent pulmonary hypertension during the 
course of ECMO. Further multicenter, randomised controlled clinical trials using the 
intravenous formulation are warranted. 
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Abstract 
 
Background 
Extracorporeal membrane oxygenation (ECMO) is a supportive cardiopulmonary bypass 
technique for babies with acute reversible cardiorespiratory failure. We assessed 
morbidity in ECMO survivors at the age of 5 years, when they start primary school and 
major decisions for their school careers must be made. 
 
Methods 
5-year-old neonatal venoarterial-ECMO survivors from the two designated ECMO 
centres in the Netherlands (Erasmus MC - Sophia Children’s Hospital in Rotterdam, and 
University Medical Center Nijmegen) were assessed within the framework of an 
extensive follow-up program. The protocol included medical assessment, neuromotor 
assessment, and psychological assessment by means of parent and teacher 
questionnaires. 
 
Findings 
Seventeen of the 98 children included in the analysis (17%) were found to have 
neurological deficits. Six of those 17 (6%) showed major disability. Two of those six had 
a chromosomal abnormality. Three were mentally retarded and profoundly impaired. The 
sixth had a right-sided hemiplegia. These six children did not undergo neuromotor 
assessment. Twenty-four of the remaining 92 (26%) showed motor difficulties: 15% 
actually had a motor problem and 11% were at risk for this. Cognitive delay was 
identified in eleven children (14%). The mean IQ score was within the normal range 
(IQ = 100.5). 
 
Interpretation 
Neonatal ECMO in the Netherlands was found to be associated with considerable 
morbidity at 5 years of age. It appeared feasible to have as many as 87% of survivors 
participate in follow-up assessment, due to co-operation between two centres and small 
travelling distances. Objective evaluation of the long-term morbidity associated with the 
application of this highly invasive technology in the immediate neonatal period requires 
an interdisciplinary follow-up program with nation-wide consensus on timing and actual 
testing protocol. 
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Introduction 
 
Extracorporeal membrane oxygenation (ECMO) is a cardiopulmonary bypass technique 
for providing life support in acute reversible cardiorespiratory failure when conventional 
management is not successful. Most patients receiving ECMO support are neonates 
suffering from persistent pulmonary hypertension of the newborn (PPHN), primary or 
secondary to meconium aspiration syndrome, sepsis or congenital diaphragmatic hernia. 
Worldwide, over 18,700 neonates have been treated with ECMO for respiratory 
problems, and the overall survival rate was 77% (ELSO Registry Report January 2004). 
 
The UK Collaborative ECMO Trial Group in 1996 presented the results of a randomised 
controlled clinical trial, showing a significant survival benefit of ECMO, without a 
concomitant rise in severe disability at 1 year of age.1,2 Even for the 35 neonates with 
congenital diaphragmatic hernia (CDH) the risk of death was reduced (RR 0.72, 95% CI 
0.54 to 0.06; p = 0.03). However, of the 18 neonates with CDH allocated to ECMO, 14 
died (one after discharge) and only three children survived to age 4. All 17 infants in the 
conventional management arm died before discharge.3 No other therapeutic intervention 
(i.e., high frequency oscillatory ventilation, surfactant and inhaled nitric oxide) for 
neonatal acute respiratory failure has such a positive impact on mortality and morbidity.4 
 
Nevertheless, the severity of illness of potential candidates for ECMO, as well as the 
risks associated with the procedure itself, places the ECMO survivor at high risk of 
developing brain injury and subsequent function deficits. All patients receiving ECMO 
support have suffered from severe respiratory failure prior to treatment. Prolonged 
episodes of severe hypoxaemia may occur, despite the administration of 100% oxygen. 
The inevitable high ventilatory pressures and hyperventilation may cause alterations in 
cerebral bloodflow.5,6 In veno-arterial ECMO the right common carotid artery and right 
internal jugular vein are cannulated and subsequently ligated after bypass is finished. 
And finally, the heparin that is administered to prevent the blood from clotting might 
cause intracranial haemorrhage as a confounder for long-term morbidity. It is not easy, 
therefore, to predict the long-term outcome of neonates treated with ECMO. The few 
reports on structural follow-up of ECMO survivors either describe infants up to age 2 or 
patients from a single centre with wide age distribution.2,7-14 They point out that logistic 
problems may prevent patients from being available for predetermined, structural 
evaluation. Major disabilities in terms of severe developmental delay or neuromotor 
disabilities were reported in some 20% of ECMO survivors.2,7,9,11 The range of morbidity 
widens with evaluation after age 1, when assessment of cognitive skills, co-ordination, 
behavioural difficulties and sensory loss can be more precise.15 Long-term longitudinal 
follow-up of these children seems thus essential for placing ECMO results in perspective. 
Only two studies describe longitudinal neurodevelopmental evaluation at school age.15,16 
Although surviving children treated for severe life-threatening respiratory failure soon 
after birth show considerable long-term morbidity, the results of the UK-ECMO trial point 
to a favourable profile of long-term morbidity in the group assigned to ECMO.15 
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Glass et al. reported a 61% response rate; 25% did not participate because of the long 
travelling distances in the USA.16 In the Netherlands neonatal ECMO is provided in two 
designated centres only, authorised by the Dutch government. All parents of ECMO 
survivors are invited to enter their child in a redesigned follow-up program. High 
response rates are feasible because travelling distances are short in the Netherlands 
and regionalised high-risk perinatal care, including ECMO, is available. The children are 
scheduled to undergo assessment at ages 6, 12, 18 and 24 months and 5, 8 and 12 
years. In this paper we present the follow-up findings at age 5 years, when children are 
in the first or second year of primary school and major decisions for their future school 
careers must be made. 
 
 
Patients and methods 
 
Patients 
The study population included 5-year-old neonatal venoarterial ECMO survivors from 
both ECMO centres in the Netherlands, i.e. the Erasmus MC - Sophia Children’s Hospital 
Rotterdam and University Medical Center Nijmegen. They were seen either between 
May 2001 and December 2003 (Rotterdam) or between March 1998 and December 
2003 (Nijmegen).  
 
Assessment protocol (Fig. 1) 
Complete assessment included a one-hour medical assessment by a paediatrician/ 
neonatologist experienced in follow-up evaluation, a one and a half hour neuromotor 
assessment by a paediatric physiotherapist and a three-hour neuropsychological 
assessment by a psychologist or psychological test assistant. In Nijmegen a speech 
therapist assessed speech and language development, in Rotterdam the psychologist 
who performed the neuropsychological assessment. The complete assessment took 
place in one day. The sequence of the different assessments could vary for logistic 
reasons. In addition, one month before assessment parents were invited to complete 
questionnaires on parental socio-economic status and the child’s current general health 
and behaviour.  
Perinatal characteristics such as birthweight, gestational age, age at start of ECMO, 
duration of ECMO, primary diagnosis, and possible intra-cranial abnormalities were 
obtained from each centre’s ECMO registry and are included in the ELSO registry (ELSO 
Registry Report January 2004). 
 
Medical assessment 
Medical assessment consisted of taking the child’s medical history, measurement of 
growth parameters, and standard physical examination followed by standard neurological 
examination. Length and weight were expressed as SD score using the Dutch Growth 
Analyser, version 2.0 (Dutch Growth Foundation). The results of the neurological 
examination were categorised into normal (no neurological abnormalities), minor 
neurological dysfunction (neurological abnormalities without influence on normal posture 
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or movement) and major neurological dysfunction (neurological abnormalities with 
abnormal posture or movements, including seizure disorders). 
 
Neuromotor assessment 
The Movement Assessment Battery for Children (M-ABC) was used to measure motor 
functioning.17 A Dutch standardisation study has shown that the original norm scores and 
cut-off points can also be applied to Dutch children. Good validity and reliability have 
been demonstrated.17,18 
The M-ABC was developed for children aged 4 - 12 years. It has four age-related item 
sets, each consisting of eight items. Three manual dexterity items: a time-related task for 
each hand separately, a bimanual co-ordination task and a graphical task with the 
preferred hand. Two ball skill items: a task of catching a moving object and a task of 
aiming at a goal. Three balance items: static balance, dynamic balance while moving fast 
and dynamic balance while moving slowly. Scores may range from 0 - 5 for each item. A 
high score on the M-ABC indicates poor performance. The total impairment score, which 
is the sum of the item scores, was calculated into a percentile score. A score below the 
5th percentile is indicative of a motor problem, a score between the 5th and 15th percentile 
means borderline performance and a score above the 15th percentile is a normal score.17 
 
Exercise test. The children seen in Rotterdam performed a graded, maximum exercise 
test using a motor driven treadmill. The treadmill was programmed for increases in angle 
of inclination and speed every 3 minutes according to the Bruce-protocol.19,20 The Bruce-
protocol starts with a speed of 2.7 km per hour at an incline of 10%. The children are 
encouraged to perform to voluntary exhaustion. The maximal endurance time was used 
as criterion of exercise capacity and compared to data reported by Cumming and 
colleagues.20 
 
 
Figure 1 Assessment protocol at 5 years of age 
 Time 
(hours) 
Instrument Nijmegen Rotterdam
Medical assessment  
 (paediatrician) 
1 Physical and neurological 
 examination 
x x 
Neuromotor assessment  
 (paediatric physiotherapist) 
1.5 Movement ABC 
Exercise test 
x x 
x 
Neuropsychological assessment 
 (psychologist and speech therapist) 
3    
  Intelligence  RAKIT/WISC-R x x 
  Concentration  Bourdon-Vos  x 
  Visual-motor integration  Beery  x 
  Receptive language development  Reynell x x 
  Expressive language development  Schlichting x x 
  Behaviour  CBCL/TRF x x 
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Neuropsychological assessment 
Cognitive development. A short version of the revised Amsterdam intelligence test for 
children (RAKIT) was used to evaluate cognitive development. The RAKIT is a well-
known standardised instrument in the Netherlands for children aged from 4 - 11 years. 
Good reliability and validity have been demonstrated.22,23 The short version contains six 
sub-tests. The raw sub-test scores are converted into standardised scores, which are 
then transformed into a short RAKIT IQ with a mean of 100 and a standard deviation 
(SD) of 15. Cognitive delay was defined by a test result of more than -1 SD below the 
norm (i.e., IQ ≤ 85).  
 
Visual-motor integration. The Developmental Test of Visual-Motor Integration (VMI 
Beery) for children from 3 - 18 years measures the integration of visual perceptual and 
motor abilities.24 Children are asked to copy figures of increasing geometric complexity. 
The computed raw item scores are transformed into a VMI standard score with a mean 
of 100 and a SD of 15. 
 
Behaviour. The Dutch versions of the Child Behaviour Checklist (CBCL) and the 
Teacher’s Report Form (TRF) were completed by parents and teachers, respectively.25,26 
Both have been standardised for the Dutch population from 4 - 18 years and rate 120 
problem behaviour items on a 3-point scale ranging from 0 = not true, 1 = somewhat true 
or sometimes true, 2 = very true or often true.27,28 A total problem score is computed by 
summing the scores of all items. Two broadband scales were constructed: an 
Internalising scale including withdrawn behaviour, somatic complaints without physical 
cause, and anxious-depressive feelings, and an externalising scale including aggressive 
and delinquent behaviour. Total scores ≥ 60 classify children in the borderline/clinical 
range. 
 
Language development. Language development was assessed with the Reynell Test 
and the Schlichting Test. The Reynell test assesses receptive language development of 
Dutch speaking children between ages 1 and 6 years.29 Expressive language is not 
required since the children may respond non-verbally. 
The Schlichting Test assesses language expression of Dutch speaking children between 
ages 1 and 6 years.30 Two subtests were applied, one testing knowledge of grammatical 
structure (syntactical development), the other measuring active vocabulary (lexical 
development).  
The numbers of correct answers in the tests were transformed into standard quotient 
scores with a mean of 100 and a SD of 15. The following categories were discerned: 
delayed/abnormal development (score < -2 SD), at risk (score -1 to -2 SD) and normal 
(score > -1 SD). 
 
Data analysis 
Data are presented for the entire group and also by diagnosis. When appropriate an 
independent samples Student t-test was performed to analyse differences between the 
study group and general population norms with p < 0.05 for statistical significance.  
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A chi-square test was performed to test if the motor performance scores in this ECMO 
population differed significantly from the distribution in the normal population; p-values 
< 0.05 were considered statistically significant. 
 
 
Results 
 
A total of 144 neonates received VA-ECMO support from January 1996 up to and 
including December 1998. Thirty-one of them (22%) died before age 5 years, all during 
first admission at median age 21 days (IQR 11 - 35 days/range 2 - 120)). Fourteen 
infants were lost to follow-up for various reasons. Of two the present addresses could not 
be traced, the families of three moved abroad, and parental consent was withheld for 
five. Four other children failed to appear, even after repeated invitations. Thus, 99 infants 
participated in the follow-up program (Fig. 2.)  
However, the parents of one child withheld consent to use data for publication purposes, 
so eventually we present data of 98 children (Rotterdam 35, Nijmegen 63) (87%). 
Their perinatal and ECMO-treatment characteristics are presented in Table 1. Their basic 
characteristics at time of follow-up are presented in Table 2.  
 
 
Figure 2 Flow sheet infants included in follow-up program. 
 
 
 
144 
neonates received VA-ECMO support between 
January 1996 and December 1998 
31 infants 
died 
113 infants eligible for 
follow-up 
2 unknown residence 
3 moved to abroad 
6 no consent  
4 unknown reason
98 infants participated in 
follow-up program 
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Table 1  Perinatal and ECMO characteristics 
Male / Female 60 / 38 
Birthweight (kg) 3.3 (2.9 - 3.8) 
Gestational age (wk.) 40 (38 - 41) 
Apgar score at 1/5 min. 5/7 
Primary diagnosis: MAS 
     CDH 
     Sepsis 
     PPHN 
     CCAML 
51 
20 
11 
15 
1 
Outborn (No.): 
     Home 
     > 20 km from ECMO centre 
     < 20 km from ECMO centre 
91 
10 
51 
30 
Oxygenation index prior to ECMO* 39 (24 - 58) 
AaDo2* 622 (606 - 637) 
Age at start of ECMO (hours) 28 (17 - 43) 
Duration of ECMO support (hours) 155 (127 - 188) 
Duration of mechanical ventilation (days) 16 (13 - 22) 
Supplemental O2 after ECMO (days) 8 (4 - 16) 
Duration of first admission (days) 38 (30 - 55) 
Haemorrhagic intracranial abnormalities (No.) 
     Minor: IVH grade 1 and 2 
     Major: IVH grade 3 and 4  
 
8 
0 
Nonhaemorrhagic intracranial abnormalities (No.) 
     Minor: ventricular dilatation and focal atrophy 
     Major: general atrophy and infarcts 
 
17 
4 
Observed infants with epileptic insults (No.) 27 
Patients treated with phenobarbital as prophylaxis (No.) 37 
Duration of phenobarbital treatment in infants with epileptic insults (days) 49 (21 - 90) 
Presented are the perinatal characteristics of the group of 98 children available for analysis. Data 
given are number (%) of infants or median (IQR).  
MAS  meconium aspiration syndrome.  
CDH  congenital diaphragmatic hernia.  
PPHN  persistent pulmonary hypertension of the newborn.  
CCAML congenital cystic adenoid malformation of the lung.  
Oxygenation index was calculated as [(Mean airway pressure × FiO2)/PaO2] × 100.  
AaDO2 Alveolar arterial oxygen distention gradient and was calculated as Patm- PH2O- PaO2 - 
PaCO2 (PaO2 and PaCO2 in mmHg).  
IVH  Intraventricular haemorrhage. 
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Table 2  Basic characteristics of the study group at 5 years of age 
 Total group 
n = 98 
Males/females   60/38 
Age (months)   62 (3.0) 
Weight SD score   -0.5 (1.5)* 
Height SD score   -0.4 (1.2)** 
Weight for height SD score   -0.4 (1.4)*** 
SES High (%) 
  Normal (%) 
  Low (%) 
  Unknown (%) 
  26 (27) 
  49 (50) 
  19 (19) 
  4 (4) 
Ethnic group: White (%) 
  African (%) 
  Asian (%) 
Turkish or Moroccan (%) 
  85 (87) 
  3 (3) 
  1 (1) 
  9 (9) 
Data are presented as number (%) of patients or mean (SD).  
SES: socio-economic status.  
Mean weight, height and weight for height in SD score for the entire population were all significantly 
below zero (* p = 0.001, ** p = 0.002, *** p = 0.008) 
Children with CDH had significantly lower height and weight than children with MAS (p < 0.001) 
 
 
Outcome medical assessment 
Seventeen children (17%) were found to have a neurological disorder. Six of those (6%) 
showed major neurodevelopmental disability, including two with a chromosomal 
abnormality. Of the latter, one was known with Down syndrome and the second 
(diagnosed with CDH) showed unbalanced translocation of chromosome 11 - 22 
(unknown at the time of ECMO). This boy was severely impaired and mentally retarded, 
and is known to have died at age 6 years. One of the other four children with major 
neurological disorder had a right-sided hemiplegia caused by nonhaemorrhagic infarction 
during ECMO. He walked with an orthesis and attended special education. The second 
had developed a right-sided hemiplegia as a result of left-sided cerebral hemi-atrophy. 
He was confined to a wheelchair and was mentally retarded. The third (diagnosed with 
MAS) had severe asphyxia and had been resuscitated in the immediate postnatal period. 
Still suffering from a seizure disorder, she used a walking frame and was mentally 
retarded. The fourth suffered from seizures, used a wheelchair and was mentally 
retarded.  
Eleven children (11%) showed minor neurological dysfunction, varying from strength 
differences in upper and lower extremities to very mild hemiplegia and a mild form of 
West syndrome (one child). 
Mean (SD) weight and height in SD score for the entire population was -0.5 (1.5) and 
-0.4 (1.2), respectively (Table 2). Both were significantly below zero (p = 0.001 and 
p = 0.002 respectively). Eighteen children (18%) had respiratory complaints. Twelve of 
them regularly used a combination of beta-sympathicomimetic drugs and inhalation 
steroids. None of the children needed supplemental oxygen. Two children were followed 
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because of a muscular ventricular septal defect (VSD), without haemodynamic 
consequences; one because of atrial septal defect (ASD). One of the twenty children 
diagnosed with CDH was still on (nightly) tube feeding because of low weight (-3,4 SD) 
and pulmonary problems, and a second had received tube feeding until his fourth 
birthday. The child who was known with unbalanced translocation of chromosome 11-22 
was fed through a gastrostomy drain and had undergone a Nissen fundoplication 
because of gastrooesophageal reflux. Another child, not diagnosed with CDH, was fed 
through a gastrostomy drain as well.  
 
Outcome neuromotor assessment 
Excluding the 6 children with major neurodevelopmental disability, 92 of the 98 children 
were tested using the Movement Assessment Battery for Children (M-ABC). Twenty-four 
children (26.1%) were classified as having some kind of motor difficulty (percentile score 
< P 15), which represents a significantly higher proportion than expected (Chi-square: 
p < 0.005). 
Fourteen children (15.2%) had scores indicative of a motor problem (percentile score 
< P 5) (Chi-square: p < 0.001), ten (10.9%) had borderline performance (percentile score 
< P 15; > P 5) and 68 (73.9%) performed normally (percentile score > P 15) (Table 3). 
A comparison with population norms revealed that the mean (SD) M-ABC score of the 
total group was significantly below reference value; 8.4 (8,1) versus 5.2 (5.6) p < 0.001.17 
 
 
Table 3 Movement-ABC results  
 Total group  
n = 92 
MAS 
n = 49 
CDH 
n = 19 
Sepsis 
n = 11 
PPHN 
n = 12 
Total impairment score mean (SD) 8.4 (8,1)*  6.8 (6.6) 13.4 (10,3) 7.5 (7.5) 7 (7.1) 
< P 5  motor problem n (%) 14 (15.2%)** 3 (6.1) 7 (36.8) 1 (9.1) 2 (16.7) 
P 5 - P 15 borderline n (%) 10 (10.9%) 3 (6.1) 4 (21.1) 2 (18.2) 1 (8.3) 
> P 15  normal n (%) 68 (73.9%)*** 43 (87.8) 8 (42.1) 8 (72.7) 9 (75) 
*  t-test   significant p < 0.001 
**  Chi square significant p < 0.001 
***  Chi square  significant p < 0.005 
 
 
Table 4 Exercise test 
 Total group 
n = 29 
boys 
n = 15 
girls 
n = 14 
Endurance time in minutes (mean (S.D.))  9.0 (1.2)* 9.2 (1.8) 
< -2 SD  abnormal [n(%)] 1 (3.4%) 0 1 
-1 SD - -2 SD suspect  [n(%)] 8 (27.6%) 7 1 
> -1 SD  normal  [n(%)] 20 (69.0%) 8 12 
Score according to Cumming et al. 
* t-test  significant p < 0.001 
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Twenty-nine of the 35 children seen in Rotterdam performed the exercise test according 
to the Bruce protocol (Table 4). Five children with major neurological impairment could 
not perform the test. One child (diagnosed with CDH) was too anxious to use the 
treadmill and performed a six-minute walking test instead. Height and weight of the 29 
children (15 boys) were expressed as SD-scores. These were not significantly below or 
above reference value (SD = 0) and there were no significant differences between boys 
and girls. Comparison of endurance times to the Canadian norms reported by Cumming 
et al.20 revealed significantly lower mean (SD) endurance time for the boys; 9.0 (1.2) 
versus 10.4 (1.9) (p < 0.005). Mean endurance time for the girls was not significantly 
different: 9.2 (1.8) versus 9.5 (1.8) (p = 0.6). 
 
Outcome neuropsychological assessment 
In order to create a mutually comparable group, three children with chromosomal or 
syndromal abnormalities as well as 11 children who did not have Dutch as a native 
language and one with severe hearing problems were excluded from data analysis. One 
child’s data on all neuropsychological tests were lost, leaving 82 children for analysis. 
For three children all data on cognitive development were missing. Three children could 
not be successfully tested on expressive language, and one neither on expressive nor on 
receptive language. In Rotterdam visual-motor integration was tested in 28 out of 35 
children. Major neurological impairment precluded testing in five children and data of two 
other children were missing. Neuropsychological outcome data are presented in Table 5. 
 
Cognitive development Eleven children (14.1%) showed cognitive delay. The mean 
RAKIT score of the total group (IQ = 100.5) did not differ significantly from the Dutch 
norm. 
 
Language development In the expressive language test, 13 children (16.7%) scored 
≥1SD below the norm on grammar and vocabulary. In the receptive language test, six 
children (7.3%) scored ≥ 1SD below the norm. The mean scores on grammar and 
receptive language were significantly above the Dutch norm. 
 
Visual-motor integration Seven children (25%) scored ≥ 1SD below the norm. The 
mean score of the total group did not differ significantly from the Dutch norm. 
 
Behaviour The results of the Child Behaviour Checklist are presented in Table 6. Of all 
children, 12.8% had a total problem score above 63, indicating behavioural problems. 
Internalising problems occurred slightly more than did externalising problems. 
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Table 5 Neuropsychological outcome 
 Total group  
(n = 82) 
IQ (n = 79) 
 70 - 85  
 51 - 70  
 ≤ 50  
100.5 (19.7) 
4 (5.1%) 
3 (3.9%) 
4 (5.1%) 
Expressive Language (n = 78) 
Grammar  
 70 - 85  
 51 - 70  
 ≤ 50  
Vocabulary  
 70 - 85 
 51 - 70  
 ≤ 50 
 
104.2a (17.9) 
11 (14.1%) 
2 (2.6%) 
- 
103.2 (19.6) 
6 (7.8%) 
5 (6.5%) 
2 (2.6%) 
Receptive Language (n = 81) 
 70 - 85 
 51 - 70 
 ≤ 50 
104.3a (15.3) 
1 (1.2%) 
5 (6.1%) 
- 
Visual-Motor Integration (n = 28) 
 70 - 85 
 51 - 70 
 ≤ 50 
96.6 (13.7) 
7 (25%) 
- 
- 
Data are presented as mean (SD) and or as n (% of total number) 
a significant difference (p < .05) from the Dutch population norm 
 
 
Table 6 Child behaviour checklist 
CBCL  n = 86 
Total problem score  
< 60 
60 - 63 
> 63  
 
72 (83.5%) 
5 (5.9%) 
9 (10.5%) 
Internal problem score 
< 60 
60 - 63 
> 63 
72 (83.7%) 
7 (8.1%) 
7 (8.1%) 
 
External problem score  
< 60 
60 - 63 
> 63 
76 (88.4%) 
6 (7.0%) 
4 (4.7%) 
Presented are number of patients (%). The internal scale includes withdrawn behaviour, somatic 
complaints without physical cause and anxious-depressive feelings. The external scale includes 
aggressive and delinquent behaviour. Scores ≥ 60 but < 63 are in the borderline range. Scores ≥ 63 
are in the clinical range. 
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Discussion 
 
This report presents nation-wide neurodevelopmental sequelae of 98 VA-ECMO-treated 
neonates at age 5 years (87% of all survivors). Seventeen children (17%) presented with 
major or minor neurological disorders. Another 24 (26.1%) presented with some kind of 
motor difficulty, 14 of whom (15.2%) had an actual motor problem and ten (10.9%) were 
at risk for that. Cognitive delays were identified in eleven children (14%). 
 
Two of the 17 children with neurological disability had a chromosomal disorder 
accounting for neurological impairment and one child had West syndrome associated 
with mental retardation and seizures. Four of the remaining 14 patients (14%) had major 
and 11 had minor neurological impairment without an underlying disorder. Our findings 
seem not completely consistent with findings reported by Glass et al.16 in 103 children: 
17% had one or more major disability versus 14% in our group. However, Glass et al. 
ranked mental disability, as well as motor disability and seizure disorders, also under 
major disability. Had we included children who scored abnormal in the medical, motor or 
mental assessment as well, we would have found a similar proportion (17%). 
 
The UK-ECMO Trial Group has reported on the outcome of ECMO-treated neonates at 
age 4 years.15 A consistent comparison is hampered by the fact that methods were 
different. In the UK one paediatrician assessed the children in six clinical domains, 
including cognitive ability, neuromotor skills, general health, behaviour, vision and 
hearing. Nineteen percent of the children had test scores outside the normal range. With 
regard to ‘disability’, 13% of the children were moderately to severely disabled, which is 
consistent with the 14% we report. 
 
The rate of motor difficulties in our cohort was 26% (score < P15); 15% had an abnormal 
motor score (score < P5). This 15% exceeds the 6% reported by Glass et al.16 
Unfortunately, few follow-up studies have used standardised tests such as the M-ABC to 
assess neuromotor outcome. Even in our study some of the children with minor motor 
difficulties were assessed normal at neurological examination. However, in the M-ABC 
assessment they are stressed to move under velocity or accuracy demands. Such 
circumstances are more sensitive to detect motor performance problems. It is essential 
therefore that professionals with specific experience should assess the developmental 
domains in the context of a structured follow-up program. 
 
In our study 29 children performed a maximum exercise test. The maximal endurance 
time was used as criterion of exercise capacity and we compared outcomes with data 
presented by Cumming and colleagues.20 Binkhorst et al. in 1992 published references 
values for normal exercise performance in Dutch boys and girls aged 4 - 18 years using 
the Bruce treadmill protocol.21 However, they included few 4-year-olds, the number of 6-
year-olds is unclear, and did not provide means and standard deviations for these ages. 
This is why we did not use these Dutch reference values. Nevertheless 41% of the 
children in our study would score below the 5th percentile according to these Dutch 
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reference values. The question is whether this can be explained by impaired physical 
condition of ECMO-treated patients or by the fact that the reference values established 
by Binkhorst et al. insufficiently reflect the exercise performance of contemporary healthy 
Dutch children. Future studies are needed and will be performed in Erasmus MC – 
Sophia Children’s Hospital in the near future. 
 
Follow-up at age 5 is important because children are in their first or second year of 
primary school, at the start of their further school career. Eleven children (14%) showed 
cognitive delay, a proportion comparable to that reported by Glass et al. (13%). The IQ 
summary scores are comparable as well: 100 in our cohort versus 96. Although in the 
UK-ECMO trial cognitive ability at age 4 did not show evidence of a difference between 
the two trial groups, 26% of ECMO-treated children showed cognitive delay defined as 
an IQ>-1SD.15  
 
Behavioural problems beyond the clinical cut-off point were identified in eleven children. 
These problems might contribute to school failure, even in the absence of cognitive 
delay.31  
Language development scores were all above population norms. However, children 
without Dutch as their native language who had difficulty understanding and speaking 
Dutch were excluded from these tests. Still, language development seems not affected. 
 
In the absence of a matched control group it remains difficult to establish to what extent 
ECMO treatment contributes to the outcome. The UK-ECMO trial did show a benefit of 
ECMO based on the primary outcome of death or severe disability. At age 4 there was 
no evidence of significant difference regarding cognitive ability and motor disability 
between the conventional treatment and ECMO groups.15 The rate of disability (i.e. 
cerebral palsy) reported in a study of 89 surviving children with moderate to severe 
perinatal asphyxia at age 8 years was 15%. Ten percent had profound cognitive delay.32 
The intelligence quotient in a group of non-disabled children with mild and moderate 
perinatal asphyxia was 106 (±14).32 These proportions are in the same range as the 
proportions reported in this study.  
 
In conclusion, the outcome figures of ECMO-treated neonates at follow-up at age 5 years 
presented in this study do not greatly differ from those reported in previous publications 
on ECMO treated neonates.15,16 The high response rate of 87 % (vs. 61% by Glass et al.) 
was feasible for various reasons: co-operation between two centres, small travelling 
distances as well as the quality of the health care system in the Netherlands. We believe 
that a successful follow-up programme of severely ill neonates should be structured in 
consultation with representatives from different disciplines, such as a paediatrician, a 
paediatric physiotherapist, a psychologist and a speech therapist. Further longitudinal 
follow-up studies will focus on the relationship between neonatal status and test results 
at 5 years and on detailed analysis of the different domains. Within the framework of the 
nation-wide follow-up program longitudinal data at ages 8 and 12 years are expected to 
become available in due time. 
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Abstract 
 
Neonates with reversible cardio-respiratory failure may be treated with extracorporeal 
membrane oxygenation (ECMO). We evaluated lung function longitudinally at 6 and/or 
12 months of age in a group of ECMO survivors. Functional residual capacity (FRCp) and 
forced expiratory flow at FRC (V'maxFRC) were measured and expressed as Z scores. 
We studied 45 infants, 35 were evaluated at 6 months and 35 at 12 months; 25 infants 
completed both measurements. Mean (SEM) FRCp in Z score was -0.2 (0.2) and 0.1 
(0.2) at 6 and 12 months respectively. Mean (SEM) V’maxFRC in Z score was significantly 
below normal values (p < 0.001) at 6 and 12 months: -1.3 (0.2) and -1.2 (0.2), 
respectively. Infants with congenital diaphragmatic hernia (CDH) had a higher mean 
(SEM) FRCp in ml/kg compared to infants with meconium aspiration syndrome; 32.3 (2.4) 
versus 26.6 (1.3) (p = 0.047). In CDH infants, FRCp in Z score was above reference 
value at 12 months of age (p = 0.03). 
 
We conclude that during the first year of life, these infants have normal lung volume and 
reduced expiratory flow. Flows showed normal development at a level below average. 
This study is the first, providing data on longitudinal development of lung function post 
ECMO, in early infancy. 
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Introduction 
 
Extracorporeal membrane oxygenation (ECMO) is a supportive intensive care technique 
mainly used for newborn infants with acute reversible cardio-respiratory failure and a 
high mortality risk with conventional management. Conventional management ranges 
from pressure controlled ventilation to high frequency ventilation, with or without inhaled 
nitric oxide (NO). ECMO consists of prolonged cardiopulmonary bypass while resting the 
lungs and using minimal ventilator settings. It is thought that this promotes lung healing 
and prevents further injury from high oxygen concentration and barotraumas.1 The UK 
ECMO trial conferred a survival advantage of ECMO over conventional management, 
without a concomitant increase in severe disability.2,3 However, ECMO may promote 
survival of infants with severe respiratory dysfunction, who would otherwise have died. 
This could result in a poor respiratory status in infants treated with ECMO. On the other 
hand, the (early) institution of ECMO in selected cases avoids prolonged “aggressive” 
ventilation and its sequelae (inflammatory response, volutrauma), which has been shown 
to be associated with subsequent alterations in respiratory mechanics.4,5 Hence, 
investigation of the respiratory function of survivors is important to assess whether or not 
ECMO results in a survival advantage.6 Several groups studied respiratory function in 
infants during or shortly after ECMO,7-9 at 6 months10 or at 12 months.6 These studies 
found a reduction in pulmonary function during the first year of life as sequelae of severe 
respiratory disease, despite ECMO. Longitudinal data are only available for infants 
during or shortly after ECMO, ranging from 1 day to1month after decannulation7,8 To our 
knowledge, no study evaluated lung function in ECMO survivors longitudinally during the 
first year of life. Therefore, we evaluated lung function in a prospective longitudinal study 
at 6 and 12 months of age, in a group of ECMO survivors. Furthermore, we studied the 
relationship between lung function and perinatal patient characteristics.  
 
 
Methods 
 
Subjects 
A follow-up study was conducted in neonates who received veno-arterial ECMO support 
between February 2001 and September 2003 at the Pediatric Surgical Intensive Care 
Unit of the Sophia Children's Hospital. ECMO support was given in case of reversible 
severe respiratory failure and when a mortality risk of 80% was estimated. Indications for 
ECMO were derived from the “classical” criteria of the National Medical Center ECMO 
Team, which remained unchanged during the study period.11 Criteria used to define this 
mortality risk were an oxygenation index > 40 in 3 to 5 subsequent arterial blood gases, 
an alveolar arterial oxygen gradient (AaDO2) > 600 during 8 hours with a FiO2 of 100% 
and signs of barotrauma. Exclusion criteria for ECMO support were:  
a. gestational age < 34 weeks or a birth weight of < 2 kg,  
b. intraventricular hemorrhage grade II,  
c. known bleeding disorders,  
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d. high pressure ventilation for more than 10 days prior to ECMO support,  
e. any reason to question continuation of conventional management (for example a 
major congenital or chromosomal anomaly).  
 
Artificial ventilation was administered by conventional mechanical ventilation (CMV) 
(Babylog 8000, Dräger Medical, Germany) or high-frequency oscillatory ventilation 
(HFOV) (Oscillatory Ventilator, model 3100A, Sensormedics, the Netherlands). The initial 
ventilation strategy was not randomized in our study. According to hospital practice 
surfactant therapy was occasionally used, based on the attendings preference, in the 
treatment of meconium aspiration syndrome (MAS). As a consequence Surfactant 
therapy was not randomized in this study. The study was part of a structured clinical 
follow-up program. According to the Dutch law, approval from a medical ethical 
committee was therefore not required. All parents gave written informed consent. 
 
Lung function 
The technique used in measuring lung function was previously described.12 In brief, lung 
function measurements were performed at 6 and 12 months of age, when the infants had 
no signs of infection or acute respiratory symptoms for at least one week prior to testing. 
Infants with a known bronchopulmonary dysplasia (BPD), defined as oxygen 
dependence at age 28 days and a chest radiogram at one month of age typical for BPD, 
were excluded.13 To prevent the infants from waking up during the measurements, they 
were sedated with choral hydrate (50 - 75 mg/kg). First, airway resistance was measured 
using the interrupter technique (Rint) (MicroRint, Micro Medical Ltd, Rochester, UK). 
Then, functional residual capacity (FRCp) was measured by means of a modified whole 
body plethysmograph (Baby Body, Jaeger, Würzburg, Germany). Mean FRCp of 3 to 5 
technically acceptable measurements was expressed as Z score.14 Finally, forced 
expiratory flow at FRC (V’maxFRC), used as a measure of airway patency, was assessed 
using the end-tidal rapid thoracoabdominal compression (RTC) technique (Custom-made 
equipment. Department of Experimental Medical Instrumentation, Erasmus University 
Medical Center, Rotterdam). Equipment and procedures were in accordance with 
guidelines.14-16 Mean V'maxFRC of 3 to 5 technically acceptable measurements was 
expressed as Z score.17  
 
Analysis  
Demographic data of the 25 infants with paired measurements were compared with the 
20 infants with single measurements using Mann-Whitney of chi-square test where 
applicable. Lung function measurements at 6 and 12 months and lung function 
measurements of MAS and CDH were compared using mixed-model ANOVA (SAS, 
PROC MIXED). Where applicable, the difference in lung function was evaluated using 
paired Student’s T-test or one sample T-test. The influence of various perinatal variables 
(gestational age, birthweight, number of surfactant dosages, mean airway pressure, age 
at start ECMO, duration of ECMO therapy, duration of oxygen and days of ventilation) on 
level of lung function was evaluated by multiple regression analyses. The significance 
level was set at p < 0.05. 
Lung function during the first year of life in infants following ECMO 
 91
Results 
 
Between February 2001 and September 2003, 69 neonates received ECMO treatment of 
which 54 infants survived. Lung function measurements were performed from February 
2002 until May 2004 in 45 infants. Four patients were lost to follow-up, the parents of one 
patient did not give consent, two patients were excluded because of BPD together with 
another patient who was neurological unstable, 1 patient did not sleep during the 
procedure (Figure 1). Except for the two infants with BPD, the oxygenation index and 
total days of mechanical ventilation did not significantly differ from the study group (data 
not shown). 
Twenty-five infants were measured both at 6 and 12 months of age. Reasons for not 
completing both measurements were being older than 6 months at the beginning of the 
study (n = 10) or being younger than 12 months at the end of the study (n = 10).  
 
 
Figure 1 Flow-sheet of included and excluded infants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
69 neonates received ECMO support between 
February 2001 and May 2003 
15 infants died (10 CDH, 
4 sepsis, 1 PPHN) 
 
1 No informed consent 
53 infants enrolled in study 
4 Lost to follow up 
2 BPD 
1 Neurological unstable 
1 Not sleeping 
Lung function measurement in 45 Infants: 
 
35 infants at 6 months. 
(10 too old at study entry) 
 
35 infants at 12 months. 
(10 too young at end of study) 
 
25 infants had paired measurements 
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Table 1 Demographic data 
 
 
Total group 
 
n = 45 
Measurement at 
6 months 
n = 35 
Measurement at 
12 months 
n = 35 
 
Gestational age (wk) 
 
40.3 (1.4) 
 
40.3 (1.2) 
 
40.3 (1.4) 
Birth weight (g) 3527 (570) 3497 (600) 3464 (499) 
Males 23 18 19 
MAS 26 21 20 
CDH 8 5 7 
Sepsis 3 1 3 
PPHN 3 3 3 
IRDS 5 5 2 
Age at start of ECMO support (hours) 24 (5 - 398) 22 (5 - 398) 22 (5 - 252) 
MAP prior to ECMO (cm H2O) 20 (5) 20 (5) 20 (4) 
PIP prior to ECMO (cm H2O) 35 (8) 36 (7) 36 (8) 
FiO2 prior to ECMO  1 (0) 1 (0) 1 (0) 
Oxygenation index prior to ECMO* 38 (10 - 167) 39 (10 - 143) 38(10 -167) 
Inhaled NO prior to ECMO (ppm) 20 (0 - 40) 20 (0 - 40) 20 (0 - 40) 
Duration of ECMO support (hours) 115 (53 - 253) 115 (53 - 238) 118 (53 - 253) 
Duration of mechanical ventilation (days)# 14 (6 - 47) 14 (6 - 47) 14 (6 - 47) 
Duration of oxygen dependence (days) 18 (5 - 76) 21 (8 - 74) 26 (5 - 76) 
Surfactant treated newborns 18 14 15 
Data given are number of infants or mean (SD) or median (range). Shown are the total group, and the 
subgroups of infants measured at 6 months, and measured at 12 months of age.  
GA  gestational age 
MAS Meconium aspiration syndrome 
CDH Congenital diaphragmatic hernia 
PPHN Persistent Pulmonary Hypertension of the Newborn 
IRDS Respiratory distress syndrome of infancy  
MAP Mean Airway Pressure 
PIP Peak inspiratory pressure 
HFOV high-frequency oscillatory ventilation 
FiO2 Fraction of inspired oxygen 
NO  Nitric oxide (parts per million)  
*  Oxygenation index was calculated as: [(Mean airway pressure * FiO2)/PaO2] •100 
#  Duration of mechanical ventilation includes mechanical ventilation prior and after ECMO 
treatment 
 
 
Demographic data of the cohort of 45 infants are shown in table 1. Except for birthweight 
the demographic data of the 25 infants with paired measurements were comparable with 
the 20 infants with single measurements. Reasons for ECMO support were meconium 
aspiration syndrome (MAS) (n = 26), congenital diaphragmatic hernia (CDH) (n = 8), 
persistent pulmonary hypertension of the newborn (PPHN) (n = 3), sepsis (n = 3) and 
respiratory distress syndrome of infancy (IRDS) (n = 5). All CDH infants had undergone 
surgical repair after decannulation from the ECMO-circuit. The first and second lung 
function measurements were performed at a mean (SD) age of 6.4 (0.5) and 12.2 (0.6) 
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months, respectively. The results of the Rint, FRCp and the V'maxFRC measurements are 
shown in table 2.  
 
 
Table 2 Lung function during first year of life in infants following ECMO 
 Measurement at 
6 months 
(Mean ± SEM) 
Measurement at 
12 months 
(Mean ± SEM) 
Mean difference 
(95% CI) 
Length (cm) 68.2 (0.5) 76,7 (0.5)  
Weight (kg) 7.4 (0.2) 9.5 (0.2)  
Rint (kPa/l/s) 3.5 (0.2) 3.2 (0.2) -0.3 (-0.8 to 0.2) 
FRCp (ml/kg) 26.8 (0.9) 27.8 (1.0) 1.0(-0.5 to 2.5) 
FRCp (Z score) -0.2 (0.2) 0.1 (0.2) 0.3 (-0.1 to 0.7) 
V’maxFRC (ml/s) 128.0 (11.7) 189.3 (14.6) 61.2 (36.3 to 86.1)* 
V’maxFRC (Z score)† -1.3 (0.2)# -1.2 (0.2)# 0.05 (-0.3 to 0.4) 
Results of lung function measurements in infants following ECMO during the first year of life. At 
measurement 1 and 2, the mean (SD) corrected age was 6.4 (0.5) and 12.2 (0.6) months, respectively. 
Rint   airway resistance measured by means of interrupter technique 
FRCp  functional residual capacity 
V’maxFRC forced expiratory flow at FRC 
*   p < 0.0001 
#   Significantly below normal (p < 0.0001) 
 
 
For the whole group, mean (SEM) V'maxFRC in Z score was significantly below zero 
which, for Z scores, corresponds to the normal value both at the first and second 
measurement (p < 0.001) (table 2, figure 2). Between the two measurements there was a 
mean (95% CI) change of V'maxFRC in Z score of 0.05 (-0.3 to 0.4) (p = 0.75). Similar 
results were seen within the subgroup of 25 infants who completed both measurements: 
Mean (SEM) V’maxFRC in Z score at 6 and 12 months was -1.5 (0.2) and -1.4 (0.2), 
respectively, with a mean (95% CI) difference of 0.1 (-0.3 to 0.4)(p = 0.67).  
 
Infants who received ECMO for MAS or CDH were analyzed separately. Their lung 
function results are shown in table 3. At 12 months of age, infants with CDH had a higher 
mean (SEM) FRCp in ml/kg as compared to infants with MAS; 32.3 (2.4) and 26.6 (1.3) 
respectively, with a mean (95% CI) difference of 5.6 (0.2 to 11.0) (p = 0.047). FRCp in Z 
score in CDH infants was significant above the reference value (Z score = 0) at 12 
months of age (Mean (95% CI) difference: 1.3 (0.1 to 2.4) (p = 0.03)).  
 
There was a significant correlation between days of mechanical ventilation (prior and 
after ECMO) and FRCp in ml/kg and in Z score at 6 months (r = 0.52, p = 0.002 and 
r = 0.54, p = 0.002, respectively) and at 12 months (r = 0.62, p < 0.001 and r = 0.66, 
p < 0.001, respectively) (Figure 3) None of the other perinatal patient characteristics, 
including age at receiving ECMO or the duration of ECMO, correlated with lung function 
parameters when adjusted for the effect of days of mechanical ventilation. 
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Table 3 Lung function differences between MAS and CDH 
 Measurement at 6 months Measurement at 12 months 
 MAS 
n = 21 
CDH 
n = 5 
Mean difference 
(95% CI) 
MAS 
n = 20 
CDH 
n = 7 
Mean difference 
(95% CI) 
Rint (kPa/l/s) 3.8 
(0.3) 
3.2 
(0.5) 
-0.5 
(-1.7 to 0.5) 
3.2 
(0.3) 
3.3 
(0.4) 
0.1 
(-0.9 to 1.1) 
FRCp (ml/kg) 26.4 
(1.2) 
30.4 
(2.4) 
3.9 
(-1.4 to 9.2) 
26.6 
(1.3) 
32.3 
(2.4) 
5.6 
(0.2 to 11.0)* 
FRCp (Z score) -0.2 
(0.3) 
0.7 
(0.5) 
0.9 
(-0.3 to 2.1) 
-0.1 
(0.3) 
1.1 
(0.6)# 
1.3 
(0.0 to 2.6) 
V’maxFRC (ml/s) 106.0 
(13.8) 
122.9 
(27.4) 
17.0 
(-43.1 to 77.1) 
177.8 
(20.2) 
193.3 
(34.9) 
15.5 
(-63.7 to 94.7) 
V’maxFRC (Z score) -1.7 
(0.2) 
-0.9 
(0.4) 
0.8 
(-0.1 to 1.7) 
-1.5 
(0.3) 
-1.0 
(0.4) 
0.4 
(-0.6 to 1.4) 
Mean (SEM) lung function data between infants who received ECMO because of meconium aspiration 
syndrome (MAS) or congenital diaphragmatic hernia (CDH) 
* p = 0.047 
# Significantly above reference value (p = 0.03) 
 
 
Figure 2 Lung function data of 36 infants following ECMO 
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Lung function data of 45 infants following ECMO. The first (n = 35) and second (n = 35) measurement 
were done at a mean (SD) age of 6.4 (0.5) and 12.2 (0.6) months, respectively. Mean (SEM) V’maxFRC 
in Z score was -1.3 (0.2) and -1.2 (0.2) at the first and second measurement respectively. Twenty-five 
infants completed both measurements (connected datapoints). 
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Figure 3  Correlation between FRCp in z-score and days of mechanical ventilation 
 
Correlation between FRCp in Z score and days of mechanical ventilation. There was a significant 
correlation between days of mechanical ventilation (prior and after ECMO) and FRCp in Z score at 6 
months (r = 0.54, p = 0.002 resp.) and at 12 months (r = 0.66, p < 0.001). 
 
 
Discussion 
 
In this study we prospectively evaluated lung function during the first year of life in a 
cohort of 45 infants who received ECMO support. Furthermore, we studied the 
relationship between lung function and perinatal patient characteristics. We found normal 
lung volume and subnormal forced expiratory flow during the first year of life.  
 
To our knowledge, this is the first longitudinal study on the growth of airway function 
during the first year of life in survivors of ECMO. Two cross-sectional studies were 
published. Greenspan and colleagues9 studied pulmonary function in 25 infants prior to 
ECMO, immediately after decannulation and at time of nursery discharge at 
approximately 1 month of age. FRC at time of discharge were comparable with our 
results; i.e. 26 ml/kg. The V’maxFRC is best compared when using the normative data by 
Sly and colleagues.15 the V’maxFRC in Z score at 1 month of age in this study was 
approximately -0.3 SD. It was not feasible to calculate the V’maxFRC in Z score using the 
normative data by Hoo and colleagues, as no information about length at time of 
measurement was provided.  
 
Beardsmore and colleagues6 found a V’maxFRC at 12 months of -1.6 SD in Z score 
(personal communication A. Hoo), using the normative data by Hoo and 
colleagues.17Using the normative data by Sly and colleagues,15 the V’maxFRC is 
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approximately -1.7 SD. These cross-sectional data from different studies suggest a 
decrease in forced expiratory flow during the first year of life in ECMO survivors. This is 
in contrast with our longitudinal data, which shows a normal FRCp and V’maxFRC values 
at a level below average but without a decrease during the first year of life. It can be 
speculated that clinics have different criteria for ECMO, and this could explain discrepant 
follow-up results. For example, we placed infants on ECMO earlier compared with 
Beardsmore and colleagues (median (IQR) age in hours: 24 (13 - 46) versus 32 (19 - 
68).6 However, this is difficult to substantiate, also because data on the oxygenation 
index prior to ECMO were not available from the study of Beardsmore and colleagues. 
 
It is not clear what the separate effects are of mechanical ventilation on the one hand, or 
the underlying disease on the other hand. One could hypothesize that, if infants received 
ECMO support earlier, the duration of mechanical ventilation and its potential negative 
effects is reduced which could lead to “improved” lung function. However, we did not find 
a correlation between lung function and the age (hours after birth) at receiving ECMO. In 
contrast, we did find a significant correlation between days of mechanical ventilation 
(prior and after ECMO) and FRCp in ml/kg and in Z score at 6 and at 12 months. A 
possible explanation could be that mechanical ventilation leads to peripheral airway 
damage, which could lead to airtrapping. Conversely, one could reason that the 
increased lung volume after prolonged ventilation is not the result of this ventilation, but 
infants with increased lung volume, possibly due to increased gastrapping, were more 
likely to require prolonged ventilation.  
 
When infants were subgrouped by primary reason for ECMO, infants with CDH had a 
higher mean FRCp in ml/kg at 12 months of age, as compared to infants with MAS. In 
CDH infants, FRCp in Z score was significant above reference value at 12 months of age. 
Helms and Stocks found normal lung volumes (FRCp) in 4 infants and low lung volumes 
in 5 infants with a surgically repaired CDH at the postnatal age of 2 to 8 weeks.18 They 
argued that a normal lung volume in these infants does not necessarily mean that 
intrauterine lung development has been normal. The development of a normal lung 
volume later in infancy19 may be the combined result of alveolar distension and 
destructive emphysema of a hypoplastic lung.20,21 Nagaya and co-workers studied lung 
volume at 3 months of age, by computed tomography scan, and pulmonary perfusion in 
infants following surgical repair of CDH and ECMO treatment.22 They found that these 
infants had low ipsilateral lung volumes (61% of contra-lateral lung volume), which 
increased during follow-up to 88% of contralateral lung volume. In contrast, the perfusion 
of the affected side remained low, or decreased to below the initial value. It was 
concluded that the lung of the affected side has limited ability to develop arterial 
branches and that enlargement of lung volume may depend on over-expansion or even 
progressive emphysema, rather than tissue growth.22 To our knowledge, our study is the 
first that found an increased lung volume in infants following surgical repair of CDH and 
ECMO treatment. Possibly, with the introduction of ECMO, more severe cases of CDH 
have survived, with consequently more severely hypoplastic lungs. We speculate that a 
high-normal lung volume is most likely explained by hyperinflation of a hypoplasitc lung. 
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However one must take into account that sample size differences between the two 
groups may have affected these results. 
 
We did not find a correlation between age at receiving ECMO and any lung function 
parameter. This is in contrast with Greenspan and coworkers who found that infants who 
received ECMO late had lower V’maxFRC at discharge, as compared with infants who 
received ECMO earlier.9 However, as Greenspan and coworkers studied the infants at 
discharge, at approximately 1 month of age, an effect of age at receiving ECMO on lung 
function may only be present during the first months of life.  
 
We conclude that during the first year of life, infants who received ECMO support had a 
normal FRCp and reduced expiratory flows, with a normal development of flow at a level 
below average. We interpretate the findings with prudence, considering the lack of a 
comparison group and the limited number of repeated measurements in these infants 
with a variety of underlying diagnosis. Still, this study does not only contribute to our 
understanding of the effects of ECMO in severe respiratory insufficiency, but also 
provides data on longitudinal growth of lung function in early infancy. 
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Abstract 
 
Extracorporeal membrane oxygenation is a life-saving therapy for neonates with 
potentially reversible cardio-respiratory failure. Lung function was evaluated in 28 5-year-
old and in 14 8-year-old ECMO survivors hypothesising that airway obstruction would 
already be observable in children at these ages.  
Airway resistance was measured using the interrupter technique (Rint) during expiration 
and expressed as Z score at both 5 and 8 years. Together with measurements of FVC, 
FEV1, FEV1/VC-ratio and MEF25 using a spirometer. At 8 years helium dilution was used 
to determine TLChe, residual volume of helium (RVhe), VChe,, FRChe and RV/TLC-ratio.  
Mean (SEM) airway resistance was for both 5 and 8 year olds within normal range; 0.3 
(0.3) resp. 0.8 (0.3). After bronchodilatation airway resistance decreased significantly in 
both age groups to -0.8 (0.3) and -0.8 (0.3) respectively.  
Mean (SEM) FEV1/VC ratio and MEF25 before bronchodilatation in 8-year-olds showed 
mild airway obstruction; 86 (2) and 57 (8) respectively. Values were significantly lower 
than that in 5-year-olds (p = 0.01 and p = 0,03). Diffusion capacity was within the normal 
range. Despite the limitations of this study these data confirm the presence of long-term 
pulmonary sequelae despite the use of lung rest during ECMO. 
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Introduction 
 
Extracorporeal membrane oxygenation (ECMO) is a heart-lung bypass system that can 
be used as a life-saving treatment modality in neonates with severe but potentially 
reversible cardio-respiratory failure. Conditions most commonly treated with ECMO in the 
neonatal period are meconium aspiration syndrome (MAS); primary or secondary 
persistent pulmonary hypertension of the newborn (PPHN); congenital diaphragmatic 
hernia (CDH); sepsis; and pneumonia. One of the major problems in treating neonates 
with severe respiratory failure is that extremely high ventilator settings are required to 
keep these patients alive. Aggressive ventilation with high oxygen concentrations and 
damaging pressures can lead to pulmonary barotrauma and oxygen toxicity.1,2 During 
ECMO the ventilator can be turned back to mild settings and allow the lungs to ‘rest’ 
modifying the severity of chronic lung disease, while the patients vital functions are safely 
supported. On the other hand, ECMO may promote survival of infants with severe 
respiratory dysfunction, who would otherwise have died. Survival could then potentially 
result in a poor respiratory status on the long term. In fact, reported incidences of 
bronchopulmonary dysplasia (BPD) in newborns treated with ECMO range from 4% to 
38%, and there is an association with delayed use of ECMO.3  
 
Data on long-term pulmonary outcomes following ECMO are limited. Boykin et al. 
reported mild lower airway obstruction and air trapping in ECMO survivors at 10 - 15 
years of age.4 Recently Hamutcu et al. also found airway obstruction in a group of 50 
ECMO survivors aged 9 - 13 years.5 Since February 2002 we have been performing lung 
function tests on a regular basis as part of an extensive prospective follow-program for 
children treated with ECMO. Pulmonary function is measured at ages 6 and 12 months 
and at ages 5, 8 and 12 years. In addition we retrospectively studied lung function of 
ECMO-treated children aged 5 and 8 years. Our hypothesis was that airway obstruction 
would already be observable in children at these ages. 
 
 
Patients and methods 
 
The study population included 5- and 8-year-old neonatal venoarterial ECMO survivors. 
Lung function tests were performed between February 2002 and December 2004. 
Clinical data were obtained from the charts, including underlying diagnosis, birthweight, 
gestational age, oxygenation index prior to ECMO, maximum dosage of inhaled nitric 
oxide (iNO) prior to ECMO, mean airway pressure (MAP), number of pneumothorax prior 
to ECMO, age at onset of ECMO in hours, duration of ECMO support in hours, duration 
of mechanical ventilation and duration of oxygen dependence in days.  
At the time of lung function testing a medical history was taken including personal history 
of atopy and lung disease, presence of respiratory symptoms and use of medication for 
pulmonary diseases. Physical examination was performed including length, weight, heart 
rate, blood pressure and auscultation of heart and lungs. 
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Lung function testing 
At 5 and 8 years 
Airway resistance was measured using the interrupter technique (Rint) during expiration 
(MicroRint, Micro Medical Ltd, Rochester, UK). Rint values are expressed as z-score 
using reference values by Merkus et al.6 
Dynamic lung volumes were obtained using a heated Fleisch pneumotachograph 
(Number 3.1184; Godart Statham, Bilthoven, The Netherlands) connected to a computer 
or a water-sealed spirometer (Volutest Model VLT; Mijnhardt, Zeist, the Netherlands). 
FVC, FEV1, FEV1 /VC-ratio and maximal expiratory flows at 25% of the FFVC (MEF25) 
were determined and the best of three consecutive measurements was recorded. All 
values, except FEV1/VC-ratio, were expressed as percentage of predicted values.7 
Measurements were performed before and after inhalation of 1 mg of terbutaline.  
 
At 8 years 
A water-sealed spirometer (Expirograph; Godart Statham, Bilthoven, the Netherlands) 
filled with a known concentration of helium was used to determine TLChe, residual 
volume of helium (RVhe), VChe,, FRChe and RV/TLC-ratio. Volumes were expressed as 
percentage of predicted values except for RV/TLC-ratio.7 
When children were able to perform the above-mentioned tests, bodyplethysmography 
(Jaeger Masterlab, Würzburg, Germany) was also performed to determine TLCpleth, 
RVpleth, and RV/TLCpleth. Volumes were expressed as percentage of predicted values 
except for RV/TLC. Then carbon monoxide diffusion capacity (DLco) was measured using 
a single breath method (Jaeger Masterlab, Würzburg, Germany). Reference values for 
DLco and DLco corrected for alveolar volume (DLco/Va) were based on a study by Stam et 
al.8 
 
All lung function tests were performed with subjects in sitting position. 
 
Data analysis 
All data are expressed as median (IQR) or mean (± SEM) unless stated otherwise. 
Differences before and after bronchodilatation and differences between the two age 
groups were tested with the Mann-Whitney U test. Significance level was set at p = 0.05 
 
 
Results 
 
During the study period 40 five-year-old children and 22 eight-year-old children were 
eligible for follow-up after ECMO. Parents of 3 of the 62 children did not give consent, the 
families of 2 other children moved abroad and 6 children could not be traced. 
Thus, 37 five-year-olds and 14 eight-year-olds visited our outpatient department. Lung 
function test were not performed, however, in 9 of the five-year-olds, for reasons 
presented in Figure 1. 
The perinatal characteristics of the 51 children who performed lung function tests are 
presented in Table 1.  
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Five children (2 five-year-olds) (12%) had a history of atopy (asthma, eczema, or hay 
fever) and there was a history of atopy in the parents or siblings of three (2 five-year-
olds) children. Three children (2 five-year-olds) had been exposed to prenatal maternal 
smoking. Eleven children (8 five-year-olds) used bronchodilators or inhaled steroids up to 
the age of 2. At time of pulmonary function testing seven children (17%) (6 five-year-
olds) still used bronchodilators or inhaled steroids. (Table 2) 
 
Lung function testing 
Rint 
Rint before bronchodilatation with 1mg of terbutalin was measured in 16 five–year-olds 
and in 10 eight–year-olds; after bronchodilatation in 12 and 9, respectively. In both age 
groups Rint had decreased after bronchodilatation. This decrease was only significant for 
the eight-year-olds. (p = 0.006) (Table 3) Before bronchodilatation Rint did not differ 
between the two age groups (p = 0.08). For the eight-year-olds, Z score before 
bronchodilatation was significantly above reference values (z score 0) but within the 
normal range. After bronchodilatation z scores for both groups decreased signifianctly 
and are below reference values (Table 3). 
 
Flow/volume 
Flow/volume curves before inhalation of terbutalin were obtained in 20 five-year-olds. 
One child had already inhaled 1 mg of terbutalin when performing the flow/volume curve 
so 21 performed after inhalation.  
Flow/volume curves were obtained in all 14 eight-year-olds. One child was too tired to 
perform another session after inhalation of terbutalin. 
There was no significant difference in values before and after bronchodilatation. 
62 children eligible 
for follow-up 
37 
Five-year-olds 
14 
Eight-year-olds 
-3 no consent 
-6 could not be traced 
-2 moved abroad 
28 
Pulmonary function 
tests
1 Down syndrome 
2 psychomot handicapped 
5 too difficult 
1 logistic reason 
14 
Pulmonary function 
tests 
chapter 9 
 106
The FEV1/VC ratio and MEF25 in 8-year-olds was significantly lower than that in 5-year-
olds before bronchodilatation (p = 0.01 and 0.03 respectively). After bronchodilatation, 
significant difference between the two age groups sustained for the FEV1/VC ratio. 
(Table 4). 
 
Table 1 Patient characteristics 
 5-year-olds 
n = 28 
8-year-olds 
n = 14 
Male/female 15/13 7/7 
Diagnosis:   MAS 13 10 
    CHD 3 3 
     Sepsis 5 0 
     PPHN 7 1 
Birthweight (kg) 3.4 (2.9 to 3.8) 3.4 (3.0 to 3.9) 
Gestational age (weeks) 39+5 (37+5 to 41+1) 40+3 (39+5 to 41+4) 
No. of children with inhaled NO prior to ECMO (%) 26 (93%) 5 (36%) 
Maximum dosage of iNO (ppm) 20 (17 to 33) 30 (20 to 40) 
Oxygenation index 29 (16 to 50) 58 (29 to 70)* 
MAP (cm H2O) 20 (15 to 22) 19 (17 to 22) 
Maximal FiO2 (%) 100 100 
No. of children with pneumothorax prior to ECMO (%) 5 (18) 5 (29) 
Age at start ECMO (hours) 30 (23 to 60) 25 (12 to 43) 
Duration of ECMO support (hours) 137 (115 to 190) 119 (115 to 149) 
Duration of mechanical ventilation (days)# 13 (8 to 21) 9 (7 to 18) 
Duration of oxygen dependence (days) 20 (12 to 34) 25 (12 to 42) 
Data are presented as numbers of patients (%) or median (IQR).  
MAS  Meconium Aspiration Syndrome 
CDH  Congenital Diaphragmatic Hernia 
PPHN  Persistent Pulmonary Hypertension of the Newborn 
FiO2  Fraction of inspired oxygen prior to ECMO 
iNO  Inhaled Nitric Oxide. Oxygenation index was calculated from the last known arterial   
   bloodgas value before ECMO as; [(Mean airway pressure x FiO2)/PaO2] x 100 
#   Duration of mechanical ventilation includes mechanical ventilation prior, during and after 
   ECMO 
*    p = 0.02 
 
 
Table 2 Data at follow-up 
 5-year-olds 8-year-olds 
Age at follow-up (yrs) 5.4 (5.3 to 5.5) 8.5 (8.2 to 8.6) 
Weight (kg) 21.8 (19.4 to 23.9) 26.8 (22.4 to 33.2) 
Weight SD score 0.5 (-0.5 to 1.1) -0.3 (-1.6 to 0.6) 
Height (cm) 116.5 (114 to 119.8) 130.7 (129.6 to 133) 
Height SD score 0.4 (-0.6 to 1.0) -0.8 (-1.5 to -0.04) 
History of atopy (n) 2 3 
Inhalation medication during first 2 yrs of life (n) 8 3 
Inhalation medication at follow-up (n) 6 1 
Data are presented as numbers of patients or median (IQR).  
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Table 3 Rint 
 Before bronchodilatation After bronchodilatation 
Rint (kPa/l/s)  5 years 
    8 years 
0.80 (± 0.04) 
0.72 (± 0.04) 
0.65 (± 0.04)* 
0.52 (± 0.05)** 
Rint (Z score)  5 years 
    8 years 
0.3 (± 0.3) 
0.8 (± 0.2)# 
-0.8 (± 0.3)## 
-0.8 (± 0.3)### 
Data are presented as mean (± SEM). 1mg of terbutalin was given for bronchodilatation. Rint before 
bronchodilatation was measured in 16 children at 5 years and in 10 children at 8 years. After 
bronchodilatation Rint was measured in 12 children at 5 years and in 9 children at 8 years. 
*  p = 0.05 Rint before vs after bronchodilatation in 5 year-olds. (Mann-Whitney U test) 
**  p = 0.006 Rint before vs after bronchodilatation in 8 year-olds. (Mann-Whitney U test) 
#  p = 0.007; significant above reference values (z score 0). (student t test) 
##  p = 0.04 Z score before vs after bronchodilatation in 5 year-olds (Mann-Whitney U test) 
###  p = 0.001 Z score before vs after bronchodilatation in 8 year-olds (Mann-Whitney U test) 
 
 
Table 4 Dynamic lung volumes 
 Before bronchodilatation After bronchodilatation 
FVC    5 years 
    8 years 
 91 (± 4) 
 91 (± 6) 
 99 (± 4) 
 96 (± 6) 
FEV1    5 years 
    8 years 
 97 (± 4) 
 92 (± 6) 
 105 (± 4) 
 100 (± 6) 
FEV1/VC   5 years 
    8 years 
 92 (± 3) 
 86 (± 2)* 
 93 (± 3) 
 89 (± 2)*** 
MEF25    5 years 
    8 years 
 80 (± 7) 
 57 (± 8)** 
 91 (± 10) 
 72 (± 8) 
Values are presented as mean (±SEM). All data are expressed as percentage of predicted except for 
the FEV1/VC ratio. Measurements were performed before and after inhalation of 1mg of terbutalin.  
There is no significant difference before and after bronchodilatation in both age groups.  
Differences between 5 and 8-year-olds before bronchodilatation:  
* p = 0.01 
**  p = 0.03 
Differences between 5 and 8-year-olds after bronchodilatation;  
 ***  p = 0.03 
 
 
Spirometry 
Nine 8-year-old children performed a spirometry of which 7 performed a 
plethysmography. Only 5 children were able to perform a carbon monoxide diffusion 
capacity. Results are presented in Table 5.  
 
 
chapter 9 
 108
Table 5 Helium dilution-spirometry (n = 9) and bodyplethysmography (n = 7) at 8 years 
 After bronchodilatation 
TLChe  92 (80 - 99) 
VChe  102 (95 - 111) 
FRChe  81(75 - 94) 
RVhe  42 (33 - 77) 
RV/TLChe  51 (36 - 70) 
TLCpleth  102 (90 - 106) 
RVpleth  95 (86 - 116) 
RV/TLCpleth  106 (82 - 109) 
DLco  94 (86 - 109) 
DLco/Va  89 (88 - 109) 
Data are presented as median (IQR).  
 
 
Discussion 
 
In this study we evaluated lung function in twenty-eight 5-year-old and fourteen 8-year-
old survivors after ECMO support. We found mild airway obstruction in the eldest 
children. All values were within the normal range in the youngest children. Seventeen 
percent of all children used bronchodilatation or inhaled steroids. 
During the study we noticed that some 5-year-olds had difficulties in performing a 
complete lung function test. This resulted in scattered data and results should be 
interpreted with caution. Nystad et al. however did show good feasibility of dynamic 
spirometry in children of preschool age.9 Crenesse et al. found that forced expiratory 
tests are not always feasible in young children, but that 55% of their selected population 
performed reliable maneuvers, provided that well-trained pediatric medical staff 
supervised them.10 There are few studies on pulmonary sequelae including 5-year-old 
ECMO survivors. A possible explanation for the difficulties may lie in the fact that the 
tests were part of an extended follow-up program for ECMO survivors, lasting a whole 
day. Also, Glass et al. in a similar, larger population found 17% of children to have 
neurodevelopmental disability and 6% motor difficulties.11 Nevertheless we found no 
profound bronchial obstruction.  
 
We did find mild obstruction in the 8-year-olds. As our data are not longitudinal data, the 
question is whether the 8-year-olds were perhaps in worse clinical condition before 
ECMO or perhaps were on ventilation for a longer time. Comparison of the OI, MAP, 
duration of ECMO treatment, age at start ECMO treatment, duration of ventilation and 
oxygen dependence between both age groups was only significant for the OI, measured 
using the last arterial blood gas before ECMO (p = 0.02). This could perhaps indicate 
worse clinical conditions before ECMO in a period when NO and HFO was less 
frequently used. However, a study by Beardsmore and colleagues dating from a later 
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period showed reduced expiratory flows in ECMO survivors, already present at one year 
of age.12 
 
The group of 8-year-olds included 3 children with a congenital diaphragmatic hernia. 
Obstruction may be due to different anatomy or residual lung hypoplasia in children with 
CDH.13 However, re-analysis without data from these 3 children did not change the 
outcome significantly. It is the neonatal intensive care treatment that is most likely to 
contribute to airway obstruction despite the use of lung rest during ECMO.  
 
Our findings are in concordance with those reported by Hamutcu et al. who also found 
airway obstruction in a group of 48 ECMO survivors at 11 years of age.5 Airway 
obstruction was also found in a group of conventionally treated children who suffered 
from meconium aspiration syndrome.14 Still our data need to be interpreted cautiously, as 
we did not use a control group and number of patients is very small. 
Only few children were able to perform spirometry and bodyplethysmograpy. Difusion 
capacity seemed within the normal range. Furthermore, results may indicate minor 
airtrapping since RV/TLCpleth was high and RV/TLChe. low. However, numbers are too 
small to draw definite conclusions. Continuation of the follow-up assessment will 
eventually clarify this. 
 
In conclusion we found mild airway obstruction in 8-year-old ECMO survivors, and not in 
5-year-olds. Despite the limitations of this study these data confirm the presence of long-
term pulmonary sequelae despite the use of lung rest during ECMO. In the future 
children will be followed longitudinally as part of an extensive long-term follow-up 
program for ECMO survivors. 
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This thesis presents the results of clinical studies evaluating some aspects in the acute 
phase of ECMO treatment and long-term follow-up of newborns treated with ECMO for 
respiratory failure.  
ECMO is known to have a survival advantage and is used worldwide in selected critically 
ill patients with acute therapy resistant respiratory or cardiac failure.1 The majority of 
patients treated with ECMO are newborns with respiratory failure most of whom receive 
ECMO for meconium aspiration syndrome (MAS).2 The incidence of patients with MAS in 
this thesis however is probably higher compared to the incidence in the United States. 
For one reason, their changing obstetric practice; i.e. an increased number of cesarean 
deliveries and a decrease in births after more than 41 weeks, was associated with a four-
fold decrease of meconium aspiration syndrome.3 Second, several new therapies, 
including high-frequency oscillatory ventilation (HFOV), exogenous surfactant therapy, 
and inhaled nitric oxide (iNO), have become available for the treatment of neonatal 
hypoxemic respiratory failure. The need for ECMO therapy decreased from 42.8% to 
27.7% following the application of iNO and HFOV being used more frequently. The 
incidence of MAS in these two groups decreased from 66.6% to 38.5%.4 Still, those 
patients who do require ECMO compose a more severe subset of critically ill newborns. 
As a consequence studies with a large group of infants treated with ECMO for MAS will 
become more difficult to conduct in the United States.  
 
 
Nutritional Aspects 
 
In the care of critically ill newborns nutrition is an important factor. During ECMO most 
children receive parenteral nutrition. Withholding enteral feeding in patients on ECMO is 
common practice in many centers, based partly on the risk of potential splanchnic 
ischemia resulting in loss of intestinal integrity, development of necrotising enterocolitis 
and predisposition for bacterial translocation and sepsis.5-7 Total parenteral nutrition 
however is associated with the occurrence of cholestasis.8 Forty to sixty percent of 
infants who require long term TPN for intestinal failure develop liver disease varying from 
cholestasis to hepatic fibrosis and biliary cirrhosis.9 The pathogenesis is multifactorial. 
Lack of enteral feeding leading to reduced gut hormone secretion; reduction of bile flow, 
and biliary stasis may be important mechanisms in the development of cholestasis. 
According to a review by Kelly, the management strategies for the prevention of TPN-
induced liver disease include early enteral feeding, a multidisciplinary approach to the 
management of parenteral nutrition, and aseptic catheter techniques to reduce sepsis.9 
In chapter 2 we showed that enteral nutrition in neonates on ECMO was well tolerated 
and that no major complications occurred, especially no symptoms of bilious vomiting, 
blood stained stools or abdominal distension. Also, when introducing small quantities of 
enteral nutrition in healthy neonates a significant elevation of gut hormones is 
observed.10 Gut hormones are necessary in stimulating structural and functional changes 
in the gut and other organs when adapting to enteral nutrition.11 They control 
gastrointestinal function such as motility, intestinal fluid secretion, blood flow, absorption 
and immunity.12 Splanchnic circulation may be adversely affected and intestinal integrity 
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is compromised, although not deteriorated after the introduction of enteral feeding, in 
neonates on ECMO.13 Despite these factors we did find a normal response of intestinal 
hormone secretion after the introduction of enteral nutrition. These findings do not 
sustain the arguments to withhold these infants from enteral nutrition.  
 
Apart from the existing fear of a decreased mesenteric blood flow and development of 
necrotising enterocolitis (NEC), the need for vasopressor drugs pre-ECMO can be 
another argument to withhold enteral nutrition. Use of vaso-active drugs did not have an 
influence on feeding intolerance as described in chapter 2, while 80% of our ECMO 
patients who were fed enterally received dopamine. And, so far there are no documented 
cases of NEC during ECMO in the literature. As a matter of fact neonates treated with 
ECMO receiving mother’s milk and with a gestational age over 34 weeks, are in a low 
risk category for developing NEC. 
 
Newborns on ECMO have a restricted fluid intake of 100 ml/kg. This is a known barrier to 
adequate nutrition in critically ill children.14 So when reducing costs, reducing the chance 
of developing parenteral nutrition associated cholestasis in the context of a normal gut 
hormone response with the use of enteral nutrition, future research should focus on 
whether these patients have sufficient caloric intake and protein uptake. Indirect 
calorimetry might be useful in determining energy requirements, especially in critically ill 
patients on continues flow ventilators and with a FiO2 of less then 40%.15  
 
ECMO has become a principal part in the treatment of selected newborns with congenital 
diaphragmatic hernia (CDH).16,17 Since operative repair in our hospital is routinely 
performed after decannulation from ECMO, these children do not receive enteral nutrition 
during ECMO. Still it is desirable to feed them enterally as soon as possible. However, 
one of the complications of thoracic surgery is the occurrence of a chylothorax due to 
damage of the lymphatic ducts possibly resulting in a longer period of cessation of 
enteral nutrition.18,19 Trevisanuto et al. suggested that ECMO treatment itself could be 
responsible for the development of a chylothorax. Due to the venous cannula the 
superior caval vein (SCV) possibly hinders the venous return and consequently obstructs 
the outflow of the thoracic duct. The increased pressure may had lead to (micro) 
perforations of the thoracic duct.20 In chapter 4 we did find an increased number of 
chylothorax in ECMO treated CDH patients. The majority of the CT occurred on the side 
of the hernia and not on the side of the ECMO cannula. Together with the findings that 
the presence of a patch to close the diaphragm increased the chance of developing a CT 
it is more likely that ECMO serves as a selection bias then as a primary cause for the 
development of chylothorax. Treatment modalities for a CT include repeated 
thoracocentesis or continuous drainage together with prolonged use of TPN during 3 
weeks followed by the use of formula for several weeks containing medium chain 
triglycerids. This conservative management was effective in children with a CT after 
cardiothoracic surgery in 80%.19 If conservative management fails, surgical ligation of the 
thoracic duct is a possibility, but criteria are controversial.19 Still, in our population ligation 
of the thoracic duct has not been necessary. Moreover, additional risks may come from 
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repeated surgery. A new non-surgical intervention such as somatostatin (Octreotide) 
aimed at decreasing chyle production is increasingly used. Administering Octreotide 
either as a continuous intravenous infusion or as subcutaneous dosages was reported to 
be successful in pediatric patients after cardiothoracic surgery and after CDH repair.21-24  
 
Overall, there is an important morbidity and evident risk of complications using TPN. 
Especially in patients with a CT needing prolonged periods of TPN.18 Our overall 
recommendation concerning enteral nutrition in neonates on ECMO is;  
 
- Start enteral feeding early, within 24 - 48 hours after start of ECMO. 
- Try to reach full enteral intake. 
- There are no arguments for minimal enteral feeding since strong evidence for 
an increased risk of developing NEC is lacking.  
- Additional therapy with somatostatin for chylothorax may be helpful. 
 
 
Drug studies during ECMO 
 
Patients on mechanical ventilation in the ICU are generally heavily sedated. The 
purposes of sedation are to relieve pain, decrease anxiety, decrease oxygen 
consumption and carbon dioxide production, prevent the patient from removing lines, and 
promote synchronized breathing with the ventilator. In patients on ECMO sedation and 
analgesia seem even more critical since inadequate sedation with excessive patient 
movement may result in a shift in the position, or even dislodgment of the cannula 
causing a decrease in venous drainage and arterialised return. Also when ECMO is used 
for respiratory failure the primary goal is to recover lung function. Ventilation strategies 
are therefore of great importance. Interventions or treatment that can cause further lung 
damage should be avoided. As drugs for sedation and analgesia may potentially 
increase the requirements of mechanical ventilation they may influence the chance of 
pulmonary recovery. Therefore mode of sedation and pain management is very 
important. The most frequently used drugs for sedation in newborns on ECMO are 
benzodiazepines such as midazolam. Morphine and fentanyl are most commonly used 
for analgesia in this group of patients.25 
 
During ECMO disposition of drugs is altered due to expanded blood volume and 
increased volume of distribution, an intrinsic increase of intra- and extracellular volume, 
the presence of a non-pulsatile blood flow and reduced plasma protein concentration 
with resulting effects on pharmacokinetics and dynamics.26 As described in chapter 5 
midazolam and morphine are used as primary sedative and analgesic drugs in our clinic. 
We found that midazolam and morphine alone did not provide adequate analgesia and 
sedation during ECMO. Also, plasma concentrations of morphine, M3G, M6G, 
midazolam, 1-OH-midazolam and 1-OH-midazolamglucuronide showed great variability 
between patients and over time. Pharmacokinetic studies of morphine during neonatal 
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ECMO have shown increased as well as decreased metabolic clearance of morphine to 
their metabolites M3G and M6G, each contributing to both clinical and side effects.27,28 
Geiduschek also reported that morphine clearance showed great variability in infants 
receiving ECMO and initiation of ECMO did not lead to a significant decrease in serum 
morphine concentration.29 No effect is documented of midazolam or fentanyl on 
morphine formation clearance to M3G and M6G or elimination clearance of these 
metabolites because of the fact that midazolam and morphine are glucuronidated by 
different enzyme systems.30,31 Mulla et al. reported that the volume of distribution of 
midazolam in ECMO treated neonates was 3 to 4 times greater than in critically ill 
neonates not treated with ECMO and subsequently more midazolam is required to 
achieve adequate sedation, especially during the first 10 days.32 Prolonged use of 
morphine and midazolam should be guided by clinical monitoring, preferably by validated 
pain or comfort SCALES as clearance is variable during treatment with ECMO.28,29,33 
 
The most important indications for neonatal ECMO are respiratory failure and severe 
primary or secondary pulmonary hypertension.34 In the line of treatment of pulmonary 
hypertension inhaled NO (iNO) is considered the golden standard.35 ECMO serves as 
the last resort support with ranging success percentages depending on the underlying 
pathology.36 Since there is no single therapy yet proven to be effective in all cases of 
pulmonary hypertension, new therapies focussing on selective pulmonary vasodilatation 
are still under investigation. Sildenafil (Viagra®) is one of those therapies. This 
phosphodiesterase inhibitor relaxes pulmonary smooth cells by inhibiting the degradation 
of cyclic guanosine monophosphate.37 Experience is mainly gained in adult patients. 
Sildenafil was found to be an effective pulmonary vasodilator in adult patients with 
congestive heart failure and pulmonary hypertension which effect was potentiated by 
combination with iNO.38,39 Experience in young children, especially in newborns is 
limited. We therefore analyzed retrospectively the effects of oral sildenafil in 15 
consecutive neonates with therapy resistant PPHN necessitating ECMO support. ECMO 
flow reduction (ml/kg/min) was used as an indirect parameter to assess decline of 
pulmonary hypertension due to sildenafil administration. Comparable to findings in 
adults, we found a favorable effect of sildenafil in combination with iNO. This was 
reflected by the observation that those with concomitant iNO showed greater ECMO flow 
reduction than those treated with sildenafil alone. Distinct from adult studies a significant 
reduction of systemic blood pressure was observed in this study. A decrease in mean 
arterial blood pressure was only observed after the first dose, which was a loading dose, 
and 3 - 4 times higher than the subsequent doses. However, analysis showed no dose 
dependency. Still, in a randomized control trial of infants at risk for pulmonary 
hypertension after cardiac surgery sildenafil also reduced the systemic blood pressure 
and systemic vascular resistance and worsened arterial oxygenation and the alveolar-
arterial gradient.40 In the future randomized-controlled trials in neonates are warranted 
and should focus on pharmacokinetics to determine the optimal dosage and routing of 
sildenafil together with attention for possible systemic (side-) effects. Unfortunately, 
recently an international multicenter trial stopped due to the absence of safety data in the 
newborn population. Moreover in neonates with CDH who form the largest group of 
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therapy resistant pulmonary hypertension, intestinal absorption is unpredictable with 
continuous nasogastric drainage. Pharmacokinetics will be difficult to interpret and 
studies with an intravenous form of sildenafil for PK-PD studies are needed in this group 
of patients. However, pharmacodynamics will also be difficult to evaluate. Cardiac 
ultrasound can be used to determine a decrease in pulmonary artery pressure based on 
tricuspidal incompetence, but this is non-specific and ‘far away’ from the underlying 
pathology in CDH patients.41 In the analysis for expression of vasoactive mediators in 
newborns with CDH results are not conclusive whether endothelial nitric oxide synthase 
(eNOS) is decreased or not.42-45 More consensus was found in an upregulation of 
endotheline-1; an endothelial derived vasoconstrictor in patients with CDH.43,46,47 It is 
questionable whether or not future perspectives in medical treatment of PPHN should 
focus on blocking vasoconstriction with for instance Bosentan, an orally administered 
endothelin receptor antagonist instead of stimulating vasodilatation with sildenafil.48  
 
 
Long-term effects 
 
Over the years development of high frequency ventilation (HFV), iNO, surfactant and 
changing policy in the delivery room, demographic data of neonates treated with ECMO 
have changed. Over a time period from 1988 to 1998 neonates were exposed to an ever-
expanding group of new therapies, they appeared to be healthier based on indices of gas 
exchange, and were cared for at centers that reported fewer cases per year.49 Another 
study in the United States showed a decrease in the number of neonates treated with 
ECMO for respiratory failure from 1989 to 2001. However, the increased use of iNO an 
HFV were associated with an increase of the age at ECMO initiation (from 40.5 hours to 
68.5 hours) and an increased length of ECMO run from 154.7 hours to 174.5 hours in the 
last 4 years.50 Still the overall mortality remained unchanged. There is no doubt that new 
techniques will still be developed and the number of neonates needing ECMO support 
for respiratory failure will probably decrease. However, currently approximately 40 
patients a year still need ECMO support in the newborn period in the Netherlands. 
Follow-up studies of neonates treated with ECMO in the UK and United States showed 
considerable morbidity with major disability in terms of severe developmental delay or 
neuromotor disabilities up to 20% at 1 to 5 years of age.51-54 These data are comparable 
to our findings of a nation wide follow-up study at 5 years of age presented in chapter 7. 
Therefore follow-up of these infants remains necessary. Especially with increasing age, 
expectations of the children rise and assessment of different domains can be more 
precise. In our opinion a successful follow-up program should be structured in 
consultation with representatives from different disciplines, such as a pediatrician, a 
pediatric physiotherapist, a psychologist and a speech therapist. In 2000 van Baar et al. 
presented a systematic and standardized program for neonatal follow-up in the 
Netherlands.55 This protocol functioned as a guideline for a standardized protocol 
developed for the follow-up of ECMO survivors (Fig. 1). We added age 12 and 18 years 
since this is again a major step in school career determining future educational 
perspectives and job opportunities. 
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As part of this follow up program lung function tests were performed at different ages. It 
remains essential to assess lung function whether or not ECMO results in a survival 
advantage.56 So far only cross sectional studies on lung function during the first year of 
life following ECMO are published suggesting a decrease of lung function during the first 
year of life.56,57 In chapter 8, lung function was evaluated longitudinally during the first 
year of life in infants following ECMO support. We found normal lung volumes and 
normal expiratory flows with a normal development at a level below average during that 
year. Furthermore we found higher lung volumes at both 6 and 12 months in infants 
receiving ECMO for CDH compared with infants receiving ECMO for MAS. Nagaya et al. 
studied lung volumes in infants following surgical repair of CDH and ECMO treatment at 
3 months of age. These infants had low ipsilateral lung volumes (61% of contra-lateral 
lung volume), which increased during follow-up to 88%. The perfusion however of the 
affected side remained low, or decreased to beneath the initial value. It was concluded 
that the lung of the affected side has limited ability to develop arterial branches and that 
enlargement of lung volume may depend on over-expansion or even progressive 
emphysema, rather than tissue growth.58 We suggest that in infants after CDH repair a 
high-normal lung volume is most likely explained by hyperinflation of hypoplastic lung. 
However, numbers in this study were very small and future research on lung function in 
infants after CDH repair is necessary to clarify the presence of increased lung volume. 
For instance alternative ways to evaluate lung growth in combination of lung function with 
visualization of the architecture of the lung might be the use of a CT-scan. Especially in 
the follow up of infants with CDH it is important to evaluate growth potential of the 
pulmonary blood vessels and airways.  
 
In one year olds we found a forced expiratory flow within normal ranges but at a level 
below average. This could suggest an increased incidence of airway obstruction at a 
later age. However from the age of 18 months to 5 years it is impossible to perform a 
reliable lung function test. Boykin et al. reported mild lower airway obstruction and air 
trapping in ECMO survivors at 10 - 15 years of age.59 Recently Hamutcu et al. also found 
airway obstruction in a group of 50 ECMO survivors aged 9 - 13 years.60 In chapter 9 we 
evaluated lung function at an earlier age compared to Hamutcu and Boykin. We found 
mild lower airway obstruction in 8 year olds. All values were within the normal range in 5-
year-olds. Comparison of the OI, MAP, duration of ECMO treatment, age at the start of 
ECMO treatment, duration of ventilation and oxygen dependence between both age 
groups showed only a significant higher OI in 8-year-olds. This could perhaps indicate 
worse clinical conditions before ECMO in a period when NO and HFO was less 
frequently used. 
 
In the future the one-year old infants of chapter 8 will continue their follow-up program 
and will perform lung function tests at age 5 and 8 years. These future longitudinal data 
may enhance our understanding of lung growth and function in this particular group of 
patients.  
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Overall conclusions 
In summary this thesis demonstrated that: 
 
- Introduction of enteral nutrition in critically ill newborns on ECMO was well 
tolerated and no major complications occurred.  
- Together with the fact that there were normal gut hormone responses 
following the introduction of enteral nutrition in a theoretically compromised 
intestinal circulation, these data do not provide arguments to withhold these 
newborns from enteral nutrition.  
- Pharmacokinetic and pharmacodynamic data of sedatives and analgesia are 
increasingly needed to guide optimal treatment especially in case of combined 
therapy. 
- Sildenafil in combination with iNO may be a promising adjuvant in the 
treatment for severe therapy resistant PPHN, also during ECMO.  
- Follow-up of neonates treated with ECMO at age 5 years shows a 
considerable morbidity comparable to the UK and Unites States, consolidating 
the idea that structural follow-up of these infants remains important, preferably 
with representatives from different disciplines.  
- Lung function during the first year of life showed normal lung volume and 
normal expiratory flow at a level below average with normal growth and 
development during that year. At ages 5 and 8, lower airway obstruction was 
only observed in the oldest age group.  
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Summary 
 
Extracorporeal membrane oxygenation (ECMO) is a technique for providing life support 
in severe but potentially reversible cardiorespiratory failure. The technique oxygenates 
blood outside the body, obviating the need for gas exchange in the lungs and, if 
necessary, provides cardiovascular support. This enables the lungs to rest with use of 
minimal ventilator settings, thereby preventing injury from high oxygen concentration and 
barotrauma. ECMO is most commonly used to support (nearly) mature newborn infants 
with respiratory failure and pulmonary hypertension caused by meconium aspiration 
syndrome (MAS), congenital diaphragmatic hernia (CDH), sepsis and idiopathic 
persistent pulmonary hypertension of the newborn (idiopathic-PPHN). This thesis 
addresses clinical studies evaluating several aspects of the acute phase of ECMO 
treatment and long-term follow-up of newborns treated with ECMO for respiratory failure.  
 
Chapter 1 is a general introduction to the developmental history of ECMO. It presents 
the studied aspects of the acute phase (chapters 2 to 6) and long-term follow-up 
(chapters 7 to 9) together with the study aims. 
 
In chapter 2 we retrospectively evaluated over a five-year period the feasibility and 
tolerance of a protocol of routine enteral nutrition in neonates requiring ECMO. Feasibility 
was evaluated by recording the time period needed for enteral nutrition to reach 40% of 
total fluid intake; tolerance was evaluated by reviewing data on enteral nutrition related 
morbidity. Sixty-seven of the 77 eligible patients received enteral feeding during ECMO. 
Thirty-six of these patients (54%) received 40% of total fluid intake as enteral nutrition 
within a median of 3 (range 2 - 4) days. Over the years there was a trend toward an 
increasing usage of enteral nutrition from 71% to 94%. Enteral nutrition was temporarily 
discontinued in 16 patients, with 14 showing gastric retentions, one showing discomfort, 
and one showing aspiration. Symptoms of bilious vomiting, blood-stained stool, or 
abdominal distension were not present. Overall, enteral feeding was well tolerated and 
did not show serious adverse effects. In our experience, routine use of enteral feeding in 
critically ill neonates on veno-arterial ECMO is feasible. 
 
Chapter 3 presents the effects of enteral nutrition on gut function during veno-arterial 
ECMO in newborns. The objective was to gain insight into the hormonal responses to 
enteral nutrition. We analyzed plasma gut hormone levels of gastrin, cholecystokinin and 
peptide-YY in relation to enteral nutrition in 24 consecutive newborns. Twelve received 
parenteral nutrition only. In 12 others, enteral nutrition was introduced later. The findings 
were compared with those of 16 measurements in eight non-ECMO treated age-matched 
controls. We found that concentrations of gastrin, cholecystokinin and peptide- YY were 
significantly higher in ECMO patients receiving enteral nutrition compared with ECMO 
patients who received parenteral nutrition only. The plasma hormone levels did not differ 
from those in age-matched controls. The findings from this study are consistent with 
intestinal hormone levels showing normal responses after introduction of enteral feeding. 
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The results do not provide an argument for withholding enteral nutrition even in the most 
severely ill neonates on venoarterial ECMO.  
 
In chapter 4 we retrospectively evaluated whether ECMO increased the risk of 
developing a chylothorax (CT) after congenital diaphragmatic hernia (CDH) repair. 
Eighty-nine patients with CDH - treated either with or without ECMO - were analyzed 
together with 114 patients treated with ECMO for other reasons and 100 patients who 
underwent thoracic surgery because of an esophageal atresia (EA). Postoperatively, 
10% of the CDH infants developed a chylothorax—21% in CDH patients with ECMO 
treatment and 6% in CDH patients without ECMO treatment. This difference appeared to 
be significant. The presence of a patch as independent variable for the development of 
chylothorax also showed significance. In the group of patients treated with ECMO for 
other reasons, the incidence of chylothorax was 3.5% and in 4% it occurred after an 
esophageal atresia repair. Chylothorax in CDH patients mostly occurred on the herniated 
side and not on the side of the ECMO cannula. Apart from the finding that the presence 
of a patch to close the diaphragm increased the chance of developing a chylothorax, 
ECMO more likely seems to serve as a selection bias rather then a primary cause for the 
development of chylothorax. 
 
In chapter 5 we describe the plasma concentrations of midazolam and morphine in 
neonates undergoing veno-arterial ECMO treatment. This is a preliminary report of a 
larger study on the pharmacokinetic and pharmacodynamic properties of midazolam and 
morphine administered during ECMO. We analysed plasma concentrations of 
midazolam, 1-OH-midazolam, 1-OH-midazolamglucuronide, morphine, morpine-M3G 
and morphine-M6G at separate time points after discontinuation of morphine and 
midazolam just after cannulation and again after reintroduction of the medication. Plasma 
concentrations showed great variability. All but two infants needed both midazolam and 
morphine for adequate sedation. The median (IQR) time between discontinuation and 
reintroduction of medication was 10 (7.8 to 27) hours. Median dosage of morphine used 
during ECMO support was 11.5 (10.1 to 15.5) µg/kg/hr. Median dosage of midazolam 
used during ECMO support was 0.15 (0.1 to 0.2) mg/kg/hr. Future publications will report 
on the pharmacokinetic and pharmacodynamic analysis of morphine and midazolam 
using validated scales such as the COMFORT behaviour scale and VAS. 
 
In the line of drug therapy during ECMO (chapter 6) we analysed over more than 2 
years the effects of oral sildenafil in 15 consecutive neonates over more than two years 
with therapy resistant PPHN necessitating ECMO support. Seven neonates, all with 
congenital diaphragmatic hernia, died. We compared survivors and non-survivors. There 
was no significant difference in reduction of ECMO flow 24 hours after initiation of 
sildenafil nor in duration of ECMO support. The survivors had first received sildenafil 
significantly earlier after cannulation than the non-survivors; median (IQR) 41 (17 - 90) 
hours versus 200 (161 - 334) respectively. We also compared patients with or without 
concomitant iNO administration at the start of sildenafil. ECMO flow reduction over the 
next 24 hours was greater in patients with iNO and sildenafil than in patients who 
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received sildenafil only. In 12 patients a significant decline in systemic blood pressure in 
over the first 2 hours after initial sildenafil administration was observed, not related to 
dosage. These findings indicate that sildenafil therapy might be beneficial for individual 
cases of PPHN and that administration relatively early in the disease process with 
concomitant administration of iNO might be favorable. In contrast with earlier studies in 
animals and adults, we observed a significant decline in systemic arterial blood pressure. 
 
In the long-term follow-up after ECMO (chapter 7) morbidity is reported in ECMO 
survivors at the age of 5 years when they start primary school and major decisions for 
their school careers must be made. Within the framework of an extensive follow-up 
program for neonatal veno-arterial ECMO survivors, ninety-eight 5-year-olds from the 
two designated ECMO centres in the Netherlands (Erasmus MC-Sophia Children’s 
Hospital in Rotterdam, and University Medical Center Nijmegen) were assessed. The 
protocol included medical assessment, neuromotor assessment, and psychological 
assessment by means of parent and teacher questionnaires. We found neurological 
deficits in 17% of the 98 children included in the analysis. Six of those 17 (6% of total) 
showed major disability. Two of those six had a chromosomal abnormality. Three were 
mentally retarded and profoundly impaired. The sixth had a right-sided hemiplegia. 
These six children did not undergo neuromotor assessment. Motor difficulties were found 
in 26% of the remaining 92 patients. 15% actually had a motor problem and 11% were at 
risk for this. Cognitive delay was identified in 14%. The mean IQ score (100.5) was within 
the normal range. The study revealed that neonatal ECMO in the Netherlands is 
associated with considerable morbidity at 5 years of age. It appeared feasible to have as 
many as 87% of survivors participate in follow-up assessment, due to co-operation 
between two centers and small travelling distances. We believe that objective evaluation 
of the long-term morbidity associated with the application of this highly invasive 
technology in the immediate neonatal period requires an interdisciplinary follow-up 
program with nation-wide consensus on timing and actual testing protocol. 
 
The extensive follow-up program mentioned before provides for lung function tests at 
different ages. In chapter 8 we evaluated lung function longitudinally at 6 and/or 12 
months of age in a group of ECMO survivors. Functional residual capacity (FRCp) and 
forced expiratory flow at FRC (V'maxFRC) were measured and expressed as Z scores. 
We studied 45 infants, 35 were evaluated at 6 months and 35 at 12 months; 25 infants 
completed both measurements. We found normal lung volumes and normal expiratory 
flows with normal development at a level below average during that year. Furthermore 
we found higher lung volumes at both 6 and 12 months in infants receiving ECMO for 
CDH compared with infants receiving ECMO for MAS. This study does not only 
contribute to our understanding of the effects of ECMO in severe respiratory 
insufficiency, but also provides data on longitudinal growth of lung function in early 
infancy. Especially in the follow up of infants with CDH it is important to evaluate growth 
potential of the pulmonary blood vessels and airways.  
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In chapter 9 we describe pulmonary sequelae in twenty-eight 5-year-old and fourteen 8-
year-old ECMO survivors. Airway resistance was measured using the interrupter 
technique (Rint) during expiration and expressed as Z score at both 5 and 8 years. In 
addition we measured FVC, FEV1, FEV1/VC-ratio and MEF25 using a spirometer. In the 
8–year-olds helium dilution was used to determine TLChe, residual volume of helium 
(RVhe), VChe,, FRChe and RV/TLC-ratio. Airway resistance was within normal range for 
both age groups. After bronchodilatation airway resistance decreased significantly in 
both age groups. In 8 year olds FEV1/VC ratio and MEF25 before bronchodilatation 
showed mild airway obstruction. Values were significantly lower than those in the 5-year-
olds. Diffusion capacity was within the normal range. The findings of this study confirm 
the presence of long-term pulmonary sequelae despite the use of lung rest during 
ECMO. 
 
In chapter 10 we discuss our findings and make recommendations for future studies.  
The main conclusions obtained from the studies described in this thesis are the following:  
 
- Introduction of enteral nutrition in critically ill newborns on ECMO was well 
tolerated and did not give rise to major complications (chapter 2).  
 
- Together with the finding that gut hormone responses following the 
introduction of enteral nutrition in a theoretically compromised intestinal 
circulation were normal, these data do not provide arguments to withhold 
enteral nutrition in these newborns (chapter 3). 
 
- More data on the pharmacokinetics and pharmacodynamics of sedatives and 
analgesia are needed to guide optimal treatment especially in case of 
combined therapy (chapter 5). 
 
- Sildenafil in combination with iNO may be a promising adjuvant in the 
treatment for severe therapy resistant PPHN, also during ECMO (chapter 6). 
 
- Follow-up of neonates treated with ECMO shows a considerable morbidity at 
age 5 years comparable to figures from the UK and the Unites States, 
consolidating the idea that structural follow-up of these infants remains 
important, preferably with involvement of representatives from different 
disciplines (chapter 7). 
 
- Lung function in ECMO survivors during the first year of life revealed normal 
lung volume and normal expiratory flow at a level below average with normal 
growth and development during that year. Lower airway obstruction was only 
observed in the 8-year-olds, and not in the 5-year-olds (chapter 8 and 9). 
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Samenvatting 
 
Extracorporele membraan oxygenatie (ECMO) is een techniek die wordt toegepast als 
levensondersteunende behandeling bij potentieel reversibele cardio-respiratoire 
insufficiëntie. Bij deze techniek wordt het bloed buiten het lichaam van zuurstof voorzien 
met behulp van een kunstlong. Op deze manier krijgen de longen van de patiënt de kans 
te herstellen omdat ze worden beademd met minimale beademingsvoorwaarden waarbij 
beschadiging door hoge zuurstofconcentraties en barotrauma zoveel mogelijk wordt 
voorkomen. ECMO wordt het meest gebruikt bij (bijna) voldragen pasgeborenen met 
ernstige ademhalingsproblemen en pulmonale hypertensie – hetzij primair (idiopathisch) 
of secundair optredend bij een meconium aspiratie syndroom (MAS) – met congenitale 
hernia diafragmatica of met sepsis. Dit proefschrift presenteert klinische studies naar 
bepaalde aspecten van de acute fase van ECMO-behandeling van pasgeborenen met 
respiratorische insufficiëntie evenals aspecten van de follow-up op de lange termijn.  
 
Hoofdstuk 1 geeft een algemene inleiding over de ontwikkeling van ECMO door de tijd. 
Tevens worden de aspecten geïntroduceerd die zijn onderzocht, alsmede de 
doelstellingen van het proefschrift.  
 
Hoofdstuk 2 beschrijft de resultaten van een retrospectieve studie over een periode van 
5 jaar naar aspecten van haalbaarheid en tolerantie bij het routinematig geven van 
enterale voeding aan pasgeborenen tijdens ECMO. De haalbaarheid werd beoordeeld 
door de tijdsperiode te registreren voordat 40% van de totale vochtinname voor rekening 
kwam van enterale voeding. De tolerantie werd beoordeeld aan de hand van het 
optreden van ziekteverschijnselen die met de voeding te maken hadden. Zevenenzestig 
van de 77 kinderen kreeg enterale voeding tijdens ECMO. Zesendertig van deze (54%) 
bereikten de genoemde 40% enterale vochtinname binnen een mediane duur van 3 
dagen (van 2 tot 4 dagen). Over de 5 jaar bleek een trend tot enterale voeding bij meer 
kinderen (71% tot 94%). Enterale voeding werd tijdelijk gestopt bij 16 patiënten, d.w.z. bij 
14 vanwege maagretenties, bij 1 patiënt omdat deze oncomfortabel leek en bij 1 omdat 
deze wellicht had geaspireerd. Gallig braken, bloederige ontlasting of een bol gespannen 
buik werden niet waargenomen. Over het algemeen werd de enterale voeding goed 
verdragen en werden er geen ernstige complicaties waargenomen. Wij zijn daarom van 
mening dat het routinematig geven van enterale voeding aan ernstig zieke 
pasgeborenen tijdens ECMO haalbaar is.  
 
In het vervolgonderzoek van enterale voeding voor pasgeboren tijdens ECMO wordt in 
hoofdstuk 3 het effect op de darmfunctie beschreven. Het doel was om meer inzicht te 
krijgen in de hormonale respons op enterale voeding. Plasmaspiegels van de 
darmhormonen gastrine, cholecystokinine en peptide-YY werden bepaald na de 
introductie van enterale voeding. Twaalf van 24 pasgeborenen kregen alleen parenterale 
voeding. Bij de overige 12 werd enterale voeding na enkele dagen geïntroduceerd. De 
plasmaspiegels van deze 24 pasgeborenen werden vergeleken met 16 bloedmonsters 
van een controlegroep van 8 pasgeborenen die geopereerd waren voor een aangeboren 
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afwijking –bijvoorbeeld een oesophagusatresie – maar niet met ECMO werden 
behandeld. De plasmaspiegels van gastrine, cholecystokinine en peptide-YY gemeten bij 
pasgeborenen aan ECMO die enterale voeding kregen, waren significant hoger dan die 
van de pasgeborenen die alleen parenterale voeding kregen. Er bleken geen verschillen 
te zijn met de controlegroep. Concluderend kunnen we zeggen dat de plasmaspiegels 
van de onderzochte darmhormonen een normale respons laten zien na de introductie 
van enterale voeding. De resultaten van deze studie vormen geen ondersteunend 
argument voor het vigerende beleid om enterale voeding te onthouden aan zeer ernstig 
zieke pasgeborenen die ECMO-behandeling ondergaan. 
 
In hoofdstuk 4 werd retrospectief geëvalueerd of ECMO de kans op het ontstaan van 
een chylothorax na operatieve correctie van een congenitale hernia diafragmatica 
vergroot. Bij 98 kinderen met een congenitale hernia diafragmatica, die al dan niet 
behandeld werden met ECMO, werd gekeken of ze na de operatie een chylothorax 
ontwikkelden. Dit werd ook gedaan voor 114 kinderen die behandeld werden met ECMO 
vanwege andere redenen. Als controlegroep fungeerden 100 kinderen die vanwege een 
oesophagusatresie werden geopereerd. Bij 10% van de patiënten met congenitale hernia 
diafragmatica bleek na operatie een chylothorax te zijn opgetreden; en uitgesplitst: bij 
21% van hen die met ECMO werden behandeld en 6% van hen die niet met ECMO 
werden behandeld. Dit verschil bleek significant te zijn. Het gebruik van een patch voor 
het sluiten van het defect in het diafragma bleek als onafhankelijke variabele voor het 
ontstaan van een chylothorax eveneens significant te zijn. Bij kinderen die werden 
behandeld met ECMO voor andere redenen, en bij hen die geopereerd waren vanwege 
een oesophagusatresie bleek de incidentie van een chylothorax respectievelijk 3,5% en 
4% te zijn. Een chylothorax trad meestal op aan de kant van het defect in het diafragma 
en niet aan de kant van de ECMO-canules. In samenhang met de bevinding dat de 
aanwezigheid van een patch een grotere kans geeft op het ontwikkelen van een 
chylothorax, lijkt het waarschijnlijker dat ECMO een selectiebias vormt dan dat het een 
primaire oorzaak is voor het ontstaan van een chylothorax.  
 
In hoofdstuk 5 worden de plasmaconcentraties van midazolam en morfine beschreven 
bij 20 neonaten tijdens ECMO-behandeling. Het is een vooruitlopende beschrijving van 
een grotere studie naar de farmacokinetiek en farmacodynamiek van midazolam en 
morfine tijdens ECMO. Plasmaconcentraties van midazolam, 1-OH-midazolam, 1-OH-
midazolam-glucuronide, morfine, morfine-M3G en morfine-M6G werden bepaald op 
verschillende tijdstippen na het staken van morfine en midazolam na cannulatie en 
tevens na herintroductie van deze middelen. De plasmaconcentraties van zowel morfine 
als midazolam lieten een grote variabiliteit zien. Achttien kinderen hadden zowel morfine 
als midazolam nodig voor toereikend sederen. De mediane (IQR) tijdsduur tussen het 
stoppen van de medicatie en de herintroductie hiervan was 10 (7,8 - 27) uur. De 
mediane dosering van morfine tijdens ECMO was 11,5 (10,1 - 15,5) µg/kg/hr. Van 
midazolam was dit 0,15 (0,1 - 0,2) mg/kg/hr. In nadere onderzoeken is het de bedoeling 
de farmacokinetische en –dynamische eigenschappen van morfine en midazolam te 
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evalueren, daarbij gebruik makend van gevalideerde pijnscores zoals de COMFORT en 
VAS.  
 
In het kader van onderzoek naar medicijngebruik tijdens ECMO hebben we in 
hoofdstuk 6 naar de effecten gekeken van orale toediening van sildenafil (Viagra®) bij 
15 pasgeborenen die ECMO-behandeling kregen omdat ze pulmonale hypertensie 
hadden die niet met een conventionele therapie kon worden behandeld. Van deze 15 
overleden er 7; allen met een congenitale hernia diafragmatica. De bevindingen bij de 
overlevenden werden vergeleken met die bij de overledenen. Er bleek geen verschil in 
de ECMO-duur en in het dalen van de ECMO-flow 24 uur na introductie van sildenafil. 
De overlevenden hadden sildenafil significant eerder na cannulatie gekregen dan de 
overledenen; respectievelijk 41 (17 - 90) uur en 200 (161 - 334) uur. Sommige kinderen 
kregen ook iNO toegediend gelijktijdig met sildenafil, en die werden vergeleken met de 
kinderen die geen iNO kregen. De kinderen die beide kregen vertoonden een grotere 
afname van de ECMO-flow in de eerste 24 uur na sildenafil-toediening dan de kinderen 
die alleen sildenafil kregen. Bij 12 kinderen werd een significante daling van de 
bloeddruk waargenomen in de eerste 2 uur na de eerste toediening van sildenafil. Deze 
daling hing niet samen met de dosis. De bevindingen van deze studie laten zien dat een 
behandeling met sildenafil gunstig kan zijn voor individuele gevallen van pulmonale 
hypertensie. Toediening van sildenafil relatief vroeg in het ziekteproces, en dan samen 
met iNO, geniet de voorkeur. In tegenstelling tot eerdere onderzoeken bij dieren en bij 
volwassenen werd in ons onderzoek een daling van de systemische arteriële bloeddruk 
waargenomen.  
 
In het kader van de follow-up op de lange termijn wordt in hoofdstuk 7 de morbiditeit 
beschreven bij 98 kinderen die nu 5 jaar oud zijn en als pasgeborenen ECMO-
behandeling hadden ondergaan. Op deze leeftijd staan kinderen aan het begin van de 
basisschool en worden belangrijke beslissingen genomen voor de verdere 
schoolcarrière. Deze kinderen waren behandeld in de twee door de overheid 
aangewezen behandelcentra in Nederland; het Erasmus MC-Sophia kinderziekenhuis in 
Rotterdam en het Universitair Medisch Centrum st. Radboud in Nijmegen. Het follow-up 
programma bestond uit een medisch onderzoek, een neuro-motorische beoordeling en 
een psychologische evaluatie onder meer met behulp van vragenlijsten voor ouders en 
leerkracht. Bij 17% van de 98 kinderen werden neurologische afwijkingen gevonden. Bij 
6 van deze 17 kinderen was sprake van een ernstige neurologische afwijking; 2 van de 6 
hadden een chromosomale afwijking, 3 waren mentaal geretardeerd en motorisch 
gehandicapt. De zesde had een rechtszijdige hemiplegie. Deze 6 kinderen ondergingen 
niet het neuro-motorische onderdeel van het follow-up programma. Motorische 
problemen werden gevonden in 26% van de overgebleven 92 kinderen. Van deze had 
15% daadwerkelijk een motorisch probleem, en 11% bevond zich in een risicogebied 
hiervoor. Bij 14% van de kinderen werd een cognitieve achterstand gevonden. De 
gemiddelde IQ score was normaal, d.w.z. 100,5. De resultaten tonen aan dat ECMO 
geassocieerd is met een aanzienlijke morbiditeit op de leeftijd van 5 jaar. Dankzij een 
goede samenwerking tussen de twee centra en een relatief korte reistijd voor kinderen in 
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Nederland was het mogelijk een groot aantal van 87% van de overlevende kinderen 
terug te zien in dit follow-up programma. Naar onze mening is er behoefte aan een 
multidisciplinair follow-up programma met nationale consensus over tijdstippen van 
meten en het te gebruiken testprotocol. Alleen dan kan de lange-termijn morbiditeit die 
voortvloeit uit de toepassing van een dergelijk invasieve technologie in de directe 
neonatale periode objectief worden geëvalueerd. 
 
Als onderdeel van het eerder genoemde uitgebreide follow-up programma worden op 
verschillende leeftijden longfunctietesten verricht. In hoofdstuk 8 worden de resultaten 
beschreven van longfunctietesten 6 en 12 maanden na neonatale ECMO-behandeling. 
De functionele restcapaciteit (FRCp) en de geforceerde expiratoire flow op het moment 
van FRC (V’maxFRC) werden uitgedrukt in z scores. 35 kinderen ondergingen een 
longfunctieonderzoek op de leeftijd van 6 maanden en 35 op de leeftijd van 12 maanden; 
25 kinderen werden zowel op 6 als op 12 maanden onderzocht. Er werden normale 
longvolumes en normale expiratoire flows gevonden bij een normale ontwikkeling op een 
benedengemiddeld niveau gedurende het eerste jaar. Daarnaast werden bij kinderen die 
met ECMO werden behandeld vanwege een congenitale hernia diafragmatica grotere 
longvolumes gevonden dan bij degenen die ECMO nodig hadden vanwege een 
meconium aspiratie syndroom. Dit was het geval zowel op de leeftijd van 6 als van 12 
maanden. Dit onderdeel geeft ons niet alleen inzicht in de effecten van ECMO op 
ernstige respiratoire insufficiëntie, maar levert ook gegevens over longitudinale 
ontwikkeling van de longfunctie op jonge leeftijd. Met name voor de follow-up van 
kinderen met een congenitale hernia diafragmatica is het van belang de groeipotentie 
van luchtwegen en longvaten te blijven evalueren.  
 
Hoofdstuk 9 beschrijft onderzoek naar de longfuncties van 28 vijf-jarigen en 14 acht-
jarigen die als pasgeborenen ECMO-behandeling hadden ondergaan. De 
luchtwegweerstand werd gemeten op de leeftijd van 5 en 8 jaar met behulp van een 
interruptietechniek (Rint) tijdens de expiratie. De resultaten werden uitgedrukt in z scores. 
Tevens werd met behulp van de spirometer de FVC, FEV1, FEV1/VC-ratio en MEF25 
gemeten. Op de leeftijd van 8 jaar werd met een heliumdilutiemeting de TLChe, het 
restvolume helium (RVhe), VChe, FRChe, en de RV/TLC ratio gemeten. De 
luchtwegweerstand lag voor beide leeftijden binnen normale grenzen. Na 
bronchodilatatie daalde de luchtwegweerstand in beide leeftijdsgroepen significant. Bij 
de 8-jarigen werd voor bronchodilatatie een lichte luchtwegobstructie geconstateerd 
n.a.v. een verlaagde FEV1/VC ratio en MEF25. Deze waardes waren significant lager dan 
bij de 5-jarigen. De diffusiecapaciteit bij de 8-jarigen was normaal. De bevindingen van 
deze studie bevestigen de aanwezigheid van longschade ondanks de rust die de longen 
wordt gegund tijdens behandeling met ECMO.  
 
Hoofdstuk 10 is een bespreking van de bevindingen van alle studies en bevat tevens 
aanbevelingen voor verder onderzoek. De belangrijkste conclusies zijn: 
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- Introductie van enterale voeding werd goed verdragen door ernstig zieke 
pasgeborenen tijdens ECMO-behandeling en had geen ernstige complicaties 
tot gevolg (hoofdstuk 2). 
 
- Gezien het feit dat er normale darmhormoonwaarden in plasma werden 
gevonden na de introductie van enterale voeding bij neonaten met een in 
theorie verminderde intestinale doorbloeding, is dit geen reden om deze 
neonaten niet enteraal te voeden (hoofdstuk 3). 
 
- Optimale sedatie en pijnstilling van pasgeborenen aan ECMO zijn in 
toenemende mate gebaat bij de beschikbaarheid van farmacokinetische en 
farmacodynamische gegevens. 
 
- Sildenafil in combinatie met iNO zou een veelbelovende aanvulling kunnen 
zijn in de behandeling van ernstige therapieresistente PPHN, ook tijdens 
ECMO (hoofdstuk 6). 
 
- Bij vijfjarigen die als pasgeborenen met ECMO zijn behandeld, blijkt er een 
aanzienlijke morbiditeit te bestaan, vergelijkbaar met soortgelijke patiënten in 
Engeland en de Verenigde Staten van Amerika. Dit bevestigt nogmaals dat 
structurele follow-up van deze kinderen belangrijk blijft, bij voorkeur in 
samenwerking met deskundigen van verschillende disciplines (hoofdstuk 7). 
 
- Longfuncties gedurende het eerste levensjaar toonden een normaal 
longvolume en een normale expiratoire flow bij normale groei en ontwikkeling 
op een benedengemiddeld niveau. Tests op de leeftijd van 5 en 8 jaar lieten 
alleen in de oudste leeftijdsgroep een milde lagere luchtwegobstructie zien 
(hoofdstukken 8 en 9).  
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List of abbreviations 
 
AaDO2 Alveolar arterial oxygen gradient 
ASD  Atrial septal defect 
BIS  Bispectral Index Monitor 
BPD  Bronchopulmonary dysplasia 
CBCL  Child Behaviour Checklist 
CCK  Cholecystokinin 
CDH  Congenital Diaphragmatic Hernia 
CMV  Conventional mechanical ventilation 
CT  Chylothorax 
DLco  Diffusion capacity 
ECMO Extracorporeal Membrany Oxygenation 
ELSO  Extracorporeal Life Support Organisation 
FEV1  Forced expiratory volume in one second 
FRC  Fucntional Resicual Capacity 
FVC  Forced vital capacity 
HFO  High frequency oscillation 
iNO  Inhaled nitric oxide 
IRDS  Respiratory distress syndrome of infancy 
IQ  Intelligence quotient 
M-ABC Movement Assessment Battery for Children 
MAS  Meconium aspiration syndrome 
MEF25  Maximal expiratory flow at 75% of expirated air. 
NEC  Necrotising enterocolitis 
OI  Oxygenation Index 
PPHN  Persistent pulmonary hypertension of the newborn 
PYY  Peptide-YY 
RAKIT  Revised Amsterdam Intelligence Test 
RTC  Thoracoabdominal compression technique 
RV  Residual volume 
SCV  Superior caval vein 
TLC  Total lung capacity 
TPN  Total parenteral nutrition 
TRF  Teacher’s Report Form 
VAS  Visual analogue scale 
VC  Viral capacity 
VSD  Ventricular septal defect 
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follow-up programma en daarmee hoofdstuk 7. Moge de samenwerking nog lang zo 
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afgelopen jaar. Ik had me geen betere opleider kunnen wensen, Ik vind het een eer dat 
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